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Platelets are crucial players in many (patho)physiological processes including haemostasis, 
thrombosis and inflammation. The immunoreceptor tyrosine-based activation motif (ITAM)-
containing receptor glycoprotein VI (GPVI) is the major platelet signalling receptor for 
collagen, which is exposed upon vascular injury. Once bound to collagen, multiple GPVI 
dimers cluster at the platelet surface increasing the avidity for collagen and regulating the 
signalling. In suspension, GPVI is cleaved by the metalloproteinases ADAM10/17 upon 
collagen activation. This thesis aimed to elucidate the signalling dynamics underlying GPVI 
clustering in platelets spread on collagen. Super-resolution microscopy and two-layer cluster 
analysis revealed that immobilised collagen induces long-term GPVI clustering and signalling 
in tandem with minimal shedding and low levels of GPVI/ADAM10 colocalisation. 
Conversely, GPVI is massively shed and the signalling rapidly downregulated in platelet 
suspensions stimulated with collagen. Syk, but not Src, kinase-dependent signalling is 
required to maintain clustering of the collagen integrin receptor α2β1, whilst neither is 
required for GPVI. This thesis proposes that GPVI clustering on immobilised collagen 
protects GPVI from shedding, thereby enabling longer-lasting Src and Syk-dependent 
signalling, integrin α2β1 activation and stable adhesion to collagen. Nanobodies targeting 
human GPVI have potential uses in many different biological applications from anti-platelet 
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Platelets are abundant, small anucleate blood cells which are widely known for playing a 
pivotal role in haemostasis and thrombosis. Under physiological conditions, platelets remain 
in a quiescent, or resting, state within the circulatory system and are unable to interact with 
other cells, for example endothelial cells or other platelets. Platelets become activated at sites 
of endothelial lesions to rapidly form a platelet plug, thereby maintaining vascular integrity 
and restoring the blood flow. However, more recently it has been demonstrated that activated 
platelets also participate in the onset of other physiological or pathological states including 
atherosclerosis (Nording et al., 2015), inflammation (Ho-Tin-Noe et al., 2018), infection 
(Hottz et al., 2018) and cancer (Schlesinger, 2018) as well as vascular development (Bertozzi 
et al., 2010), angiogenesis (Walsh et al., 2015) and wound repair (Nurden et al., 2008).  
Low platelet count leads to the generation of a condition known as thrombocytopenia which 
can be inherited or acquired as a consequence of a multisystem disorder. The 
thrombocytopenic state can result in severe, life-threatening bleeding which is usually 
resolved with the improvement of the primary pathological condition or via transfusions 
(Thachil and Warkentin, 2017). 
Therefore, due to their wide repertoire of (patho)physiological roles, platelets represent an 
important topic of study for the development of different therapeutic approaches. The aim of 
antiplatelet therapies is to preserve the normal haemostasis while specifically targeting 
platelet mediators involved in the onset of different diseases. This Chapter will describe the 
main aspects of platelet biology with a particular focus on the regulatory mechanisms 





1.2  Platelet physiology 
1.2.1 Platelet biogenesis 
Platelets are derived from the cytoplasmic fragmentation of megakaryocytes (MKs) in the 
bone marrow (Machlus et al., 2014). Due to the ability of MKs to migrate, platelet formation 
has also been observed in the lung and peripheral blood. However, the function of this 
extramedullary platelet production remains unclear and controversial (Borges et al., 2017, 
Lefrancais et al., 2017). MKs are highly specialized precursor cells which descend from 
haematopoietic stem cells (HSCs) and undergo different phases of development to produce 
fully matured MKs (Woolthuis and Park, 2016). During the early stage of MK development, 
the pluripotent stem cells become committed to the myeloid lineage by differentiating into a 
common myeloid progenitor (CMP). The MK differentiation continues through the generation 
of different precursor cells,  including burst-forming unit (BFU) and colony-forming unit 
(CFU)-MKs, which become increasingly committed to the MK lineage (Briddell et al., 1989). 
The terminal differentiation is characterised by the formation of immature MKs 
(promegakaryocytes) which undergo a process of endomitosis to evolve into mature polyploid 
MKs (Machlus et al., 2014). During the last stage, the MK cytoplasm reorganises into thin, 
branching processes, known as proplatelets, extending into the vessel lumen (Patel et al., 
2005a). The cytoskeletal network represents the primary motor of proplatelet formation. In 
particular, continuous microtubule polymerisation and sliding highly contribute to proplatelet 
enlargement and elongation, respectively (Patel et al., 2005b). The platelet release is finally 
triggered by the high shear forces present in the circulatory system which shed the proplatelet 
ends (preplatelets) (Thon et al., 2010). The large preplatelets further divide within the 
circulation to ensure an average platelet count of 150-400 × 10
9
/L in humans (600-1,200 × 
10
9





This orchestrated process is regulated by diverse factors including cytokines, extracellular 
matrix (ECM) components and stiffness, blood circulation and topographical surface features 
(e.g. spatial arrangement and orientation) (Leiva et al., 2018). Undoubtedly, the major 
regulator of platelet production is the cytokine thrombopoietin (TPO), although some in vitro 
experiments have suggested that TPO is not fundamental for proplatelet formation (Ito et al., 
1996). TPO binds to its receptor c-Mpl on MKs and activates the JAK-STAT signalling 
cascade which ultimately regulates the gene expression necessary to induce MK 
differentiation and maturation and maintain the platelet pool at a constant level (Deutsch and 
Tomer, 2006). The life-span of circulating platelets is ~7-10 days in humans (~3-5 days in 
mice) before undergoing clearance into the reticuloendothelial system of spleen and liver. 
This limited life-span is strictly controlled by members of the Bcl-2 protein family which, 
through the regulation of the apoptotic cascade, act as a “molecular clock” to maintain a 












                
Figure 1.1. Different stages of platelet production from megakaryocytes. The 
megakaryocyte (MK) development in the bone marrow initiates with the commitment of 
haematopoietic stem cells (HSCs) to the myeloid lineage through the differentiation into a 
common myeloid progenitor (CMP) which in turn develops into different precursor cells such 
burst-forming unit (BFU) and colony-forming unit (CFU)-MKs. The MK differentiation 
culminates in the formation of immature cells (promegakaryocytes) which, via endomitosis, 
develop into mature polyploid MKs and extend pseudopodial protrusions (proplatelets) into 
the vessel lumen. The platelet shedding from proplatelet ends (preplatelets) is induced by 
blood shear stress. The preplatelets undergo further cellular division within the circulatory 





1.2.2 Platelet structure 
Despite the indubitable variability between different individuals, the platelet anatomy is 
characterised by numerous features which are well-conserved. Human platelets measure only 
2-3 μm (mouse platelets only 0.5 μm) in diameter and exhibit a biconvex discoid shape in a 
resting state (Schmitt et al., 2001). Because platelets are cell fragments derived from MKs, 
they lack a nucleus but the entire set of organelles including mitochondria, endoplasmic 
reticulum, Golgi apparatus and lysosomes, is present (Hartwig, 2006). The platelet plasma 
membrane (PM) is characterised by numerous invaginations extending into the cytoplasm and 
forming the so-termed open canalicular system (OCS) (Behnke, 1967). The OCS functions as 
a duct for the granule release and supplements the PM with extra surface during platelet 
activation and spreading (Selvadurai and Hamilton, 2018). A dense tubular system (DTS) is 
also present in the membrane: it is the storage compartment of calcium (Ca
2+
) (Brass, 1984) 
and the site of prostaglandin synthesis (Carey et al., 1982). 
In addition, platelets have a prominent actin and microtubule (MT) cytoskeleton as well as a 
spectrin membrane skeleton. The actin cytoskeleton, consisting of dynamic actin polymers (F-
actin) cross-linked by actin-binding proteins such as filamin and α-actinin, provides structural 
support to circulating platelets exposed to high blood shear stress (Boyles et al., 1985, 
Hartwig and DeSisto, 1991). The tetrameric network of spectrin, in combination with 
different binding proteins, anchors the actin cytoskeleton to the PM and integrins, forming a 
continuous framework to mechanically stabilise flowing platelets (Boyles et al., 1985, 
Hartwig and DeSisto, 1991). The disruption of the spectrin organisation results in the 
destabilisation of the membrane system as well as impairment of proplatelet formation and 
architecture (Patel-Hett et al., 2011). The primary function of the MT cytoskeleton, consisting 





forming a rigid bundle beneath the PM surrounding the platelet perimeter (Patel-Hett et al., 
2008, White and Rao, 1998). Platelet activation leads to the dismantling of the MT coil and 
extensive reorganisation of the actin cytoskeleton to allow the shape change during platelet 
spreading (Paknikar et al., 2019).  
1.2.3 Platelet granules 
Platelets contain three different types of secretory granules: alpha (α)-granules, dense (δ)-
granules and lysosomes. 
Being the largest (200-500 nm in diameter) and most abundant (40-80 per platelet) secretory 
vesicles, α-granules represent the repository of a variety of surface receptors and soluble 
proteins with different functions including integral membrane and adhesion proteins, 
coagulant and anticoagulant factors, chemokines and growth factors (Flaumenhaft and 
Sharda, 2019). Platelet activation triggers the discharge of the α-granule soluble contents, 
including fibrinogen, thrombospondin and von Willebrand factor (vWF) as well as the 
exposure of surface proteins, most importantly P-selectin (marker of platelet activation), to 
mediate platelet adhesion. α-granules also contain other membrane-associated proteins such 
as integrins, glycoprotein (GP)Ib-IX-V, GPVI and tetraspanin superfamily members which, 
contrarily to P-selectin, are constitutively located at the cell surface.  
Fewer in number (4-8 per platelet) and smaller (150 nm in diameter), δ granules are so-called 
because of their electron-dense core. Exclusively found in platelets, they are highly enriched 
with divalent cations and phosphates as well as bioactive amines (serotonin and histamine) 
and nucleotides such as the second messenger adenosine diphosphate (ADP). Release of δ-
granule components acts as positive feedback for the recruitment of additional platelets and 





Platelet lysosomes share common features with those present in other cell types: they store 
acid hydrolases which catalyse the proteolytic degradation of proteins, carbohydrates and 
lipids and require a stronger stimulation than α- and δ-granules to induce the secretion 
(Flaumenhaft and Sharda, 2019). 
1.3 Platelets in haemostasis and thrombosis 
1.3.1 Platelet activation and thrombus formation 
As the principal physiological role of platelets is to prevent bleeding and safeguard normal 
haemostasis, they must be competent at recognising and blocking any vascular damage 
without occluding the blood flow. When a vascular injury occurs, platelets switch from a 
resting to an activated form to immediately build a stable platelet plug and seal the damaged 
vessel wall, thereby preventing excessive bleeding and restoring haemostasis. This activatory 
transition is mediated by the interaction between platelet receptors, signalling mediators and 
soluble agonists with components of the ECM exposed after vascular injury. The resulting 
activation of the signalling machinery triggers a series of changes in the platelet 
conformation, fundamental for their rapid adhesion to the vessel wall and to other platelets to 
minimise blood loss (Lee, 2019). The multistep process of thrombus formation is described 
below and schematised in Fig. 1.2. 
Initiation phase. The formation of a stable plug initiates with platelet tethering and rolling 
when ECM components (Collagen type I and III) are exposed to the bloodstream at sites of 
vascular injury. Soluble vWF present in the plasma is unable to tether circulating platelets. 
However, when it is trapped by the collagen structure, vWF becomes highly responsive 
towards moving platelets (Cruz et al., 1995, Pareti et al., 1987). This is caused by the shear 





for the receptor GPIbα expressed at the platelet surface (Miura et al., 2000, Morales et al., 
2006). As a consequence, platelets are tethered to vWF/collagen complexes and start to form 
a monolayer at the site of vessel breach (Kanaji et al., 2012, Reininger, 2008). 
Stable adhesion phase. In the second step, the weak interaction between platelets and 
collagen is reinforced by the binding of the major signalling collagen receptor expressed at 
the platelet surface, the GPVI-Fc receptor γ-chain complex (GPVI-FcR-γ) (Nieswandt and 
Watson, 2003). GPVI-collagen interplay results in a strong platelet activation which triggers 
the conformational change of integrins αIIbβ3 and α2β1 from low to high-affinity state, in a 
process called ‘inside-out signalling’. These coordinated signalling events enable firm platelet 
adhesion (Lecut et al., 2004). 
Spreading phase. The spreading phase is triggered when platelets become fully adhered to 
the subendothelial ECM complex. It is characterised by sequential remodelling of the actin 
and MT cytoskeleton. Studies using LifeAct-GFP mouse platelets (Calaminus et al., 2008, 
Poulter et al., 2015b) or silicon-rhodamine (SiR) labelled actin and tubulin probes (Paknikar 
et al., 2019) have enabled live-cell visualisation of the cytoskeletal dynamics within spreading 
platelets. This process involves the initial formation of actin nodules (Calaminus et al., 2008, 
Poulter et al., 2015b) followed by the formation of finger-like protrusions, called filopodia. In 
the later stage of platelet spreading, filopodia are replaced by lamellipodia which expand the 
platelet surface area and reinforce the interaction with the ECM. In fully-spread platelets, the 
actin cytoskeleton organises into stress fibre-like structures which help to maintain the 
characteristic shape of spread platelets (Bearer et al., 2002). Inhibition of actin polymerisation 
by cytochalasin D or latrunculin A has been shown to prevent platelet spreading (Casella et 
al., 1981, Qiu et al., 2014). In addition, platelet spreading leads to disassembly of the MT ring 





demonstrated that the simultaneous inhibition of MT polymerisation by nocodazole and 
myosin II function by blebbistatin does not disintegrate the MT ring and consequently 
abrogates platelet spreading (Paknikar et al., 2019).  
Secretion and aggregation phase. At the site of a thrombus, platelet activation and spreading 
trigger the secretory machinery to release the granule contents which act as secondary 
mediators through the engagement of G protein-coupled receptors (GPCRs) (Golebiewska 
and Poole, 2015). In particular, once secreted, ADP binds to its specific receptors P2Y1 and 
P2Y12 whereas thromboxane A2 (TxA2) engages the thromboxane receptor (TP) (Woulfe, 
2005). In addition, vWF and fibrinogen are discharged from α-granules and can bind to 
integrin αIIbβ3 to enhance the positive signalling feedback and induce the recruitment of 
additional platelets to form an aggregate (Bennett, 2005).  
Thrombus formation phase. The onset of thrombus formation is characterised by the 
activation of the coagulation cascade. Following prolonged stimulation and sustained Ca
2+ 
influx, a sub-population of platelets (procoagulant platelets) undergo ballooning, expose 
phosphatidylserine (PS) at the surface and recruit coagulation factors (most importantly FXa 
and FVa) to proteolytically convert prothrombin into the active form (Agbani and Poole, 
2017, Fager et al., 2010). Indeed, the major actor of this phase is thrombin which, through the 
interaction with protease-activated receptors (PARs)1 and 4 in human (PAR3 and 4 in mouse) 
(Ofosu, 2003), induces a vigorous platelet activation as well as catalyses the conversion of 
fibrinogen into insoluble fibrin polymers (Monroe and Hoffman, 2006). Fibrin binds to 
integrin αIIbβ3 (Podolnikova et al., 2014) and creates a film at the thrombus core to facilitate 
its growth and stabilisation. Recent evidence has also shown that GPVI plays a critical role in 
the clot development, through its interaction with fibrin, which has been discovered to be a 





Induruwa et al., 2018, Mammadova-Bach et al., 2015, Onselaer et al., 2017). Finally, the 
formed clot undergoes contraction induced by non-muscle myosin II to prevent excessive 










    
Figure 1.2. Main steps of platelet activation and thrombus formation. The process of 
platelet activation and thrombus formation at sites of vascular injury can be divided into five 
main steps: 1. Tethering and rolling induced by GPIb-vWF interaction; 2. Stable adhesion 
mediated by GPVI-collagen interplay followed by platelet activation and integrin ‘inside-out’ 
signalling; 3. Spreading which involves the cytoskeleton reorganisation to allow full adhesion 
of platelets to the ECM. 4. Secretion of granule contents such as ADP and TxA2 which 
amplifies the activation and induces the recruitment of additional platelets to form a platelet 
aggregate. 5. Thrombus formation which is characterised by thrombin generation to reinforce 








1.3.2 Platelet function in haemostasis, thrombosis and beyond 
The initial anatomical and functional characterisation of platelets has been attributed to Giulio 
Bizzozero in 1882 (Bizzozero, 1882). In his elegant in vivo studies conducted via intravital 
microscopy in the mesentery of guinea pigs, Bizzozero discovered the presence of platelets 
with a disc-like structure in circulating blood and then demonstrated their primary role in 
haemostasis and experimental thrombosis. Although haemostasis and thrombosis are usually 
used to refer to the same mechanism, they are very different processes with heterogeneous 
consequences on human health. In classical haemostasis, formation of a platelet clot at sites of 
vessel damage aims to restore the blood flow. However, inappropriate platelet activation leads 
to life-threatening thrombi which are a major cause of different thrombotic conditions, 
including sepsis (Dewitte et al., 2017), atherosclerosis (Nording et al., 2015), heart attack 
(Chung and Lip, 2006) and stroke (Nieswandt et al., 2011). Indeed, at sites of vascular 
inflammatory lesions, such as atherosclerotic plaques, excessive thrombus formation leads to 
the blockage of the blood flow directly or through vessel embolism. The so-called 
‘atherothrombotic disease’ can generate myocardial infarction and stroke which are the 
primary triggers of morbidity and mortality around the world (25% of worldwide deaths) 
(Kaplan and Jackson, 2011). Furthermore, recently a non-canonical role of platelets in 
maintaining vascular integrity at sites of inflamed vessels has emerged. This has been termed 
inflammatory haemostasis (Ho-Tin-Noe et al., 2018). The immune functions of platelets have 
also been characterised in the past few years: they are able to sense, phagocytize and kill 
pathogens (bacteria and viruses), directly eliminate them through the release of antimicrobial 
agents and recruit leukocytes at sites of infection enhancing the production of neutrophil 
extracellular traps (NETs) (Hottz et al., 2018). In addition, platelet-derived chemotactic 





al., 2019). This is achieved through their ability to regulate the angiogenesis which also aids 
vascular development (Bénézech et al., 2014, Finney et al., 2012, Lowe et al., 2015a) as well 
as maintaining the blood/lymphatic vessel separation (Suzuki-Inoue et al., 2010). Conversely, 
platelet-induced angiogenesis has aberrant consequences in pathological conditions such as 
cancer (Janowska‐Wieczorek et al., 2005), atherosclerosis (Burger and Wagner, 2003) and 
rheumatoid arthritis (Boilard et al., 2010). In particular, numerous studies have shown an 
important role of platelets in promoting cancer metastasis via the formation of a platelet 
monolayer which protects tumour cells from shear stress and the attack of immune cells. 
Subsequently, platelets release growth factors which help the metastatic dissemination of 
tumour cells to distant organs (Schlesinger, 2018). This diverse research has demonstrated 
that platelets are versatile cells. Therefore, understanding the signalling mechanisms involved 
in their activation will impact positively upon not only cardiovascular research but the entire 
medical field. 
1.4 Platelet activation  
As platelets circulate in the bloodstream in a resting state, in order to interact with their 
surroundings they must become ‘activated’. This involves the engagement of numerous 
signalling and adhesive receptors which act at different stages of the platelet activation 
process. These signalling cascades all converge on a common pathway which leads to Ca
2+
 
mobilisation from intracellular stores and platelet secretion. The large range of platelet 
activatory receptors can be divided into three main classes in accordance with their structures 
and functions: 1) protein tyrosine kinase (PTK)-linked receptors; 2) GPCRs and 3) 






1.4.1 PTK-linked receptors 
This category includes the integrin superfamily and GPIb-IX-V complex whose function is 
fundamental for stable platelet adhesion and early activation. Platelets contain six different 
integrin heterodimers: α2β1, α5β1, α6β1, αLβ2, αIIbβ3 and αvβ3 (Clemetson and Clemetson, 
2019). However, only integrin α2β1 and αIIbβ3 will be discussed in this thesis for their 
relevance to platelet functions. 
1.4.1.1 GPIb-IX-V 
GPIb-IX-V complex is essential for platelet reactivity since its deficiency leads to the onset of 
the rare bleeding disorder, Bernard-Soulier syndrome (Savoia et al., 2014). Among the four 
subunits (GPIbα, GPIbβ, GPIX and GPV), GPIbα is the largest one and is fundamental for the 
interaction with different ligands. Indeed, its N-terminal leucine-rich domain represents the 
ligand-binding domain (LBD) for a variety of proteins, most importantly vWF, P-selectin, 
thrombin and the coagulation FXII (Li, 2019). In particular, GPIb-vWF interaction induces 
platelet aggregation under high shear stress (Reininger, 2008). GPIbα also regulates the actin 
cytoskeleton through a double interaction between its cytoplasmic tail, filamin-1 and the 
adaptor protein 14-3-3ζ (Chen et al., 2018). In addition, GPIbβ-14-3-3ζ binding contributes to 
the phosphorylation-dependent regulation of actin polymerisation to decelerate the rapid 
movement of platelets at the ECM during the first step of platelet adhesion (Chen et al., 
2018). GPIb-IX binding to 14-3-3ζ is essential for vWF functions as it has been shown that 
the chemical or mutagenic disruption of this interplay impairs GPIb-IX-vWF interaction, 







1.4.1.2 Integrins αIIbβ3 and α2β1  
With ~80,000 copies per cell (Burkhart et al., 2012), integrin αIIbβ3 is only expressed in 
platelets and its absence causes one of the most common bleeding disorder, Glanzmann 
thrombasthenia (Kannan et al., 2009). Integrin α2β1 is expressed at a much lower level than 
integrin αIIbβ3, only ~4,000 copies per platelet (Burkhart et al., 2012). In resting platelets, 
integrins are found at the cell surface in a low-affinity state. Upon activation, they switch to a 
high-affinity conformation capable of binding their ligands following ‘inside-out’ signalling. 
Activated integrins then initiate the ‘outside-in’ signalling which involves the same signalling 
kinases of the classical pathway mediated by ITAM-containing receptors (Kasirer‐Friede et 
al., 2007).  
Integrin αIIbβ3 contains the binding domain for numerous components of the ECM including 
fibrinogen, fibronectin, vitronectin, thrombospondin-1 and vWF (Bennett, 2005). Integrin 
α2β1 is well-known as the major adhesion receptor for collagen and it is believed to only 
weakly contributes to the activation signalling (Auger et al., 2005). Integrin α2β1 and GPVI 
bind to distinct amino acid sequences on collagen: GPVI binds to the three-residue repeat 
GPO (Glycine-Proline-Hydroxyproline) (Asselin et al., 1999) whereas the integrin binds to 
the six-residue sequence GFOGER (Glycine-Phenylalanine-Hydroxyproline-Glycine-
Glutamate-Arginine) (Knight et al., 1998). Ligand binding of integrins mediates firm platelet 
adhesion to the ECM. In addition, the interaction of integrin αIIbβ3 with fibrinogen and vWF 









Upon activation and spreading, platelets produce and release soluble agonists, most 
importantly ADP, TxA2 and thrombin which act as a positive feedback of thrombus formation 
through GPCR-dependent signalling (Lee, 2019). In particular, the second-wave messengers 
interact with their specific GPCRs: ADP with P2Y1 (Gq-coupled) and P2Y12 (Gi2-coupled) 
receptors and TxA2 with TP (Gq-coupled) receptor. These interactions involve the activation 
of multiple signalling kinases and effectors leading to the increase of intracellular Ca
2+
 and 
reduction of the cytosolic cyclic adenosine monophosphate (cAMP) and converge in integrin 
αIIbβ3 activation through the ‘inside-out’ signalling (Woulfe, 2005). Proteolytically produced 
at the platelet surface, thrombin also potentiates thrombus growth and stabilisation through its 
interaction with members of the GPCR superfamily, PAR1 and 4 in human (PAR3 and 4 in 
mouse) (Ofosu, 2003). PAR1 (Gq and G13-coupled) and 4 (Gq-coupled) are activated upon 
thrombin-mediated proteolytic cleavage of N-terminal recognition sequences, strengthening 
platelet activation as well as inducing cytoskeleton remodelling and shape change (Ofosu, 
2003). Using specific inhibitors or blocking antibodies, it has been shown that PAR1 is more 
reactive than PAR4 which is dependent on higher doses of thrombin to induce platelet 
aggregation (Covic et al., 2000). Another, but less studied, platelet GPCR is the adrenergic 
receptor α2A which mediates the signalling activation reducing intracellular cAMP. Table 1.1 
shows the signalling mechanisms and relative effectors of GPCRs expressed in human 
platelets. 
The importance of GPCRs in pathological conditions characterised by unregulated platelet 
activation such as myocardial infarction and ischemic stroke is demonstrated by the 
therapeutic use of antiplatelet drugs targeting GPCR signalling components and by the 





P2Y12 receptor are affected by bleeding disorders and antagonists of this receptor such as 
clopidogrel are clinically effective anti-thrombotic drugs used in the prevention of 
cardiovascular diseases (Dorsam and Kunapuli, 2004). Mice deficient in TP receptor have 
reduced injury-induced platelet activation and retarded atherogenesis and inhibition of TxA2 
production via aspirin is the most common therapeutic approach used for the treatment of 
patients at high risk of cardiovascular events (Warner et al., 2011). PAR3 and 4-deficient 
mice have haemostatic defects and are completely protected against experimental thrombosis 
(Hamilton et al., 2004, Weiss et al., 2002). PARs represent alternative target candidates for 
the development of new anti-thrombotic drugs to reduce the bleeding risk associated with the 
current antiplatelet therapy (aspirin or aspirin and clopidogrel). In clinical studies, the PAR1 
antagonist vorapaxar reduced the risk of cardiovascular events in patients with a previous 
history of myocardial infarction and peripheral arterial disease but failed to attenuate the 


























1.4.3 ITAM-containing receptors 
Despite the activatory role of PTK-linked receptors and GPCRs, vigorous and sustained 
platelet activation is mediated by three different receptors containing an ITAM motif. The 
FcR-γ, linked to GPVI, and FcγRIIA contain a dual ITAM conserved sequence (YxxI/LX6-
12YxxI/L) (Gibbins et al., 1997, Huang et al., 1992) whereas the C-type lectin-like receptor 2 
(CLEC-2) is considered as hemITAM receptor because of the presence of a single ITAM 
(YxxI/L) in its intracellular domain (Suzuki-Inoue et al., 2006). The consensus sequence 
within the ITAM motif is fundamental for initiating and transmitting the receptor signals 
through the docking of Src homology (SH)2 domain-containing proteins (Isakov, 1997). 
Being the main focus of my PhD, the GPVI-FcR-γ complex will be extensively explored in a 
separate section.  
1.4.3.1 FcγRIIA 
With a physiological role in haemostasis and thrombosis as well as the immune response to 
pathogens, FcγRIIA (also called CD32) is a low-affinity receptor for the constant (Fc) domain 
of monomeric Immunoglobulins (Igs) G. Its contains two extracellular Ig-like loops, a 
transmembrane domain and a cytoplasmic region harbouring two ITAM motifs. FcγRIIA 
shares a common signalling mode with the GPVI-FcR-γ complex involving the activation of 
Spleen tyrosine kinase (Syk) and the effector PLCγ2 (Clemetson and Clemetson, 2019). It is 
not expressed in mice; therefore the relevance of this platelet receptor in physiological/non-
physiological thrombosis has been studied only in in vitro systems or transgenic mice. These 
experimental models have been pivotal in determining the important role of FcγRIIA in 
platelet interaction with bacteria and viruses as well as the contribution of platelets to the 
pathogenesis of immune-related diseases (Arman and Krauel, 2015, Arman et al., 2014, 





induced thrombocytopenia (HIT) via immune-complex-mediated platelet activation (Arman 
and Krauel, 2015, Reilly et al., 2001). Furthermore, it has been proposed an additional 
function of FcγRIIA in IgG-independent haemostasis as an amplifier of the αIIbβ3 ‘outside-
in’ signalling, although the experimental evidence of their physical interaction has not been 
reported (Boylan et al., 2008).  
1.4.3.2 CLEC-2 
CLEC-2 is a type II transmembrane receptor and member of C-type lectin superfamily of 
proteins. It is highly expressed in MKs and platelets; however lower levels are also present in  
B lymphocytes and myeloid cells (Lowe et al., 2015b, Suzuki-Inoue et al., 2006). Its structure 
is characterised by the presence of an extracellular C-terminal carbohydrate-like recognition 
domain (CRD), a transmembrane region and a cytoplasmic tail harbouring the hemITAM 
motif at the N-terminus (Weis et al., 1998). The link between CLEC-2 and platelet activation 
has been attributed by Suzuki-Inoue et al. (2006) with the discovery of the specific ligand for 
CLEC-2, the snake venom toxin rhodocytin (Suzuki-Inoue et al., 2006). A year later, the same 
group identified podoplanin as the physiological CLEC-2 agonist (Suzuki-Inoue et al., 2007). 
Podoplanin is expressed at the surface of a broad range of cells including glomerular 
podocytes, lymphatic endothelial cells, lung alveolar cells and cancerous cells (Ugorski et al., 
2016). Surprisingly, podoplanin is not present in the blood vasculature, ruling out a critical 
role for CLEC-2 in the haemostatic process. Indeed, in vitro and in vivo studies by Hughes et 
al. (2010) have demonstrated that tail bleeding and platelet aggregation under flow do not 
change in CLEC-2 deficient mice (Hughes et al., 2010a) in contrast with previous 
observations by May et al. (2009) who proposed a critical role for CLEC-2 in haemostasis and 
thrombosis (May et al., 2009). In the same year, Suzuki-Inoue et al. (2010), using mice 





partial decrease in collagen-induced platelet aggregation under flow (Suzuki-Inoue et al., 
2010), likely due to the differences in the experimental procedure. More recently, evidence 
has emerged for a possible blood-borne ligand or counter-receptor for CLEC-2 as mice 
expressing a novel knockin of a CLEC-2 receptor (Y7A KI), that can not signal through its 
hemITAM, still form stable platelet aggregates on collagen under flow (Haining et al., 2017a).  
The CLEC-2-podoplanin axis and its signalling cascade is also fundamental for maintaining 
separation of the blood and lymphatic vascular systems (Suzuki-Inoue et al., 2010), lymph 
node development and integrity of the brain vasculature (Bénézech et al., 2014, Finney et al., 
2012, Lowe et al., 2015a) as well as promoting tissue repair (Suzuki-Inoue et al., 2018). 
Furthermore, recent evidence has shown that CLEC-2-podoplanin interplay mediates some of 
the non-canonical functions of platelets, most importantly in vascular integrity and 
thromboinflammation (Suzuki-Inoue et al., 2018). 
The signalling mechanisms by which CLEC-2 mediates these functions have common 
features with the classical ITAM-mediated signalling (Fig. 1.3). It is expressed in a dimeric 
form in resting platelets (Hughes et al., 2010b) and, once bound to the ligand and further 
clustered, the dual hemITAM motif becomes phosphorylated upon interaction with Syk 
(Suzuki-Inoue et al., 2006). However, in contrast to the canonical ITAM-dependent 
signalling, Src family kinases (SFKs) signal downstream, contributing to the regulation of 
Syk and that of other effectors, most importantly PLCγ2 (Séverin et al., 2011). In addition, 
whereas the adapter protein Src homology 2 domain-containing leukocyte phosphoprotein of 
76 kDa (SLP-76) and the Rho family guanine nucleotide exchange factors (GEFs) Vav1 and 
Vav3 play a critical role in GPVI signalling, platelets from mice deficient in these proteins 
can still fully aggregate in response to high concentrations of rhodocytin (Suzuki-Inoue et al., 






























   
 
Figure 1.3. CLEC-2 signalling pathway. Upon ligand binding, the CLEC-2 signalling 
cascade initiates with the phosphorylation of the hemITAM motifs which allows binding of 
Syk. Syk engagement and activation, through auto-phosphorylation or SFKs-dependent 
phosphorylation, leads to the recruitment of the linker of activated T cells (LAT). Formation 
of the LAT-based signalosome involves the activation of a series of adaptor and effector 
molecules and culminates with the phosphorylation of PLCγ2. Activation of PKC and Ca
2+ 
mobilisation from intracellular stores characterise the endpoint of the cascade leading to 
secretion of granule contents, integrin activation and platelet aggregation. Adapted from 





1.5 Platelet GPVI receptor  
Since its first discovery in a patient affected by autoimmune thrombocytopenic purpura (ITP) 
(Sugiyama et al., 1987), platelet GPVI receptor has been an attractive topic of study 
worldwide for nearly 30 years. This interest stems from the fact that platelets lacking GPVI 
exhibit only mild bleeding in both patients (Arai et al., 1995, Boylan et al., 2004, Dumont et 
al., 2009, Matus et al., 2013, Takahashi and Moroi, 2001) and mouse models (Kato et al., 
2003, Lockyer et al., 2006, Nieswandt et al., 2000, Nieswandt et al., 2001b). Contrarily, the 
absence of GPVI provides protection from occlusive thrombus formation in experimental 
models of thrombosis (Bender et al., 2011, Cheli et al., 2008, Lockyer et al., 2006, Nieswandt 
et al., 2001b). The mechanism behind its divergent role in haemostasis and thrombosis is still 
unknown but it is the reason why GPVI is considered as an important target in anti-
thrombotic therapy (Dütting et al., 2012). In addition, the limited expression of GPVI on MKs 
and platelets (Berlanga et al., 2000, Jandrot-Perrus et al., 2000, Lagrue-Lak-Hal et al., 2001) 
represents a further advantage for the development of novel anti-thrombotic drugs due to the 
limited off-target effects. 
1.5.1 GPVI-FcR-γ structure 
Cloned and purified in 1999 using a human bone marrow cDNA library, GPVI is a type 1 
transmembrane receptor belonging to the Ig superfamily (Clemetson et al., 1999). Human 
GPVI gene, GP6, was mapped on the chromosome 19q13.4 and encodes a ~62 kDa protein 
made up by 339 amino acids (Ezumi et al., 2000). Only MKs and platelets express GPVI 
reaching up to ~9600 copies per human platelet (Burkhart et al., 2012). Lacking intrinsic 
catalytic activity, GPVI is expressed at the platelet surface associated with the disulphide-
linked homodimer FcR-γ which exhibits one copy of the ITAM motif in its cytosolic region 





an Ig, human GPVI extracellular domain is characterised by the presence of two Ig-C2-like 
loops, called D1 and D2, associated with a mucin-like stalk region enriched in sites for O-
linked glycosylation (Fig. 1.4). It has been demonstrated that the D1 loop represents the major 
collagen-binding domain (CBD) of GPVI (Smethurst et al., 2004). The stalk domain, 
harbouring the cleavage site for members of the A disintegrin and metalloproteinase (ADAM) 
family of metalloproteinases, is involved in the receptor shedding from the platelet surface 
(Gardiner et al., 2007). It also connects the receptor extracellular and transmembrane 
domains. The arginine group (Arg
273
) in the transmembrane domain represents the binding 
site for the FcR-γ (Berlanga et al., 2002, Nieswandt et al., 2000, Tsuji et al., 1997). The 
transmembrane domain converges in the cytosolic region (GPVI-tail) which has been shown 
to be fundamental for intracellular signalling through the interaction between a proline-rich 
domain (PRD) and the SH3 domain of SFKs (Ezumi et al., 1998, Schmaier et al., 2009, 
Suzuki-Inoue et al., 2002). GPVI tail also contains an important site for the binding of 
calmodulin (CaM). Indeed, CaM is constitutively bound to GPVI in platelets and it 
dissociates from the receptor tail upon cellular activation, although the function of this 
association is still unknown (Andrews et al., 2002). Murine GPVI receptor has a very similar 
structure and shares approximately 64% homology with the human amino acid sequence. 
However, its intracellular domain lacks the 23 amino acids located at the C-terminus of the 
human GPVI PRD and the experimental evidence of the functional relevance of this 





           
Figure 1.4. Structural domains of platelet GPVI receptor. Three different domains 
characterise the GPVI receptor structure: 1. the extracellular domain made up by two Ig-like 
domains D1 and D2 linked to a mucin-like stalk region containing the cleavage site for the 
sheddase ADAM10; 2. the transmembrane domain harbouring an arginine group (Arg
273
) 
necessary for the association with the FcR-γ and 3. the cytosolic tail including the binding site 






1.5.2 GPVI dimerisation 
GPVI is expressed at the platelet surface under two different conformations: the monomeric 
form which has no physiological affinity for fibrous collagen whereas the dimeric form is able 
to bind collagen with significantly higher affinity. This was demonstrated by measuring the 
binding of recombinant monomeric (GPVIex) and dimeric (GPVI-Fc2) GPVI extracellular 
domains to immobilised collagen by enzyme-linked immunosorbent assay (ELISA) and 
surface plasma resonance (SPR) (Miura et al., 2002). Interestingly, they found that GPVI does 
not interact with soluble collagen and both monomeric and dimeric GPVI bind to CRP with 
the same affinity, highlighting the specificity of dimeric GPVI for the quaternary structure of 
fibrous collagen. The proof of concept was obtained in 2006 with the crystal structure of 
dimeric GPVI. The crystallographic data revealed the presence of an additional CBD located 
in the juncture region at the interface of the D2 domains when two receptor monomers bind 
each other to form a parallel, back-to-back dimer (Horii et al., 2006) (Fig. 1.5). In 2009, Jung 
et al. confirmed the presence of GPVI dimers at the surface of resting platelets, using a 
specific m-Fab-F against divalent GPVI (Jung et al., 2009). However, the controversial debate 
to determine the extent of receptor dimerisation in resting and activated platelets and its 
functional relevance is still unresolved. In 2012, Jung et al., using another specific Fab 204-11 
against the dimeric conformation of GPVI, reported a constitutive expression of GPVI dimers 
in resting platelets: 29% which rises to 39% and 44% upon activation by CRP and thrombin, 
respectively (Jung et al., 2012). Both anti-dimeric GPVI Fabs, m-Fab-F and 204-11, blocked 
collagen-induced platelet aggregation, highlighting the critical role of receptor dimerisation 
for activation (Jung et al., 2009). Contrarily, several groups have detected the dimeric form of 
GPVI only upon platelet activation. Arthur et al. (2007) demonstrated the presence of 





agonists, identifying the Cys-388 in the intracellular tail as the specific residue involved in the 
dimerisation. The appearance of dimers in activated platelets was independent of GPVI 
signalling and stabilised by the inhibition of receptor shedding (Arthur et al., 2007). Loyau et 
al. (2012), using an anti-GPVI monoclonal antibody 9E18 which binds specifically dimeric 
GPVI, showed that monomeric GPVI is predominant on resting platelets (only 14% of the 
dimeric form was detected) and dimerises upon platelet activation by vWF and other soluble 
agonists through a mechanism that involves the activation of the tyrosine phosphatase CD148 
and low levels of cyclic nucleotides (Loyau et al., 2012). Although the homodimeric FcR-γ is 
required for GPVI expression at the platelet surface, it is not fundamental for receptor 
dimerisation as shown by the formation of a three-helix interface which would incorporate 












Figure 1.5. Crystal structure of dimeric GPVI. GPVI forms a parallel, back-to-back dimer 
in the crystal which contains an additional CBD (indicated by a black arrow) at the interface 
of the D2 domains of each monomer (highlighted in green and magenta). Figure generated 


















1.5.3 GPVI ligands 
GPVI was first proposed as a collagen receptor in the late 1980s with the discovery of the 
patient affected by auto-immune thrombocytopenia (Sugiyama et al., 1987). Since then 
numerous studies in GPVI-deficient patients (Arai et al., 1995, Boylan et al., 2004, Dumont et 
al., 2009, Matus et al., 2013, Takahashi and Moroi, 2001) and mouse models (Kato et al., 
2003, Lockyer et al., 2006, Nieswandt et al., 2000, Nieswandt et al., 2001a, Nieswandt et al., 
2001b) have demonstrated the critical role of GPVI-collagen interaction in mediating platelet 
activation. To date, GPVI is considered the major signalling collagen receptor expressed in 
platelets with integrin α2β1 contributing to the initial interaction (Auger et al., 2005). 
Collagen is the most abundant component of the ECM with fibrillar type I and III showing the 
highest affinity for GPVI among the nine types present in the vascular system (Jung et al., 
2008). Using site-specific mutagenesis, it has been found that the D1 domain in the 
extracellular region of GPVI binds specifically to the three-residue repeat GPO (Glycine-
Proline-Hydroxyproline) within the triple-helix of the collagen structure (Smethurst et al., 
2004). As stated above, an additional CBD has been identified by crystallography studies only 
in the dimeric conformation of the receptor (Horii et al., 2006) and may explain the ~200-fold 
higher affinity of dimeric GPVI for collagen in comparison with the monomeric conformation 
(Jung et al., 2012). Synthetic ligands such as the collagen-related peptide (CRP), which 
contains multiple GPO triplets, have been developed to study GPVI-mediated platelet 
activation independently of integrin α2β1 (Asselin et al., 1997, Morton et al., 1995). 
Interestingly, only cross-linked CRP (CRP-XL) is able to induce efficient platelet activation, 
underlining that GPVI binds native fibrillar collagen at multiple sites. Snake venom toxins 
such as alborhagin, convulxin (CVX) and crotarhagin have also been described as non-





al., 2007). In particular, CVX binds to GPVI with higher affinity, faster association and 
slower dissociation rates than collagen and CRP. It forms a dimer of α4β4 rings in solution 
and can cluster up to eight copies of GPVI, indicating the presence of multiple binding sites 
(Horii et al., 2009). The CVX-binding sites are different from those of collagen and receptor 
dimerisation is not required for CVX binding (Miura et al., 2002). However, despite being a 
strong GPVI agonist, CVX induces a transient response whereas collagen stimulation results 
in a delayed but sustained activation as demonstrated in platelets and cell line models 
(Tomlinson et al., 2007). Diesel exhaust particles (DEP) and sulphated polysaccharides are 
also exogenous GPVI ligands which induce GPVI (and/or CLEC-2)-mediated platelet 
activation (Alshehri et al., 2015b). In addition to collagen, GPVI interacts with other ECM 
components (e.g. laminin) (Inoue et al., 2006) and the extracellular matrix metalloproteinase 
inducer (EMMPRIN) (Pennings et al., 2014) as well as the protein hormone adiponectin (Riba 
et al., 2008) and amyloid β (Aβ)42 (Elaskalani et al., 2018). 
Recently, two proteins have been added to the list of physiological GPVI agonists, fibrinogen 
and fibrin. In 2015, Alshehri et al. and Mammadova-Bach et al. firstly discovered fibrin as a 
novel ligand for GPVI using GPVI-deficient patients and GPVI-deficient mice in a ferric 
chloride (FeCl3) injury model, respectively (Alshehri et al., 2015a, Mammadova-Bach et al., 
2015). In 2018, Induruwa et al. and Mangin et al. reported that fibrinogen supports platelet 
adhesion and activation through GPVI (Induruwa et al., 2018, Mangin et al., 2018). Whether 
these two novel ligands bind the monomeric and/or dimeric conformation of GPVI is 
controversial and represents a matter of current investigation in the platelet biology field 
(Slater et al., 2019). Mammadova-Bach et al. (2015) demonstrated binding of recombinant 
dimeric GPVI-Fc to polymerised fibrin but not fibrinogen which supported thrombin 





et al., 2015). In contrast, in the study by Alshehri et al. (2015), monomeric fibrin was able to 
induce platelet spreading whereas in solution only fibrin polymers induced GPVI activation, 
likely due to the formation of receptor clusters (Alshehri et al., 2015a). Recently, Onselaer et 
al. (2017) confirmed this finding and demonstrated that recombinant monomeric but not 
dimeric GPVI-Fc interacts with fibrin in the D-dimer region and the binding site is different 
from that of collagen (Onselaer et al., 2017). Lastly, only recombinant dimeric GPVI-Fc 
showed binding to immobilised fibrinogen and fibrin through their D-domains in the report 
from (Induruwa et al., 2018). Contrarily, Mangin et al. (2018) reported that immobilised 
fibrinogen activates human, but not mouse platelets, through monomeric GPVI (Mangin et al., 
2018).  
The physiological relevance of these interactions is not clear. It has been proposed that fibrin 
may support thrombus growth and stabilisation through its interaction with GPVI. Indeed, 
fibrin was found within the thrombus core in the revised model of thrombus formation 
(Stalker et al., 2014) which was later contradicted by another study showing that fibrin 
polymers cover also the shell of the thrombus (Macrae et al., 2018). The interaction between 
GPVI and fibrinogen leads to full platelet spreading and block of this interplay impaired 
platelet aggregation independently of collagen and fibrin (Mangin et al., 2018). Therefore, it 
is clear that GPVI may play multiple roles in haemostasis and thrombosis: it may contribute 
to thrombus growth and stabilisation through the interaction with fibrin whereas the binding 
to fibrinogen may support platelet spreading and aggregation. Only crystallography and cryo-
electron microscopy studies will provide further insights into the exact conformation adopted 
by GPVI bound to fibrinogen and fibrin, allowing investigation of the physiological relevance 






1.5.4 GPVI signalling transduction 
Upon ligand binding, GPVI signalling initiates with Lyn, Fyn and Src-mediated 
phosphorylation of two conserved tyrosines within the ITAM motif of the co-receptor FcR-γ 
(Séverin et al., 2012). In particular, it has been shown that Lyn is the major SFK in priming 
GPVI-mediated signalling activation, being constitutively associated with GPVI-PRD in the 
cytosolic tail. On the contrary, Fyn is not linked to GPVI in resting platelets and it associates 
upon stimulation, contributing to sustained receptor activation (Schmaier et al., 2009). 
Phosphorylation of the FcR-γ ITAM motifs induces the engagement and following activation 
of the tyrosine kinase Syk, through auto-phosphorylation of tyrosines 525/526 (Y525/526 in 
human or Y519/520 in mouse) and SFKs-mediated phosphorylation of tyrosine 352 (Y352) 
(Speich et al., 2008). Syk contains tandem SH2 domains which allow binding to the 
phosphorylated ITAM motifs and the onset of a downstream signalling cascade involving 
several adapters and effectors. LAT represents one of the most important adaptor proteins of 
the GPVI signalling pathway, together with SLP-76 (Pasquet et al., 1999). Once 
phosphorylated by Syk on specific tyrosine residues, LAT forms a platform at the platelet PM 
in order to assemble the so-called ‘LAT signalosome’ which culminates in the 
phosphorylation and activation of the effector PLCγ2. Other adaptor proteins, with a minor 
role in mediating activation by GPVI, are recruited at the LAT signalosome such as the 
growth factor receptor-bound protein 2 (Grb2) and the Grb2 related adaptor (Gads) (Asazuma 
et al., 2000). In addition, the Rho family GEFs Vav1 and Vav3 contribute to GPVI-mediated 
PLCγ2 activation in a redundant way as demonstrated by in vivo studies using double knock-
out mice (Pearce et al., 2004). The translocation of the protein/lipid kinase PI3K to the 
signalosome followed by the generation of phosphatidylinositol 3,4,5-trisphosphate (PIP3) is 





kinases also contributing (Atkinson et al., 2003). Upon activation, PLCγ2 liberates the second 
messengers inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol (DAG), which in turn 
induce the Ca
2+
 movement from intracellular compartments and activation of PKC, 
respectively. The final events of this orchestrated signalling cascade (Fig. 1.6) are 
characterised by granule release, activation of integrin αIIbβ3 through ‘inside-out’ signalling 





















     
 
Figure 1.6. GPVI signalling pathway. Upon ligand engagement, the GPVI signalling 
cascade initiates with the SFKs-mediated phosphorylation of FcR-γ in its ITAM motifs and 
the subsequent recruitment and activation of the tyrosine kinase Syk. Syk, in turn, induces the 
phosphorylation of LAT which forms a platform at the PM for the recruitment of a variety of 
adaptors and effectors, most importantly PLCγ2. The final events are characterised by the 
activation of PKC and Ca
2+
 influx from intracellular compartments which lead to granule 





1.6 Regulation of GPVI spatial organisation and signalling transduction 
In order to coordinate platelet responses and prevent unregulated platelet activation, GPVI 
signalling and surface expression are tightly regulated by a variety of inhibitory mechanisms. 
For example, prostacyclin (prostaglandin I2, PGI2) and nitric oxide (NO), which are released 
by endothelial cells, play a critical role in maintaining platelets in a deactivated state within 
the circulation and prevent their accumulation at sites of vascular damage (Nagy and 
Smolenski, 2018). Platelet inhibition is also mediated by the activation of inhibitory receptors 
containing an immunoreceptor tyrosine-based inhibitory motif (ITIM) which are able to 
dephosphorylate key proteins of ITAM-signalling pathways via the action of SH2 domain-
containing phosphatases 1 and 2 (SHIP1 and 2) (Coxon et al., 2017). In addition to the 
endogenous and exogenous inhibitory mechanisms, GPVI signalling and distribution require 
further levels of control to mediate platelet sensitivity. These cooperative regulatory factors 
include components of the PM such as lipid rafts, the tetraspanin-enriched microdomains and 
the actin cytoskeleton. GPVI clustering and shedding as mechanisms to enhance and limit 
platelet reactivity will also be discussed in this section. 
1.6.1 Role of lipid rafts in GPVI distribution and signalling 
Exactly how GPVI organisation and clustering mediates the spatio-temporal regulation of the 
signalling transduction in platelets is still under investigation, but a number of studies have 
demonstrated that specialised membranous areas, called lipid rafts, play a critical role. 
Glycosphingolipids, saturated or non-saturated phospholipids, and arrayed cholesterol are the 
major components of lipid rafts, resulting in liquid-ordered and tightly packed structures 
(~20-50 nm in diameter) floating in the PM bilayer (Bodin et al., 2003). Found also in T cells 
and B cells, lipid rafts function as organising centres for the recruitment and assembly of 





receptor signalling transduction (Dykstra et al., 2003). The hypothesis of lipid rafts in platelet 
is highly controversial due to the limitation of the experimental procedure used for isolating 
and characterising these membranous domains. Lipid rafts are commonly isolated by sucrose 
gradients and defined as being the fractions insoluble into nonionic detergents but enriched in 
GM1 ganglioside and LAT. The latter are used as markers to determine the association of a 
specific protein with lipid rafts. Using this classical method of isolation, a variety of studies 
have highlighted the importance of these microdomains in platelet activation, especially 
mediated by ITAM-containing receptors (Bodin et al., 2003). The first observation of their 
involvement in GPVI-mediated platelet activation came from Boesze-Battaglia et al. (1996) 
who found a change in the cholesterol distribution upon collagen stimulation (Boesze-
Battaglia et al., 1996), which was confirmed many years later by different groups. In 2002, 
Locke et al. showed that GPVI is not associated with lipid rafts in resting platelets but it 
translocates to these membranous domains upon platelet activation (Locke et al., 2002). 
However, in the same year, Wonerow et al. reported that platelet activation induces no major 
change in GPVI localisation within the lipid rafts (Wonerow et al., 2002). This discrepancy is 
likely due to the different detergent used for the lipid rafts isolation (Triton X-100 vs Brij 58) 
which can affect the detection of GPVI. In accordance with Wonerow et al., Ezumi et al. 
(2002) demonstrated that GPVI-FcR-γ complex is constitutively and functionally associated 
with membrane rafts wherein SFKs and LAT are also present (Ezumi et al., 2002). Lipid rafts 
may also facilitate the interaction of GPVI with other receptors as it has been shown for 
GPIb-IX-V (Arthur et al., 2005) and the inhibitory receptor platelet endothelial adhesion 
molecule-1 (PECAM-1) (Lee et al., 2006) with further consequences on the signalling 
transduction. Finally, a proteomic comparative study reported that the lipid rafts composition 





proteins (Izquierdo et al., 2019). This raises the question of whether the high abundance of 
signalling proteins within the lipid rafts of activated platelets is due to their translocation or 
cytoskeleton reorganisation. Only the adoption of cutting-edge microscopy techniques and 
development of specific probes will confirm the lipid rafts hypothesis and clarify the 
contribution of these highly-organised PM domains to GPVI clustering and signalling as well 
as platelet activation and reactivity. 
1.6.2 Tetraspanin microdomains as organisers of GPVI localisation and 
signalling 
In addition to the lipid rafts, GPVI is also compartmentalised into specific tetraspanin-
enriched microdomains at the platelet PM (Protty et al., 2009). Tetraspanins are a family of 33 
proteins with four transmembrane domains which are able to modulate the intracellular 
maturation and trafficking as well as mobility and oligomerisation of specific partner proteins 
(Charrin et al., 2014). The importance of tetraspanins in platelet function has been 
demonstrated by the mild bleeding phenotypes of mice deficient in CD151 or Tspan32 
attributed to the altered ‘outside-in’ signalling mediated by integrin αIIbβ3 (Goschnick et al., 
2006, Orlowski et al., 2009). Since then, lots of studies have been undertaken to identify new 
platelet tetraspanins and their involvement in haemostasis and thrombosis. In 2009, Tspan9 
was identified as a novel component of the platelet tetraspanin microdomains where GPVI is 
specifically compartmentalised (Protty et al., 2009). The functional relevance of this 
interaction was revealed with the generation of a Tspan9-deficient mouse (Haining et al., 
2017b). In the absence of Tspan9, they found a mild but specific impairment of GPVI-induced 
platelet aggregation and secretion as well as GPVI signalling but not platelet adhesion to 
collagen under flow, haemostasis and arterial thrombosis. Furthermore, GPVI-Tspan9 





revealed that the absence of Tspan9 adversely affected GPVI lateral diffusion within the PM. 
This advanced the hypothesis that Tspan9, like other uncharacterised platelet tetraspanins, 
may facilitate the movement of GPVI receptors within the PM to allow the ‘fine-tuning’ of 
GPVI signalling. 
The GPVI specific sheddase ADAM10 is also compartmentalised into tetraspanin 
microdomains. Different studies have demonstrated that members of the TspanC8 subfamily, 
so called because of the presence of eight cysteine residues within the extracellular domain, 
are involved in ADAM10 maturation and trafficking (Dornier et al., 2012, Haining et al., 
2012, Prox et al., 2012). Furthermore, the specific TspanC8 tetraspanin, Tspan14 has been 
shown to inhibit ADAM10-mediated GPVI shedding in a cell line model, proposing a 
possible involvement of the tetraspanin partner in the regulation of the specificity of the 
ADAM10 target (Noy et al., 2016). Such regulation may also take place in platelets where the 
association of GPVI and ADAM10 with different tetraspanins may induce or prevent the 
receptor cleavage. This is a current matter of investigation in Tomlinson laboratory 
(University of Birmingham, UK). 
1.6.3 Actin cytoskeleton regulates GPVI organisation and signalling 
As stated in the previous sections, the actin cytoskeleton plays a fundamental role in 
maintaining platelet morphology, promoting the rapid shape change upon platelet activation 
and contributing to thrombus stability and retraction. Like in other cells, a dynamic actin 
cytoskeleton also regulates receptor conformation and movement within the platelet 
membrane as well as facilitates their clustering required for the initiation of the signalling 
transduction (Jaqaman and Grinstein, 2012). GPVI-mediated platelet activation results in the 





is controlled by members of the Rho family of small GTPases, most importantly RhoA, 
Cdc42 and Rac1 which, through the activation of specific effectors, play important roles in 
platelet aggregation, secretion, spreading and thrombus formation (Aslan and McCarty, 
2013). In particular, RhoA and Cdc42 modulate platelet contractility and secretion whereas 
Rac1 is required for platelet spreading and aggregation. Interestingly, Rac1 has emerged as a 
regulator of the pathway downstream of GPVI. Notably, platelets from Rac1-deficient mice 
exhibited impairment in GPVI-mediated PLCγ2 activation and Ca
2+ 
mobilisation (Pleines et 
al., 2009). Furthermore, in human platelets, Rac1 inhibition reduced platelet aggregation in 
response to CRP in a dose-dependent fashion (Pollitt et al., 2010). Transient deletion of 
Cdc42 in a conditional knockout mouse model also impaired GPVI-mediated platelet 
responses including filopodia formation, secretion of ATP and platelet aggregation in 
response to CRP (Akbar et al., 2011). In accordance with this, another study showed that the 
pharmacological inhibition of p21 activated kinase (PAK), a Rho GTPases effector, blocks 
platelet lamellipodia formation, secretion and aggregation in response to GPVI (Aslan et al., 
2013). Whether inhibition of Rho GTPases affects GPVI signalling via an effect on receptor 
clustering in human and mouse platelets is still unknown and it is a matter of investigation in 
the Watson laboratory (University of Birmingham, UK). Dependence of GPVI dimerisation 
and clustering on the actin dynamics has only been demonstrated through the use of different 
blockers of the actin polymerisation such as cytochalasin D and latrunculin A. In addition to 
the impairment of platelet spreading, both drugs were able to decrease GPVI dimerisation in 
resting platelets and CRP- or thrombin-activated platelets as well as depress cluster formation 
on CRP and different collagenous substrates (Poulter et al., 2017). However, in another study, 





agonists (Pollitt et al., 2010). Therefore, more investigation is required to better understand 
the correlation between GPVI signalling, clustering and the actin dynamics.  
1.6.4 Receptor clustering 
The signalling transduction initiated by cell-surface receptors is an orchestrated and 
coordinated mechanism involving a series of signalling kinases, adaptor and effector proteins 
which converges in the modulation of the final cellular response. A growing body of evidence 
suggests that the receptor organisation itself can regulate the signalling intensity and duration 
through the formation of higher-order clusters (Bethani et al., 2010). These tightly packed 
multimeric complexes could affect signalling through a number of mechanisms, including: 1) 
limiting the lateral diffusion of individual receptor monomers and potentially incorporating 
other signalling proteins; 2) concentrating secondary mediators and 3) preventing the access 
of negative regulators such as sheddases or phosphatases, ultimately leading to the 
amplification of the signalling transduction. Receptor oligomerisation has been reported for 
different categories of receptors and in a variety of cell types, including GPVI in platelets. 
1.6.4.1 GPVI clustering 
As mentioned in the ‘GPVI dimerisation’ section above, resting platelets contain up to ~29% 
of GPVI as a dimer, suggesting that an additional level of regulation is expected to occur at 
the platelet surface for GPVI signalling to take place. Indeed, different groups have suggested 
the existence of a higher-order clustering of receptors which may play a critical role in the 
potentiation of ligand avidity and signalling strength. Investigating the structural basis of 
GPVI-collagen interaction, Horii et al. (2006) hypothesized a model in which a single GPVI 
dimer is not able to trigger the signalling transduction due to the length of the stalk region. 





activation (Horii et al., 2006). This model was supported by Smethurst et al. (2007) who 
showed that CRP-XL, which contains four GPO triplets able to bind two GPVI receptors 
simultaneously, triggers platelet aggregation (Smethurst et al., 2007). Consistent with this, all 
the bivalent Fabs, but not the monovalent m-Fab-F, developed by Jung et al. (2009) were able 
to induce platelet aggregation, suggesting that a single GPVI dimer is not sufficient to trigger 
the signalling and a further level of receptor organisation is required to induce activation 
(Jung et al., 2009). Furthermore, the ability of GPVI to form tight complexes at the platelet 
surface was demonstrated by chemical cross-linking (Berlanga et al., 2007). Only the 
adoption of advanced microscopy techniques such as Single Molecule Localisation 
Microscopy (SMLM) in combination with quantitative algorithms allowed the first 
visualisation and characterisation of dimeric GPVI clusters at the surface of platelets adhered 
to different substrates (Poulter et al., 2017). These clusters colocalised with platelet areas 
enriched in tyrosine-phosphorylated proteins (markers of signalling activation), although the 
specific signalling mediators involved in the process have not been investigated. The intrinsic 
features of different GPVI ligands determined the formation of a variety of cluster templates 
which may influence the strength and duration of signalling as well as ligand avidity. In this 
context, the ability of CVX to cluster up to eight copies of GPVI may explain the reason why 
it induces robust platelet activation (Horii et al., 2009). Indeed, it has previously been shown 
that GPVI mediates both signalling and adhesion of platelets to collagen in a density-
dependent manner (Chen et al., 2002). Lastly, the contribution of fibrinogen and fibrin to 
GPVI clustering is unclear because of the contrasting findings relative to the conformation 
adopted by GPVI in the interaction with the two ligands (Slater et al., 2019). SMLM showed 
the presence of GPVI clusters in platelets adhered to an immobilised fibrinogen-coated 





Polymerised fibrin would likely induce GPVI multimerisation and strengthen the initial 
signalling mediated by GPVI-collagen interplay, a topic for future investigation.  
Receptor clustering, as a mechanism to control cellular signalling, is known to occur in many 
cell types, for example with the T cell receptor (TCR) in T cells (Goyette et al., 2019). In 
platelets, in addition to GPVI, receptor clustering has been associated with the other two 
(hem)ITAM-containing receptors, FcγRIIA (Chacko et al., 1994) and CLEC-2 (Pollitt et al., 
2014) as well as the GPIb-IX-V complex (Arya et al., 2003). In particular, live-cell imaging 
has shown that upon podoplanin engagement, CLEC-2 coalesces to form clusters, which in 
turn induces the oligomerisation of podoplanin itself, facilitating the interaction between 
platelets and lymphatic endothelial cells. It has been proposed that this mechanism is critical 
for the development of the lymphatic vasculature (Pollitt et al., 2014).  
1.6.5 Downregulation of platelet signalling 
In addition to the inhibitory function of endothelial mediators and ITIM receptors mentioned 
above, platelet reactivity can also be limited by receptor removal from the cell surface. This 
can be achieved in a number of ways including receptor endocytosis and receptor shedding. 
Endocytosis of receptors removes them from the cell surface but does not necessarily destroy 
the receptors as they can be recycled back to the cell membrane. There is some evidence that 
both GPVI (Takayama et al., 2008) and CLEC-2 (Lorenz et al., 2015, May et al., 2009) can be 
endocytosed in platelets. Receptor shedding represents the extracellular proteolysis of 
receptors expressed at the cell surface which leads to the irreversible downregulation of the 
receptor itself in order to limit cell activation. This regulatory mechanism is active in platelets 
with the receptors GPIb, GPV and GPVI being affected (Montague et al., 2018a). Activation 





binding with negative consequences on platelet signalling and activation and the generation of 
soluble fragments which can be used as markers of platelet activation as well as associated 
pathological conditions such as coronary artery disease, ischaemic stroke, thermal injury, 
sepsis and inflammatory bowel disease (IBD) (Montague et al., 2018a). 
1.6.5.1 GPVI shedding 
In light of the multiple roles played by GPVI in platelet activation and thrombus formation, 
lots of studies have been undertaken to understand the mechanisms underlying the receptor 
shedding and its role in physiology and pathology. The dynamics by which GPVI shedding 
occurs depend on the specific trigger (Fig. 1.7). In human platelets, ligand engagement 
induces GPVI shedding from the platelet surface, predominantly by ADAM10 which belongs 
to the ADAM family of metalloproteinases (Gardiner et al., 2004). In murine platelets, the 
major GPVI sheddase has not been identified, with ADAM10, ADAM17 and likely other 
metalloproteinases playing a role in the receptor cleavage (Bender et al., 2010). The 
ADAM10 cleavage site (P
260
AR˄QYY) was mapped in the stalk region of both human and 
mouse GPVI (Gardiner et al., 2007). Once shed, the ~55 kDa soluble extracellular domain 
(sGPVI) is released in the plasma whereas the ~10 kDa fragment (GPVI-tail) remains 
anchored to the membrane. To induce shedding, ligand engagement also requires the 
activation of the signalling cascade since inhibitors of key signalling kinases such as SFKs 
and Syk abrogated GPVI shedding (Gardiner et al., 2004). In addition, like receptor 
clustering, the intrinsic characteristics of different agonists determine the extent and kinetics 
of GPVI shedding, with CVX representing a stronger and faster stimulus than collagen and 
CRP (Andrews et al., 2007). GPVI signalling and therefore shedding also involves the 
dissociation of CaM from the intracellular tail (Andrews et al., 2002). Indeed, ADAM10-





CaM inhibitor W7 which stimulates the CaM release from the cytoplasmic tail (Gardiner et 
al., 2004). However, both CVX and W7-induced shedding are independent of integrin αIIbβ3 
signalling. Moreover, carbonyl cyanide m-chlorophenylhydrazone (CCCP), which causes 
mitochondrial injury, triggers GPVI cleavage through ADAM17 in murine platelets 
(Bergmeier et al., 2004). Alternatively, the thiol-modifying reagent N-ethylmaleimide (NEM) 
directly activates ADAM10 and other metalloproteinases, representing a strong trigger for 
GPVI shedding (Gardiner et al., 2007). Unlike ligand engagement, these stimuli do not 
require activation of GPVI signalling.  
In addition to GPVI agonists and synthetic compounds, other physiological/non-physiological 
stimuli can downregulate GPVI expression through the activation of receptor shedding (Fig. 
1.7). The coagulation factor FXa is fundamental to downregulate GPVI under procoagulant 
conditions (Al-Tamimi et al., 2011b). Pathophysiological shear stress also promotes GPVI 
cleavage in the absence of GPVI ligand, proposing a possible implication in thrombus 
stability (Al-Tamimi et al., 2012). Moreover, other (hem)ITAM-containing receptors 
engagement such as CLEC-2 (Gitz et al., 2014) and FcRγIIA (Gardiner et al., 2008), but not 
GPCRs activation (Montague et al., 2018b), downregulates GPVI through this mechanism. 
GPVI shedding can also be induced in vivo through the administration of anti-GPVI 
monoclonal antibodies, leading to a long-term anti-thrombotic effect (Nieswandt et al., 2001b, 
Schulte et al., 2003). This antibody-induced shedding was further described in patients 
affected by immune thrombocytopenia who developed autoantibodies against GPVI (Boylan 
et al., 2004, Sugiyama et al., 1987, Takahashi and Moroi, 2001) and in human platelets after 
injection into a non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mouse 





As stated before, ADAM10 is the essential metalloproteinase to induce loss of GPVI from the 
platelet surface. Expressed at the surface of a variety of cell types including platelets, 
ADAM10 is a type I transmembrane protease made up by an N-terminal prodomain followed 
by a catalytic domain, a region containing the disintegrin/cysteine motif, a transmembrane 
domain and the intracellular tail. Exposure to a variety of stimuli induces the proteolytic 
removal of the prodomain and the activation of the metalloproteinase domain (Anders et al., 
2001). Recently, ADAM10 activity has been monitored real-time using a new GPVI-based 
fluorescence resonance energy transfer (FRET) sensor in resting and activated platelets 
(Facey et al., 2016). Interestingly, quiescent platelets expressed mature ADAM10 on their 
surface but very little GPVI shedding occurred whilst exposure to shear and treatment with 
NEM dramatically increased the level of its activity and GPVI shedding rate. On the contrary, 
GPVI activation by collagen, CRP or CVX did not induce any change in ADAM10 activity 
but GPVI shedding increased, suggesting that different stimuli are able to trigger GPVI 
shedding via different mechanisms. 
In resting platelets, GPVI copy number is maintained at a steady level by a minimal degree of 
receptor shedding (Gardiner et al., 2007). Ligand-induced shedding decreases platelet 
responsiveness to collagen (Chen et al., 2002) which may be functional in conditions 
characterised by unregulated and excessive platelet activation such as occlusive thrombi. 
Therefore, sGPVI may be used as a specific biomarker of platelet activation for the detection 
of thrombotic/non-thrombotic disorders. Indeed, elevated levels of sGPVI have been recorded 
in the plasma of patients affected by coronary artery disease, ischaemic stroke (Al-Tamimi et 
al., 2011a, Bigalke et al., 2010) as well as inflammatory conditions such as thermal injury, 
sepsis and inflammatory bowel disease (IBD) (Montague et al., 2018b). In the latter three 






Figure 1.7. Different mechanisms of GPVI shedding. A variety of physiological/non-
physiological stimuli induce GPVI shedding via different mechanisms. The CaM inhibitor 
W7 induces GPVI shedding through ADAM10 whereas CCCP, which damages the 
mitochondrial metabolism, triggers ADAM17-dependent cleavage. The general activator of 
metalloproteinases NEM leads to a robust GPVI proteolysis. The antibody-mediated GPVI 
shedding occurs in vivo but the specific protease implicated in this process is still unknown. 
Ligand engagement, exposure to shear stress and coagulation factors as well as activation of 
other (hem)ITAM-containing receptors represent other important stimuli involved in GPVI 






1.7 GPVI function in physiology and pathology 
In light of its multitasking properties, the role of GPVI has been investigated in most of the 
canonical and newly-discovered platelet functions in both physiological and pathological 
processes. This section will provide an overview of the main regulatory functions of GPVI in 
haemostasis, thrombosis and beyond as well as the current anti-thrombotic approaches 
undertaken to target GPVI.  
1.7.1 GPVI function in haemostasis and thrombosis 
Although considered as a potent receptor activator in platelets from in vitro studies, 
deficiency of GPVI in human patients induced by genetic mutations (Arai et al., 1995, 
Dumont et al., 2009, Matus et al., 2013) or autoimmune processes (Boylan et al., 2004, 
Sugiyama et al., 1987, Takahashi and Moroi, 2001) results in a mild bleeding diathesis. The 
scarcity of clinical defects is reflected in different GPVI-deficient mouse models which 
exhibit only a moderate increase of time in tail bleeding assays. These include GPVI knockout 
mice (Kato et al., 2003, Lockyer et al., 2006), mice lacking GPVI due to FcR-γ deficiency 
(Nieswandt et al., 2000) and mice treated with antibodies against GPVI to induce the receptor 
immunodepletion (Nieswandt et al., 2001b). This discrepancy between in vitro and in vivo 
studies may be due to the redundant role of different platelet-activating pathways such as 
thrombin-mediated PAR4 activation. Indeed, GPVI and PAR4 double knockout mice 
exhibited a pronounced haemostatic defect (Bynagari-Settipalli et al., 2014). The same 
phenotype was found in mice lacking both GPVI and CLEC-2, highlighting the redundancy 
between the two receptors in the haemostatic process (Bender et al., 2013). In contrast, it is 
now accepted worldwide that GPVI is a crucial player in arterial thrombosis as demonstrated 
by in vivo models of experimental thrombosis. Loss of GPVI protects against occlusive 





2008) as well as experimentally induced pulmonary thromboembolism (Lockyer et al., 2006, 
Nieswandt et al., 2001b). On the contrary, thrombin but not GPVI has been proposed as a key 
player in thrombus formation in laser-induced vascular injury (Dubois et al., 2006, Mangin et 
al., 2006). Interestingly, the in vivo studies of experimental thrombosis suggested a 
predominant role for GPVI in thrombus growth and stabilisation, in accordance with the 
identification of fibrinogen and fibrin, which are involved in both stages of clot formation, as 
novel GPVI agonists (Bender et al., 2011, Onselaer et al., 2017). A role for GPVI has also 
been demonstrated in occlusive thrombus formation associated with the rupture of 
atherosclerotic plaques. In this context, GPVI is believed to be fundamental in the initial 
phase of clot development since it is the major receptor for collagen which is highly abundant 
in the atherosclerotic plaques (Kuijpers et al., 2009, Penz et al., 2005). 
1.7.2 GPVI as a target for anti-thrombotic therapy 
For its negligible role in haemostasis and restricted expression to MKs and platelets, GPVI is 
considered as a promising and safe target in anti-thrombotic therapy (Dütting et al., 2012). 
Different anti-platelet strategies, which target GPVI, are being investigated in vitro and in 
vivo, in order to evaluate benefits and drawbacks. One approach aims to inhibit GPVI-
collagen interaction using fusion proteins (GPVI-Fc) which occupy the same collagen-binding 
site as GPVI. Revacept (under phase II clinical trial) is an example of this strategy. In vivo 
studies showed that Revacept successfully reduced arterial thrombosis without significant 
bleeding as well as improved the cerebral infarction size after ischaemic stroke (Goebel et al., 
2013, Massberg et al., 2004). A similar, but possibly more powerful, procedure to block 
GPVI-collagen interaction relies on the use of anti-GPVI Fab fragments which irreversibly 
saturate the collagen-binding site on GPVI. The successful outcome of this approach is 





in vivo anti-thrombotic protection without bleeding complications in rats (Li et al., 2007). 
This was corroborated by ex vivo studies conducted in cynomolgus monkeys using the Fab of 
the monoclonal antibody 9012.2 against human GPVI (Ohlmann et al., 2008) and the 
humanized anti-GPVI Fab ACT017 (Lebozec et al., 2017). An additional tactic implicates the 
use of inhibitors of key signalling kinases, such as SFKs, Syk or Btk in order to block GPVI-
induced platelet activation (Busygina et al., 2018, Gratacap et al., 2009, Nicolson et al., 2018) 
but the major drawback of this strategy is the lack of specificity, since these kinases are also 
involved in immune cell signal transduction. 
1.7.3 Roles of GPVI beyond haemostasis and thrombosis 
Beyond its crucial role in thrombosis, GPVI is also involved in maintaining vascular integrity 
during inflammation. The importance of platelets in vascular integrity was first described by 
Goerge et al. (2008) when he observed severe bleeding in the skin, brain and lung of 
thrombocytopenic mice submitted to inflammatory stimulation (Goerge et al., 2008). Only a 
later study demonstrated that vascular integrity in the inflamed skin and lung requires GPVI 
as well as CLEC-2 (Boulaftali et al., 2013). This non-canonical haemostasis, also called 
‘inflammatory haemostasis’, does not culminate in thrombus formation and does not require 
integrin αIIbβ3 signalling. Instead, it has been revealed that GPVI mediates the interaction of 
single platelets with collagen exposed at sites of neutrophil-inflicted vascular damage to seal 
the vessel and prevent haemorrhage in inflamed skin (Gros et al., 2015). In addition, GPVI-
mediated vascular integrity is organ- and stimulus-dependent since its protection from 
inflammatory bleeding has been detected in the skin but not in the lung of mice with normal 
platelet count (Rayes et al., 2018). GPVI also plays a fundamental role in 
thromboinflammatory conditions such as ischaemic stroke as demonstrated by the elevated 





Experimental strategies using GPVI blocking antibodies or fusion proteins (e.g. Revacept) 
have been shown to successfully reduce the infarct size and improve the functional outcome 
in mouse models of ischaemic-reperfusion injury inflicted by middle cerebral artery occlusion 
(MCAO) (Goebel et al., 2013, Kleinschnitz et al., 2007). A recent study has shown that GPVI 
is also a key player in preventing bleeding during infection. GPVI knockout or 
immunodepleted mice, submitted to Klebsiella pneumoniae-driven sepsis, exhibited bacterial 
proliferation in the lung and in distant organs as well as reduction of platelet numbers, 
activation and platelet-leukocyte complex formation within the circulation (Claushuis et al., 
2018). The beneficial function of GPVI in local host defence may be due to the enhanced 
recruitment and activation of leukocytes as it has been found in immune complex-mediated 
inflammation (Gros et al., 2015). On the contrary, GPVI has been reported to be the platelet 
target for the Hepatitis C virus (HCV) acting as a transporter of the virus to the lung (Zahn et 
al., 2006). Finally, the involvement of GPVI in experimental cancer metastasis has been 
shown only in one study where they found a reduction of ~50% of tumour foci in the lung 
carcinoma or melanoma cells of GPVI-deficient mice (Jain et al., 2009). Taking these data 
together, it is clear that GPVI represents one of the principal platelet mediators in a variety of 
pathological conditions and could be considered as a potential anti-platelet target in disorders 
beyond thrombosis such as inflammation and infection. 
1.8 Application of super-resolution microscopy to the platelet biology 
In the past few years, the advent of super-resolution microscopy has allowed the investigation 
of cellular ultrastructures and receptor organisation in a variety of biological systems, 
including platelets, with a resolution up to 10-fold higher over the conventional fluorescence 
microscopy (Poulter et al., 2018). In this section, we will provide an overview of the 





particular focus on direct STochastic Optical Reconstruction Microscopy (dSTORM), since it 
has been widely employed in this PhD project. 
1.8.1 Super-resolution microscopy 
Due to their small size, lack of nucleus and complex ultrastructure, high-quality imaging in 
platelets has been a big challenge for many years. Electron Microscopy (EM) has been a 
powerful tool for the structural study of platelet cytoskeleton (Hartwig et al., 1999) and 
secretory granules (tot Pannerden et al., 2010). However, it does not provide any dynamic 
information and is also limited by the laborious sample processing. The advance of 
fluorescence microscopy has provided numerous benefits over EM, becoming the gold-
standard microscopy technique in the platelet field due to the simple sample preparation and 
the ability to track the dynamics of multiple proteins in real-time (Renz, 2013). However, the 
diffraction limit of light represents a significant drawback of the fluorescence microscopy 
which restricts the imaging resolution to approximately 200-300 nm in xy and ~500 nm in z, 
interfering with the visualisation of nanoscopic cellular components, such as actin filaments 
and microtubules (~10 and ~25 nm in diameter, respectively) as well as lipid rafts (~20-50 nm 
in diameter). Discovered by the physicist Ernst Abbe in 1873, the diffraction barrier of light 
under an optical microscope does not permit resolution of two objects whose distance is less 
than half of the wavelength of the light (Abbe, 1873). This represents an important 
inconvenience in the study of platelet biology since fundamental spatial features underlie the 
diffraction limit. However, recently there has been a revolution in the microscopy field with 
the introduction of sub-diffraction imaging methodologies, also called super-resolution 
microscopy techniques, which have allowed the diffraction barrier of light to be overcome 
(Huang et al., 2010) and the nanoscale organisation of platelet receptors, signalling proteins 





next section) and Structured Illumination Microscopy (SIM) are two of the most widely used 
super-resolution microscopy methodologies. Application of these advanced microscopy 
techniques has enabled the characterisation of the structure of actin nodules in human and 
mouse platelets, providing novel insights into the cytoskeletal dynamics during platelet 
spreading (Poulter et al., 2015b). Furthermore, they have proved to be powerful tools for the 
interrogation of receptors organisation within the platelet PM (Pollitt et al., 2014, Poulter et 
al., 2017) and for the diagnosis of platelet granule disorders (Westmoreland et al., 2016). 
Further applications of SMLM to the platelet biology will be discussed in the next section. 
1.8.2 Single Molecule Localisation Microscopy 
In conventional fluorescence microscopy, the entire set of fluorophores mapping a specific 
protein within the sample is excited and imaged at the same time, allowing the detection of a 
dense accumulation of molecules and resulting in a final poorly resolved image due to the 
resolution limit of light (Renz, 2013). SMLM techniques bypass the diffraction barrier of light 
by localising proteins of interest at the single molecule level via the temporal separation of 
dense fluorophores (Allen et al., 2013). This is achieved by exploiting the photochemical 
properties of a single fluorophore which is switched from a dark (“off”) to a light (“on”) state 
using high laser power and an oxidising and reducing buffer, allowing the ‘blinking’ 
performance to take place. At any one time, the majority of the fluorophores are in the dark 
state and only a small and sparse subset of them will enter the fluorescent state in a stochastic 
fashion. This way the centroid position of individual fluorescent emitter can be localised at 
each image frame with high precision by statistically fitting them to a point spread function 
(PSF) model, usually a two-dimensional (2D) Gaussian function. The repetitive iteration of 
activation, localisation and deactivation (‘blinking’ events) of single fluorophores over many 





with the highest resolution achievable, usually ~10-20 nm in the lateral dimensions (Fig. 1.8) 
(Allen et al., 2013). A critical parameter in SMLM is how precise the position of individual 
fluorescent emitter can be estimated, which highly affects the final image resolution. The 
localisation precision primarily depends on the photoswitching properties of the fluorescent 
probes (Dempsey et al., 2011). High photon yield per switching cycle allows determining the 
fluorophore position with high precision. Contrarily, high on/off duty cycle (the time frame a 
fluorophore remains in the light state) adversely affect the localisation precision. The 
switching performance of a specific fluorophore, in turn, is highly dependent on the imaging 
buffer composition and light intensity which need to be adapted in accordance with the 
photochemical properties of the probe (Dempsey et al., 2011). These and other factors such as 
the microscope setup (e.g. objective and optics) and the sample preparation (e.g. labelling 
density) are crucial determinants of the achievable spatial resolution. 
STORM (Bates et al., 2007, Huang et al., 2008, Xu et al., 2017) and PhotoActivated 
Localisation Microscopy (PALM) (Betzig et al., 2006) are the first two SMLM techniques 
that have been developed and they differ in the labelling method for the protein of interest. 
STORM uses fluorescent dyes conjugated to antibodies whereas PALM relies on fluorescent 
proteins which also permit live-cell imaging. Among the different sub-types, dSTORM is the 
most commonly used for its numerous advantages. It relies on commercial antibodies to label 
the epitope of interest in fixed samples and uses high laser power and an oxidising and 
reducing buffer to allow the photoswitching performance (Dempsey et al., 2011, Metcalf et 
al., 2013). It also enables three-dimensional (3D) (Huang et al., 2008) and multicolour 
imaging (Bates et al., 2007) as well as visualisation of intracellular proteins by cell 
permeabilisation or surface expressed receptors when combined with Total Internal Reflection 





using an evanescent wave to illuminate and excite only the fluorescent molecules in a 
restricted sample area close to the interface between the liquid medium of the sample and the 
glass coverslip, TIRFM enables the selective imaging of fluorescently labelled proteins within 
the PM with high signal-to-noise ratio (Poulter et al., 2015a).  
In the last few years, dSTORM has been revealed to be a powerful spatio-temporal 
quantitative tool to extract important numerical information such as size and density, 
elucidating the protein patterning, topography or clustering in a range of biological systems 
(Nicovich et al., 2017). However, this potential suffers from significant caveats such as the 
unknown labelling ratio and the exact identification of ‘single molecules’ during the 
switching cycles (Annibale et al., 2011, van de Linde et al., 2010). High-quality antibodies 
and an optimised switching buffer can improve the imaging performance as well as 
reconstruction and quantification of the final images. These limitations restrict investigations 
in platelets to relative quantitative comparisons rather than absolute numbers since they are 
anucleate cells and therefore unable to be transfected with PALM photoswitchable tags 
characterised by a defined labelling stoichiometry (Betzig et al., 2006). However, recent work 
from Khan et al. (2017) has demonstrated the benefits provided by CRISPR-Cas9 in tagging 
PALM fluorophores at the cellular endogenous level without encountering the issues relating 
to the transfection (Khan et al., 2017). This genome tagging technology, in combination with 
the development of in vivo models or ex vivo platelet production from induced pluripotent 
stem cells (iPSC) (Thon et al., 2017), will significantly advance the field of high-resolution 
live-cell imaging in platelets. 
Despite these limitations, numerous studies have demonstrated the benefits provided by 





particular, Poulter et al. (2015) mapped the localisation of integrin αIIbβ3 and phosphorylated 
proteins at the platelet actin nodules employing dSTORM imaging (Poulter et al., 2015b). In 
this way, they provided new insights into the structure of these actin foci, identifying 
phosphoprotein enriched-areas and integrin-depleted zones at the core of the nodule. 
Furthermore, Pollitt et al. (2014) and Poulter et al. (2017) demonstrated the importance of 
clustering for CLEC-2 and GPVI signalling exploiting the quantitative essence of dSTORM 
(Pollitt et al., 2014, Poulter et al., 2017). In 2018, Mayr et al. and Lickert et al. characterised 
the actin cytoskeleton morphology in human platelets adopting this technology (Lickert et al., 
2018, Mayr et al., 2018). Notably, Lickert et al. (2018) highlighted the diagnostic potential of 
dSTORM imaging investigating the actin morphological changes in patients affected by 
bleeding disorders.  
Ultimately, the highest dSTORM performance, in terms of spatial resolution, would be 
achieved with the use of fluorescently conjugated single-domain antibodies, also called 
nanobodies, which are much smaller (15 kDa, ~2-4 nm) than conventional antibodies (150 
kDa, ~15 nm) and Fabs (50 kDa, ~9 nm). This would place the fluorophore, which is what is 
localised in dSTORM, closer to the protein/structure of interest thereby obtaining the best 
estimation of the true size and position of ultrastructures and signalling molecules in a variety 
of biological processes (Manglik et al., 2017, Pleiner et al., 2015, Traenkle and Rothbauer, 









Figure 1.8. The basic principle of Single Molecule Localisation Microscopy. Diffraction-
limited fluorescence image (resolution: ~200 nm) of GPVI (labelled with 1G5-Fab) in 
platelets spread on collagen and secondary labelled with anti-mouse Alexa Fluor 647 
conjugated (A). Intense laser excitation and an oxidising and reducing buffer drive the 
majority of fluorophores to an “off” state, from which only a small and sparse subgroup of 
them stochastically become fluorescent in each frame (photoswitching performance, B). 
Single fluorophore positions are localised at each frame with high precision by fitting the 
point spread function (PSF) to a two-dimensional (2D) Gaussian model (C). Repetitive cycles 
of photoswitching events over a large number of frames allow to build up a final super-








1.9 Hypothesis and aims of the thesis 
GPVI clustering at the platelet surface has been proposed as a key regulatory mechanism of 
platelet signalling and activation in response to collagen. While the advent of super-resolution 
microscopy techniques has allowed us to construct a detailed map of GPVI distribution at the 
platelet surface, we still have a rudimentary understanding of how these spatial events 
modulate platelet signalling. The hypothesis behind this thesis is that GPVI clustering 
mediates the strength and duration of signalling through the recruitment and incorporation of 
downstream signalling mediators, concentration of second messengers and exclusion of 
negative regulators. This hypothesis was tested following three main research lines: 
1) Map the location of GPVI within the human platelet PM and explore receptor 
clustering employing current cluster analysis algorithms and developing further data 
analysis methods for the dSTORM data of receptor localisation. 
2) Investigate and correlate the mechanisms of GPVI clustering, signalling and shedding 
in platelets spread on an immobilised collagen monolayer.  







































2.1 Materials for platelet function and nanobody studies 
2.1.1 Antibodies and reagents 
Tables 2.1 and 2.2 contain the detailed list of primary and secondary antibodies used for 
immunofluorescence and western blot. All the platelet agonists and inhibitors are listed in 
Tables 2.3 and 2.4, respectively. If unstated, the rest of the reagents used within this thesis 
derived from Sigma (Poole, UK). 






I, immunofluorescence; WB, western blot; FC, flow cytometry 
Table 2.2. Secondary antibodies 





Table 2.3. Agonists 
 
 




















2.2 Human platelet isolation 
Human washed platelets were prepared from blood samples donated by healthy, consenting 
volunteers under the following licence: ERN_11-0175 ‘The regulation of activation of 
platelets’ (University of Birmingham). Blood was drawn via venipuncture into the 
anticoagulant sodium citrate and then acid/citrate/dextrose (ACD: 97 mM sodium citrate, 111 
mM glucose and 71 mM citric acid) added to 10% (v:v). Blood was centrifuged at 200 × g for 
20 min at room temperature (RT). Platelet-rich plasma (PRP) was collected and centrifuged at 
1,000 × g for 10 min in the presence of 0.1 μg ml
-1
 PGI2. Plasma was removed and the platelet 
pellet was resuspended in modified Tyrode’s-HEPES buffer (129 mM NaCl, 0.34 mM 
Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM MgCl2; pH 
7.3) containing ACD and 0.1  μg ml
-1
 PGI2 before centrifugation at 1,000 × g for 10 min. The 
washed platelet pellet was resuspended in modified Tyrode’s-HEPES buffer and left to rest 
for 30 min at RT. The platelet count was measured using the Coulter Z2 Particle Count and 
Size Analyzer (Beckman Coulter Ltd, High Wycombe, UK). The platelet concentration was 
then adjusted in accordance with the experimental procedure. All the studies described in this 
thesis were performed on human platelets. 
2.3 Platelet function assays 
2.3.1 Light transmission aggregometry (LTA)  





) were pre-warmed at 37 °C for 2 min in a Chrono-log 700 Lumi-Aggregometer 
(Havertown, PA, USA). An additional glass vial with the same volume of modified Tyrode’s-
HEPES buffer was used as a blank. Warmed platelets were then stirred at 1200 rpm for 1 min. 





platelets with increasing concentrations of each drug for 5 min. To induce platelet 
aggregation, Horm collagen at 10 μg ml
-1 
was added and the response was monitored for 5 
min under constant stirring conditions (1200 rpm). The area under the curve (AUC) was 
measured using the AGGRO/LINK8 software (Chrono-Log, Havertown, PA, USA). 
In the nanobody study, collagen (3 μg ml
-1
)-induced platelet aggregation after nanobody 
treatment (5 min at 10 μg ml
-1
) was monitored using Chrono-Log Optical Aggregometer 
(Labmedics, Manchester, United Kingdom), following the protocol described above. 
2.3.2 Platelet spreading and staining 
For confocal and epifluorescence imaging, 13 mm #1.5 glass coverslips (VWK, UK) were 
coated with 10 μg ml
-1 
Horm collagen diluted in a manufacturer-supplied diluent. For 
dSTORM imaging, glass bottomed dishes (MatTek Corporation, Ashland, MA, USA) were 
also coated with 10 μg ml
-1 
 CRP-XL or 100 μg ml
-1 
 fibrinogen diluted in phosphate-buffered 
saline (PBS). Fibrin coating of the dish was achieved as described below. Substrate-coated 
coverslips and dishes were left overnight at 4°C, before being blocked in 5 mg ml
-1 
heat-
inactivated fatty acid-free bovine serum albumin (BSA) for 1 hour at RT. Washed and rested 




 in modified Tyrode’s-HEPES buffer and allowed to 
spread on the substrate-coated surfaces for different time points at 37 °C. When required, 
washed platelets were labelled with 2 μg ml
-1 
1G5-Fab against Pan-GPVI (Al-Tamimi et al., 
2009) for 10 min at 37 °C before spreading. Where stated, platelets were also incubated with 
inhibitors or the control vehicle before or after spreading. To evaluate the effect of the 
nanobodies on collagen-induced platelet spreading, platelets were pre-treated with 10 μg ml
-1 
nanobodies for 10 min at 37 °C. Adhered cells were PBS-washed and fixed with 10% neutral 





intracellular proteins, spread platelets were also permeabilised with 0.1% Triton X-100 in 
PBS for 5 min, prior to blocking with 1% BSA + 2% Goat serum (in PBS) for at least 30 min. 
As stated, F-actin and platelet proteins were labelled with Alexa Fluor 488® phalloidin 
(1/300, Invitrogen, Life Technologies, Paisley, UK) and specific fluorescently-conjugated 
primary antibodies or primary + fluorescent secondary antibodies, respectively. For confocal 
and epifluorescence imaging, samples were mounted on glass slides using Hydromount 
solution (National Diagnostics, Atlanta, USA), and stored at RT. Samples for dSTORM 
imaging were stored in PBS at RT until imaged.  
2.3.3 Fibrin generation 
dSTORM MatTek dishes were incubated with 100 μg ml
-1 
fibrinogen for 30 min at RT. To 
allow fibrin generation, 1 U ml
-1 
thrombin was added to fibrinogen-coated dishes and 
incubated for an additional 15 min before being stored at 4°C overnight. Thrombin was then 
neutralised by addition of 20 μM PPACK diluted in 5 mg ml
-1
 heat-denatured BSA for 1 hour 
at RT. After PBS-washes, fibrin-coated dishes were left at RT, ready for platelet spreading 
and immunostaining. In another study, to confirm fibrin production by fluorescent imaging, 
glass coverslips were coated with 100 μg ml
-1 
fibrinogen-Alexa 488 and the above procedure 
carried out. 
2.3.4 Protein phosphorylation and receptor shedding assays 
2.3.4.1 Protein lysate preparation from platelets in solution 




 in modified Tyrode’s-HEPES buffer and 
pre-treated with 9 μM integrilin to prevent platelet aggregation. In GPVI shedding 
experiments, platelets were supplemented with 2 mM CaCl2. Platelets were left to warm in the 





(Labmedics, Manchester, United Kingdom). Warmed platelets were then stirred at 1200 rpm 




was added to the platelet 
suspension and stimulated for 90 sec, 15 min, 30 min, 1 hour and 3 hours. Unstimulated 
samples were treated with collagen diluent (vehicle) for the same times. For GPVI cleavage 
studies, platelets were stimulated with the thiol-modifying reagent NEM (2mM, Millipore 
Merck, Abingdon, UK) under the same stirring conditions for 1 hour. To investigate whether 
nanobodies induced GPVI-shedding, platelets were stimulated with 4 μg ml
-1 
nanobodies or 
PBS (vehicle) for 1 hour before lysis. Activation was stopped by the addition of of 2x lysis 
buffer (300 mM NaCl, 20 mM Tris, 2 mM EGTA, 2 mM EDTA, and 2% NP-40 detergent), 
pH 7.4 supplemented with protease inhibitors [2 mM Na3VO4, 2 mM 4-(2-Aminoethyl) 
benzenesulfonyl fluoride hydrochloride (AEBSF), 10 μg ml
-1 
 leupeptin, 10 μg ml
-1 
 aprotinin 
and 1 μg ml
-1 
pepstatin]. Whole-cell lysates (WCLs) were resuspended in 5x reducing sodium 
dodecyl sulfate (SDS) sample buffer (10 mg ml
-1 
SDS, 25% 2-mercaptoethanol, 50% glycerol, 
25% Stacking buffer, small amount of Brilliant Blue). Platelet lysates were stored at -20°C 
until tested. 
2.3.4.2 Protein lysate preparation from spread platelets 
6-well plates were coated overnight at 4°C with 10 μg ml
-1
 Horm collagen and then blocked 
in 5 mg ml
-1





in modified Tyrode’s-HEPES buffer and pre-incubated with 2 mM CaCl2 for 
receptor shedding assays, were spread on the collagen-coated surface for 15 min, 30 min, 1 
hour and 3 hours at 37 °C. Where indicated, inhibitors or the control vehicle were added to the 
platelets before or after spreading. Non-adhered platelets were removed and lysed with 2x 
lysis buffer. Adhered and spread platelets were PBS-washed and then lysed with 1x lysis 





Hemel Hempstead, UK). Once diluted to the same concentration in lysis buffer, platelet 
lysates were supplemented with an adequate volume of 5x reducing sample buffer and stored 
at -20°C until used. 
2.3.4.3 SDS-PAGE and Western blotting 
Platelet lysate samples were denatured at 95°C for 10 min and centrifuged at 13000 × rpm for 
5 min at 4°C to pellet insoluble material. Pre-cast polyacrylamide gels, Bolt or NuPAGE 4-
12% Bis-Tris Plus (Invitrogen, Life Technologies, Paisley, UK) were used to run samples. 
Proteins resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
were transferred to a low-autofluorescence polyvinylidene difluoride (PVDF) membrane 
(Trans-Blot Turbo RTA Midi LF PVDF transfer kit, Bio-Rad, Hemel Hempstead, UK) using 
a Bio-Rad semi-dry Turbo transfer system. The broad range (11-245 kDa) colour prestained 
protein standard was used to evaluate the molecular weight (MW) (New England 
BioLabs/NEB, Hitchin, UK). After transfer, the membrane was blocked for 1 hour at RT in 
blocking buffer [3% BSA (w:v), 0.1% sodium azide (w:v) and 0.1% (v:v) Tween-20 Tris-
buffered saline (TBS-T, 200 mM Tris, 1.37 M NaCl, 0.1% Tween-20, pH 7.6)]. The blocked 
membrane was then incubated with specific primary antibodies diluted in 3% BSA blocking 
buffer overnight at 4°C. Membrane washing (3 x 10 min) to remove unbound primary 
antibodies was executed in TBS-T before incubating with fluorophore 800 or horseradish 
peroxidase  (HRP) conjugated secondary antibodies (1/10,000 in TBS-T) for 1 h at RT as 
indicated. To remove unbound secondary antibodies, the TBS-T washing (3 x 10 min) was 
repeated. For the chemiluminescence-based detection of proteins, the immunoblotted 
membrane was then revealed using the enhanced chemiluminescence (ECL) substrate 
(Thermo Fisher Scientific, Waltham, MA, USA). Both chemiluminescent and fluorescent 





When stated, autoradiographic film was used for the chemiluminescence visualisation. 
Quantification of the band intensities was performed using LI-COR Image Studio v5.2.  
For loading control, the TBS-T-washed membrane was incubated in Stripping buffer (TBS-T 
+ 2% SDS) supplemented with 1% β-mercaptoethanol for 15 min at 80°C followed by 
another β-mercaptoethanol-free stripping cycle (15 min at 80°C). To remove the remnant 
stripping buffer, the membrane was washed in TBS-T (3 x 10 min), blocked in 3% BSA and 
incubated with loading control antibodies overnight at 4°C as above. 
2.4 Imaging 
2.4.1 Epifluorescence imaging 
Single-colour phalloidin-Alexa 488-stained F-actin and dual-colour imaging of Alexa 488 and 
647-labelled platelets spread on collagen were performed using a Zeiss Axio Observer 7 
Epifluorescent microscope equipped with a 63 × 1.4 NA oil immersion lens, Colibri 7 LED 
light source, Zeiss Filter sets 38 and 50 for GFP/FITC and Cy5/647, respectively and 
Hamamatsu ORCA Flash 4 LT sCMOS camera for the image acquisition. Differential 
interference contrast (DIC) images were also taken (intensity = 7.0 V and exposure time = 
100 ms) to visualise the collagen distribution. For each condition, 5 separate fields of view 
(FOVs) were imaged (intensity = 20% and 25% and exposure time = 200 ms and 100 ms for 
488 and 647, respectively) within the Zen Pro v2.3 software and then analysed in Fiji v1.52 
(Schindelin et al., 2012). 
2.4.2 Confocal imaging 
2.4.2.1 Leica TCS SP2  
Spread platelets mounted on glass slides were imaged using a Leica TCS SP2 confocal system 





confocal software version 2.61 Build 1537 was implemented to acquire 5 random z-stacks 
(step size 0.25 µm) for each condition at a resolution of 1024 x 1024 pixels and zoom of 4. 
Phalloidin-Alexa 488-labelled platelets were imaged with the 488 nm line of the Argon laser 
whereas Alexa-647-stained platelets with the 633 nm line of the HeNe laser. Dual-colour 
labelled platelets were imaged simultaneously. Single-plane reflection images were also taken 
to monitor the location of collagen fibres. The images were then processed using ImageJ 
v1.48 (NIH, Bethesda, USA).  
2.4.2.2 Zeiss LSM880 with Airyscan Fast 
Dual-colour imaging of platelets adhered to collagen and stained with Alexa-647 for GPVI 
and Alexa-488 for phosphotyrosine proteins was carried out using a Zeiss LSM 880 confocal 
microscope with Airyscan Fast detector equipped with a Plan Apo 63 × 1.2 NA water 
immersion objective lens, a 25-mW multiline Argon 458, 488, 514-nm laser and a 5-mW 
HeNe 633-nm laser for 488 and 647 excitation, respectively. At least 5 z-stacks with a step 
size 0.2 µm were randomly taken within the coverslip with simultaneous imaging of the two 
channels. The format size of the images was set to 512 x 512 pixels whereas the zoom was 
adjusted to 3. Collagen distribution was followed using the transmitted light T-PMT. Image 
acquisition and processing were executed within the Zen Pro v2.3 software. 
2.4.3 dSTORM imaging 
Super-resolution imaging of GPVI receptors was performed using a Nikon N-STORM system 
in TIRF and dSTORM mode with a 100 × 1.49 NA TIRF objective lens. The system includes 
a Ti-E microscope stand with Perfect Focus, an Agilent Ultra High Power Dual Output Laser 
bed with 170-mW 647-nm and 20-mW 405-nm lasers for the fluorophore excitation and an 





acquired on random FOVs containing both platelets and collagen fibres. An oxidizing and 
reducing buffer (100 mM MEA, 50 μg ml
-1
 glucose oxidase and 1 μg ml
-1
 catalase diluted in 
PBS, pH 7.5) was used to allow the photoswitching performance (Metcalf et al., 2013). The 
N-STORM emission cube, combined with the gradual increase of the 405 laser power (5% 
every 30 sec) to restore the appropriate number of blinking cycles, allowed the single-colour 
(Alexa647) imaging of labelled GPVI. Simultaneous dual-colour (Alexa647 and Alexa488) 
imaging was carried out using the Nikon Quad Cube. For each FOV and each colour, 20,000 
frames were acquired in Nikon NIS Elements v4.5 software using an exposure time of 9.2 
(Chapter 3) or 20 ms (Chapter 4), gain 300 and conversion gain 3. To generate the final 
super-resolved images, the Nikon STORM analysis module v3.2 was implemented, with the 
application of the drift correction and Gaussian rendering (Chapter 3). To remove poorly 
localised detections, a photon count filtering (>500 photons) was applied to the reconstructed 
images before further processing. Where indicated, the ThunderSTORM plugin for Fiji 
(Ovesný et al., 2014) was adopted to reconstruct the final images with the application of the 
Gaussian PSF model and the maximum likelihood estimator to fit the position of the 
fluorescent molecules. Drift correction and photon intensity filtering (>1000 photons) were 
applied within ThunderSTORM to post-process the reconstructed images. To minimise the 
‘multiblinking’ artifacts, detections within 75nm of another detection either in the same or 
subsequent frames were merged. The pointillistic datasets, which contain the spatial 
coordinates for each detected fluorescent blink, were finally exported as text files before 





2.5 Image analyses 
2.5.1 Platelet spreading data analysis 
The confocal and epifluorescence images of platelets spread on collagen were assessed for 
platelet count and surface area using the open-source KNIME software (Berthold et al., 2009) 
where an Ilastik (Sommer et al., 2011) pixel classifier was implemented to construct a binary 
cell segmentation. The centre of each single platelet was set manually to divide attached cells. 
The coordinates of the cell centre positions were then used to generate the final segmentation 
employing a watershed-based transformation algorithm. Only objects with a size > 1 μm
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were included in the final analysis. This is a validated data analysis for platelet spreading 
within the Birmingham Platelet Group. 
2.5.2 Colocalisation analysis 
Qualitative and quantitative colocalisation analyses of GPVI and phospho-proteins were 
performed using Fiji v1.52 (Schindelin et al., 2012). For the qualitative colocalisation 
analysis, the maximum intensity projections of z-stacks of the two individual colours were 
thresholded using the Fiji Default method and multiplied obtaining the colocalisation mask 
which shows only the colocalising pixels. For the quantitative colocalisation analysis, regions 
of interest (ROIs) were drawn around single platelet or group of platelets randomly chosen 
within the FOV and the Plugin Coloc2 was implemented to measure the degree of 










 in modified 
Tyrode’s-HEPES buffer, were incubated for 45 min at 37°C with 1 μM Oregon green-488 





in the presence of 2.8 μM PGI2 and ACD. The platelet pellet was then resuspended in the 
same volume of modified Tyrode’s-HEPES buffer and left to rest for at least 30 min before 




 for spreading. Rested platelets were then exposed to collagen-
coated MatTek dishes, prepared as previously described, allowing adhesion and spreading. 
Live-cell imaging of Ca
2+
 mobilisation was tracked using a Zeiss Axio Observer 7 
Epifluorescent microscope previously described. Where indicated, the SFK inhibitor PP2 (20 
µM) and the Syk inhibitor PRT-060318 (10 µM) or the vehicle (DMSO) were added to the 
platelets after 45 min of spreading. Images were then acquired every 1 sec for 2 min using 
Zen Pro v2.3 software. Once processed in Fiji v1.52 (Schindelin et al., 2012), the percentage 
of spiking platelets, number of spikes per platelet, amplitude and peak duration were 
measured using a custom-made algorithm in MATLAB (Mathworks, Inc., Natick, MA) in 
each single platelet within one representative FOV (~150 cells) for each condition. Signals 
were baseline-corrected by application of a linear top-hat filter. A threshold of 20 
fluorescence units was set for identification of spikes and the duration of a spike was defined 
as the time for fluorescence to reduce to below this threshold. The MATLAB code was 
written by Christopher O’Shea (University of Birmingham, UK) and can be found in 
Appendix I. 
2.5.4 Cluster analyses 
2.5.4.1 Ripley’s K-function-based cluster analysis 
Cluster analysis of GPVI was performed on the STORM images in MATLAB using a 
custom-made algorithm based on Ripley's K-function., as described by (Owen et al., 2010) 
with the adjustments detailed in (Pollitt et al., 2014). For each image, ROIs were selected 
within platelets and on and off collagen fibres. In the MATLAB code, the ROI size (2 x 2 
μm
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selected. After running the MATLAB code on the reconstructed image data, a cluster heat 
map, a binary map of clusters and an Excel file, containing quantitative information such as 
the number of clusters, number of localisations in clusters, percentage of localisations in 
clusters and cluster area, were obtained (Fig. 2.1). The threshold value was applied to the 
cluster heat map to create a binary map of clusters. Areas of the cluster heat map below the 
threshold were described as holes whilst areas above the threshold were identified as clusters. 
For GPVI clustering quantification, at least 50 ROIs on and off collagen fibres for each 











        
Figure 2.1. Ripley’s K-function-based cluster analysis workflow. 2 x 2 μm
2 
ROIs were 
placed on the reconstructed dSTORM images in regions along visible collagen fibres and 
areas outside the fibres within the boundaries of the platelets. The clustering parameters 
(ROIs size, radius and threshold) were set within the MATLAB code before running the 
algorithm on the dSTORM pointillistic datasets. The cluster analysis generated the following 
outputs: 1) a cluster heat map showing the degree of clustering L(r) where red represents 
highly clustered localisations; 2) a binary map highlighting the clusters as defined by the 











2.5.4.2 One-level and two-level DBSCAN-based cluster analyses 
The single-level cluster analysis of GPVI was carried out on the dSTORM pointillistic 
datasets by grouping individual detected localisations, including those on the edges, into 
clusters applying the Density-Based Spatial Clustering of Applications with 
Noise (DBSCAN) (Ester et al., 1996). This analysis was implemented using the R library 
RSMLM (Pike et al., 2019) and KNIME (Berthold et al., 2009) (workflow available in 
Appendix II). In the clustering settings, the radius of the neighbouring localisations was set to 
50 nm and the minimum number of reachable detections was adjusted to 10 unless otherwise 
stated. Clusters with <10 points were discarded within the analysis. GPVI clustering on Horm 
collagen was also executed at two spatial layers using different parameter values within the 
KNIME workflow (available in Appendix II). The two-level cluster analysis was performed 
by first isolating large clusters, corresponding to the collagen fibres (Level I), and then 
segmenting these large clusters into nanoclusters using different clustering parameters (Level 
II). The radii of the neighbouring localisations were set to 75nm and 30nm for Level I and II, 
respectively and the minimum number of reachable detections was adjusted to either 3 or 10 
for the different levels. Clusters with less than either 100 (Level I) or 10 (Level II) detections 
were removed. For the single-level and two-level analyses, the union of circular regions 
(radius = 30 nm) positioned around each point in a cluster was used to measure the cluster 
area applying a grid of 5 nm pixels and image-based dilation. The clustering analyses were 
carried out on the whole FOV and the outputs were exported as Excel files. This analysis was 
designed and implemented in collaboration with Dr Jeremy Pike, COMPARE Imaging 







2.5.4.3 Voronoï tessellation 
Clustering of GPVI was assessed on the localisation-based datasets employing the free 
software SR-Tesseler based on the Voronoï tessellation (Levet et al., 2015). The Voronoï 
diagram was computed on whole FOVs within the platform in order to assign each point to a 
polygonal area. The first level of segmentation created ‘objects’ after setting a density factor δ 
of 2 and a minimum area of 1μm x 1μm. In the study of GPVI clustering on collagen, these 
settings were chosen to isolate only the localisations aligned along visible collagen fibres. In 
the second level of segmentation, the density factor δ was set to 0.5 and a minimum number 
of points was adjusted to 10 in order to generate clusters within the detected objects. 
Quantitative information relative to objects and clusters were outputted into an Excel file.  
2.6 Generation of nanobodies targeting human GPVI  
2.6.1 Nanobody library construction and phage display selection 
The generation of nanobodies raised against human GPVI was contracted out to the company 
VIB Nanobody Core (Brussel, Belgium). A brief outline of the method they used is detailed 
here. We provided VIB with recombinant human GPVI fused to human IgA Fc (Fcα) with a 
His6 tag at the C-terminus [kindly made by Andrew B. Herr’s lab, Cincinnati Children’s 
Hospital, USA and detailed in (Horii et al., 2009)] which was used for the immunization of 
two llamas. A control protein containing the same Fc region was also supplied to allow for 
negative screening and the selection of GPVI-specific clones. Using the phagemid vector 
pMECS, a VHH library was constructed from each llama to screen for the presence of 
antigen-specific nanobodies. In total, 190 colonies from two rounds of pannings were 
randomly selected and analysed by ELISA for the presence of GPVI-specific nanobodies in 





Based on sequence data of the positive colonies, 54 different full-length nanobodies were 
distinguished, belonging to 33 different complementarity-determining region (CDR)3 groups. 
VIB provided us with E. coli TG1 strains harbouring the recombinant phagemid pMECS 
containing the 54 nanobody genes ready for their production and characterisation in our 


















Figure 2.2. Overview of anti-GPVI nanobody generation. The production  of nanobodies 
targeting human GPVI can be divided into three main steps: 1) immunization: two llamas 
were immunized with recombinant human GPVI fused to IgA Fc and His6 tag (hGPVI-Fcα-
His6); 2) construction of VHH libraries: the RNA extracted from the lymphocytes of each 
llama was transformed into complementary DNA (cDNA) and amplified via reverse 
transcriptase-polymerase chain reaction (RT-PCR). The nanobody encoding sequences were 
then cloned into the Pstl and NotI sites of the phagemid vector pMECS which was used to 
transform E. coli strains. Two VHH libraries were generated, each consisting of 3 x 10
8 
transformants; 3) isolation of nanobodies: phage display was carried out for the selection of 
antigen-specific phages of which 190 colonies were randomly selected and further analysed 
by ELISA. From this assay, 86 colonies scored positive for the presence of antigen-specific 
nanobodies. In total, 54 different full-length nanobodies were identified and further purified 











2.6.2 Nanobody expression and purification in TG1 E. coli strain 
In the first 2 rounds, 20 nanobodies, belonging to different CDR3 groups, were expressed and 
purified in TG1 E.coli strain. The remaining 34 nanobodies were kindly generated by the 
research technician Ying Di (University of Birmingham, UK). The nanobody genes cloned in 
pMECS vector contain a PelB signal sequence at the N-terminus which directs the nanobody 
to the periplasmic space of the E.coli. pMECS vector also codes for Ampicillin resistance 
(AmpR) and adds a C-terminal AAA linker, an HA tag and a His6 tag to the nanobody 
sequences which were used for their detection. In addition, in pMECS vector, the His6 tag is 
followed by an amber stop codon (TAG) which separates the His6 tag from the gene III of 
M13 phage (Fig. 2.3). In the suppressor TG1 E. coli strain, the amber stop codon is 
sometimes read as glutamine and therefore the nanobodies were expressed as a mixed 
population of pure nanobodies and nanobodies fused with the protein III of the phage. 
A 10 ml TG1 E. coli pre-culture [Luria-Bertani (LB) medium (10 gr L
-1
 NaCl, 10 gr L
-1 
Tryptone, 5 gr L
-1
 Yeast extract) containing 100 μg ml
-1 
Ampicillin and 1% glucose] was 
incubated at 37 °C overnight with shaking at 200-250 rpm. 1.5 ml of the pre-culture was 
added to 390 ml Terrific Broth (TB) medium (2.3 g L
-1 
KH2PO4, 12.5 g L
-1 
K2HPO4, 12 g L
-1 
Tryptone, 24 g L
-1 
Yeast extract, 4 ml L
-1 
100% glycerol) supplemented with 100 μg ml
-1 
Ampicillin, 2 mM MgCl2 and 0.1% glucose and grown at 37 °C with shaking (200-250 rpm) 
until an optical density (OD)600 of 0.6-0.9 was reached. The nanobody expression was induced 
by addition of 1 mM IPTG at 28 °C overnight (~16-18 hours) with shaking. Once it reached 
an OD600 of ~25-30, the overnight induced culture was centrifuged at 4,000 × g for 20 min. 
The cell pellet from 390 ml culture was then lysed in 5 ml TES buffer (0.2 M Tris pH 8.0, 0.5 
mM EDTA, 0.5 M sucrose) and incubated at 4 °C for 1 hour with shaking. Additional 7.5 ml 





shaking. The lysed bacterial suspension was supplemented with 1.25 ml 2M MgCl2 and spun 
down at 10,000 × g for 30 min at 4 °C. The supernatant, which contains proteins extracted 
from the periplasmic space of E. coli, was supplemented with 5 mM imidazole solution (in 
PBS). The nanobody purification was carried out by immobilised metal affinity 
chromatography (IMAC) using HisPur Ni-NTA Superflow Agarose beads (Thermo Fisher 
Scientific, Waltham, MA, USA). His-nickel resins were prepared by PBS washing and low-
speed centrifugation (700 × g for 3 min, 3x) before the overnight incubation with the 
periplasmic extract (at 4 °C with shaking). Once PBS-washed (3x), the beads were 
resuspended in 0.5 ml PBS and loaded into 0.5 ml Zeba Spin Desalting columns (cut-off 7 
kDa, Thermo Fisher Scientific, Waltham, MA, USA). The bound nanobodies were eluted 3 
times, each time by the addition of an equal volume of 0.5 M imidazole (in PBS) and 
centrifuged at 10,000 × g for 2 min. The final nanobodies were collected and the 
concentration was measured by Nanodrop (Nanodrop ND-1000 Spectrophotometer, 
Geneflow, Lichfield, UK). To remove the imidazole, nanobodies were dialysed at 4 °C 
against PBS (Slide-A-Lyzer MINI Dialysis Devices, cut-off 3.5 kDa, Thermo Fisher 
Scientific, Waltham, MA, USA). To ensure efficient dialysis, the buffer (PBS) was changed 3 
times and then the concentration was recorded again before further characterisation. 






Figure 2.3. Map of the phagemid vector pMECS (4510 bps) used for nanobody cloning. 
The different nanobodies were cloned into the PstI and NotI sites of the pMECS vector. The 
lac promoter/operator (Plac) and the PelB signal sequence are located at the N-terminus 
whereas the HA tag, His6 tag and the gene III of M13 phage lie at the C-terminus of the 











2.6.3 Nanobody expression and purification in WK6 E. coli strain 
The initial screening of all 54 nanobodies purified in TG1 E. coli strain was carried out by the 
research technician Ying Di. Based on her screening using flow cytometry, collagen-adhesion 
assay, GPVI-binding assay, NFAT assay with collagen stimulation conducted in either human 
platelets or the GPVI-EGFP DT40 cell line, three nanobodies were selected, expressed and 
purified from WK6 E. coli strain and further characterised in my PhD project. Nanobodies 
#14 (family 29) and #27 (family 1) were identified as good candidates for imaging and 
nanobody #21 (family 9) as a blocking nanobody. In non-suppressor WK6 E. coli strain 
(provided by VIB Nanobody Core), the amber stop codon which follows the His6 tag in the 
pMECS vector is read as a stop codon. Therefore the resulting nanobodies are not fused to 
protein III of the phage creating a pure preparation of nanobodies for further analysis. 
2.6.3.1 Generation of WK6 E. coli competent cells 
In order to transform WK6 E. coli with recombinant pMECS vector, the chemical (CaCl2) 
generation of competent bacteria cells was executed. Under sterile conditions, a 5 ml E. coli 
WK6 pre-culture (LB medium, no antibiotics) was prepared and incubated at 37 °C overnight 
with shaking at 200-250 rpm. 2 ml of the overnight culture was subcultured into 100 ml LB 
and incubated at 37 °C with shaking until an OD600 of 0.4 was reached. The culture was then 
incubated on ice for 5 min and centrifuged at 2,000 × g for 5 min at 4 °C. The bacterial pellet 
was resuspended with 20 ml ice-cold 75 mM CaCl2 containing 15% glycerol and incubated on 
ice for 5 min. The CaCl2 washing was repeated twice before the final resuspension in 4 ml ice-
cold 75 mM CaCl2 (15% glycerol). 100 μl of competent bacterial cells were aliquoted into 






2.6.3.2 Transformation of competent WK6 E. coli cells with recombinant 
pMECS vector 
In order to express the nanobodies cloned in pMECS vector into WK6 E. coli strain, the 
plasmid DNA was extracted from TG1 E. coli using the GeneElute Plasmid Miniprep kit 
under the manufacturer guidelines. Under sterile conditions, 1 μl of PMECS plasmid DNA 
was added into 100 μl of competent WK6 E. coli cells and incubated on ice for 30 min. The 
transformation by heat-shock was carried out by placing the tube into a 42 °C water bath for 
45 sec and then directly on ice for 2 min. Transformed cells were allowed to grow by adding 
400 μl of pre-warmed LB medium and incubating for 1 hour at 37 °C with shaking. WK6 E. 
coli harbouring the recombinant pMECS vector were plated on Ampicillin agar plates and 
incubated at 37 °C overnight before colony picking and pre-culture for nanobody expression 
and purification (as described above in TG1 E. coli strain). To increase the nanobody yield, 1 
L culture was prepared and the volumes of all the reagents were proportionally adjusted. In 
addition, 5 ml HisTrap HP (GE Healthcare, Bucks, UK) instead of 0.5 ml Zeba Spin 
Desalting columns were used for the nanobody elution. 
2.7 Nanobodies characterisation 
The purity of nanobodies was checked by Coomassie staining (InstantBlue Protein Stain, 
Expedeon, Cambridge, UK) of SDS-PAGE gel under reducing conditions. Western blot and 
anti-His6 tag secondary antibody confirmed the presence of nanobodies.   
In this section, only ELISA and flow cytometry will be described. The other assays used 






2.7.1 Enzyme-linked immunosorbent assay (ELISA) 
Binding of nanobodies #14, #21 and #27 (from WK6 E. coli) to recombinant monomeric and 
dimeric GPVI was tested using ELISA. The recombinant proteins used were: dimeric GPVI 
which corresponds to human GPVI D1, D2 domains, residues 21-203 fused to the Fc domain 
of IgG (GPVI-Fc) and monomeric GPVI which corresponds to the same residues as dimeric 
GPVI but is not fused to the Fc (mGPVI). The Fc domain was used as a negative control. All 
the recombinant proteins were provided by Dr Alex Slater (University of Birmingham, UK). 
Nunc MaxiSorp® micro-titer 96 well plates (Thermo Fisher Scientific, Waltham, MA, USA) 
were coated with 0.1 μM recombinant GPVI-Fc, mGPVI and Fc domain at 4 °C overnight. 
After 3x washing in PBS + 0.05% Tween (PBS-T), plates were blocked with filtered 3% BSA 
(in PBS) for 1 hour at RT. An extra well was coated with 3% BSA and was used as an 
additional negative control. 1 μM of each of the nanobodies, diluted in diluent blocking buffer 
(0.1 % BSA + 0.05% Tween), was then added to each well after being washed in PBS-T (3x). 
Following incubation with the nanobodies for 1 hour at RT with shaking, plates were washed 
again (5x) before adding the anti-His6 HRP conjugated (1/10,000) for the nanobody detection. 
The secondary antibody was left to incubate for 1 hour at RT with shaking followed by PBS-
T washing (5x) and addition of the 3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid 
Supersensitive ELISA Substrate for the visualisation of nanobody binding. The 
chemiluminescence reaction was stopped by the addition of 1 M H2SO4 and absorbance was 
measured at 405 nm with VersaMax microplate reader (Molecular Devices LLC, California, 
USA). 
To test nanobody binding, the ELISA assay was also performed on other recombinant GPVI 
constructs by Dr Ruben Barroso and Dr Yi Sun (University of Birmingham, UK): the 





Thr108) and the D2 domain (GPVI D2, Pro114-Thr203) of GPVI. The recombinant proteins 
contain a signal peptide, the GPVI sequence (full-length or truncated), followed by a CD4 
region and a His6 tag. The same construct, with the substitution of GPVI with another 
unrelated protein (CD200), was used as a negative control. The nanobodies were used at 300 
nM and then 1:3 serial dilution. Bound nanobodies were detected using anti-HA HRP 
conjugated secondary antibody (1/10,000). 
2.7.2 Flow cytometry 
Binding of nanobodies #14, #21 and #27 to GPVI in resting or CRP-XL and PAR1-activated 
platelets was evaluated using flow cytometry (BD Accuri C6 Flow Cytometer, BD 




 washed and rested platelets were diluted 
1/10 in PBS and simulated with 200 μM PAR1 peptide or 10 μg ml
-1
 CRP-XL when required. 
After incubated with agonists for 3 min, unstimulated and activated platelets were aliquoted 
(50 μl) and incubated with 1 μl of nanobodies (0.4 mg ml
-1
 = stock concentration of nanobody 
#14) for 30 min at RT. Firstly, all the nanobodies were diluted to the same concentration (0.4 
μg ml
-1
). To explain the lack of binding of nanobodies #21 and #27, 1 μl of the stock 
concentration of both nanobodies (1.9 mg ml
-1
 and 3.1 mg ml
-1
 for #21 and #27, respectively) 
was then added to 50 μl of platelets. Platelet activation was monitored by P-selectin exposure: 
unstimulated and stimulated platelets were incubated with 10 μl PE anti-human CD62-P (P-
selectin) antibody (1/40) for 20 min at RT in the dark. Detection of nanobodies was carried 
out using anti-His6 Alexa Fluor 647 conjugated (1/80) in both unstimulated and activated 
platelets. The secondary antibody was also used alone in unstimulated samples as the negative 
control. Following incubation (15 min, RT, in the dark), 500 μl of PBS was added to each 
sample and run by flow cytometry. Samples were gated and the positive fluorescence for P-





In the initial screening study of 20 nanobodies, anti-His6 HRP conjugated (1/500) and anti-
Mouse IgG Alexa Fluor 647 conjugated (1/500) were used for the detection of nanobodies, 
due to the lack of anti-His6 Alexa Fluor 647 conjugated. In addition, nanobodies were diluted 
at the final concentration of 1 μg ml
-1
 and GPVI binding was not investigated in PAR1-
activated platelets. 
2.8 Generation of Alexa Fluor 647 conjugated SNAP-tagged nanobody #14  
2.8.1 Cloning  
To reclone the nanobody #14 gene from pMECS to the SNAP-tag vector, the restriction sites 
BamHI and Xhol were inserted at the ends of the nanobody sequence. In the first round, the 
BamHI site (GGATCC) was inserted at the N-terminus of the nanobody gene using BamHI 
Forward and Reverse primers (annealing temperature 72 °C, Table 2.5) and Q5 site-directed 
mutagenesis kit (NEB, Hitchin, UK) under the manufacturer guidelines. 5 colonies of 
transformed 5-alpha competent E.coli cells (NEB, Hitchin, UK) were picked for DNA 
isolation (GeneElute Plasmid Miniprep kit) and verification by Sanger sequencing (Source 
Bioscience, Nottingham, UK) using BamHI Reverse primer. This first step was carried out by 
Dr Alex Slater (University of Birmingham, UK). Once confirmed as the right insertion, the 
nanobody #14 with BamHI site at the N-terminal was used as a template for the insertion of 
the Xhol site (CTCGAG) at the C-terminal using Xhol Forward and Reverse primers 
(annealing temperature 59 °C, Table 2.5) and Q5 site-directed mutagenesis kit. Upon 
sequencing validation using BamHI Forward primer, both nanobody #14 gene (1 μg), 
containing BamHI and Xhol restriction sites, and pSNAP-tag (T7)-2 vector (1 μg, NEB, 
Hitchin, UK) were digested with 1 μl of BamHI and Xhol restriction enzymes (NEB, Hitchin, 
UK) simultaneously (double-digestion) using 5 μl of Cutsmart buffer (NEB, Hitchin, UK) for 





using the GeneJet Gel Extraction kit (Thermo Fisher Scientific, Waltham, MA, USA). Once 
purified, the nanobody #14 and SNAP-tag vector were ligated using T4 DNA ligase 
(Promega, Madison, WI, USA) with 1:3 vector:insert ratio. The reaction was incubated for 10 
min at RT and overnight at 4 °C and then used to transform competent XLIB E. coli cells. The 
DNA was extracted from 5 different colonies and sent off for Sanger sequencing using the 
T7F primer provided by Source Bioscience (Nottingham, UK). 2 colonies resulted to contain 
the right insertion of the nanobody #14 into the SNAP-tag vector. 

















2.8.2 Expression and purification of SNAP-tagged nanobody #14 
In the SNAP-tagged nanobody #14 cloning, the N-terminal PelB leader, which is used for the 
purification of the nanobody from the periplasm of E. coli, was deleted whereas the His6 tag, 
used for the detection, was maintained. Therefore, the procedure used for the nanobody 
expression and purification is slightly different. 
Briefly, each positive colony was grown in 20 ml LB medium supplemented with 100 μg ml
-1
 
Ampicillin at 37 °C overnight with shaking at 200-250 rpm. 20 ml of the pre-culture was then 
added to 1 L LB medium and incubated at 37 °C for 2-5 hours with shaking until an OD600 of 
0.6 was reached. The culture was induced by the addition of 1 mM IPTG at 30 °C for 5 hours 
with shaking and then centrifuged at 3,000 × g for 20 min. The bacterial cell pellet obtained 
was resuspended in 25 ml PBS + 1mM DTT. Bacteria were then sonicated (7 x 10 sec) to 
induce cell lysis, centrifuged at 15,000 × g for 30 min and the supernatant, which contains the 
pool of proteins, was filtered and run through a fast protein liquid chromatography system 
(FPLC, ÄKTA Start chromatography, GE Healthcare, Bucks, UK) for the nanobody 
purification (with the technical help of Dr Alex Slater, University of Birmingham, UK). The 
proteins were loaded onto a 5 ml HisTrap HP (GE Healthcare, Bucks, UK) and the SNAP-
tagged nanobody was eluted by applying a gradient of 0-500 mM imidazole. Samples of the 
cell lysate for total protein and flow-through liquid were collected to verify that the SNAP-
tagged nanobody did bind to the beads and did not flow through the column. The purity of the 
SNAP-tagged nanobody #14 was checked by Coomassie staining of SDS-PAGE gel. The 
fractions 7 and 8 of the eluent, which showed the highest purity, were further dialysed at 4 °C 
against PBS or PBS + 1 mM DTT (Slide-A-Lyzer MINI Dialysis Devices, cut-off 3.5 kDa, 
Thermo Fisher Scientific, Waltham, MA, USA) to remove the imidazole. The SNAP-tagged 





30 kDa) up to 50 μM for direct labelling of the SNAP-tag with Alexa Fluor 647 in vitro 
(SNAP-Surface Alexa Fluor 647 labelling kit, NEB, Hitchin, UK). Briefly, 50 μM SNAP-
tagged nanobody #14 was incubated with 250 μM SNAP-tag substrate (dissolved in DMSO) 
and PBS + DTT (50 mM) in the dark for 30 min at 37 °C. The fluorescently labelled 
nanobody was then run on an SDS-PAGE gel and detected using the Odyssey fluorescence 
detection system. The rest of the sample was stored at -20 °C. 
2.9 Statistical analysis 
All the data presented in this thesis were expressed as means ± standard error of the mean 
(SEM). Data were analysed using GraphPad Prism 8 software (GraphPad Software, Inc., La 
Jolla, CA, USA). Significant differences were determined using unpaired two-tailed Student’s 
t-test or one-way Analysis of variance (ANOVA) with Tukey’s post-hoc test for multiple 


















Platelet GPVI receptor organisation: comparison of 
different clustering methods for the analysis of 












The main aim of this Chapter was to map the localisation and assess the clustering of GPVI in 
the human PM in platelets adhered to an immobilised substrate monolayer using a 
combination of dSTORM imaging and cluster analysis. To explore this, we compared the 
most widely used clustering methods to identify and develop the appropriate analysis for the 
quantitation of clusters on fibrous structures such as collagen or globular clusters such as 
those induced by CRP-XL, fibrinogen and fibrin. This is relevant since different cluster 
methods may generate different results, restricting the validity of the biological findings to the 
specific analysis used.  
3.2 Introduction  
GPVI spatial organisation is tightly regulated at the platelet plasma membrane to orchestrate 
the signalling transduction and prevent improper activation. Higher-order clustering has been 
proposed as a putative mechanism to facilitate and intensify the signalling required for platelet 
activation (Horii et al., 2006, Jung et al., 2009, Poulter et al., 2017, Smethurst et al., 2007). 
While wide-field and confocal microscopy techniques enable us to map the location of surface 
receptors and obtain information relative to the colocalisation with other signalling mediators, 
visualisation by conventional microscopy of receptor clusters has been hindered by the 
diffraction limit of light which restricts the resolution to ~200 nm. The SMLM technique 
dSTORM allows up to 10x increased resolution (10-30 nm in xy) over conventional 
microscopy, providing new insights into the structure of multi-molecular signalling 
complexes at the single molecule level (Owen et al., 2010, Pollitt et al., 2014, Poulter et al., 
2017). Despite numerous advantages due to the relatively easy setup and the use of 
conventional fluorescent probes to label the target protein (Dempsey et al., 2011, Heilemann 





acquisition and reconstruction of the final super-resolved image. In addition, whereas 
conventional fluorescence microscopy generates a series of pixels reflecting the localisation 
of fluorophores, a dSTORM image is essentially a high-density map containing the spatial 
localisation of all the detected molecules within the specimen, with the precision of the 
localisation varying depending on several factors such as fluorophore brightness. Indeed, the 
further level of complication of a dSTORM imaging experiment is represented by the 
complex and time-consuming data analysis. A number of quantitative algorithms have been 
applied to the pointillistic datasets to extract valuable details relative to the pattern, 
topography or oligomerisation of super-resolved cellular components, including membrane-
bound proteins (Nicovich et al., 2017). These algorithms, usually referred to as cluster 
analyses, aim to identify the presence of clusters based on the statistics of the spatial 
localisation datasets (Owen et al., 2010, Pageon et al., 2016, Sengupta et al., 2011). 
Alternatively, they allow to extract quantitative cluster information once the optimal free 
parameter settings, which are chosen by the user (e.g. density threshold and distance/radius), 
have been applied (Levet et al., 2015, Owen et al., 2010, Pageon et al., 2016). Ripley’s K-
function (Ripley, 1977), DBSCAN (Ester et al., 1996) and Voronoї tessellation (Andronov et 
al., 2016, Levet et al., 2015) are the most commonly used clustering approaches applied to the 
analysis of SMLM data (Endesfelder et al., 2013, Nan et al., 2013, Owen et al., 2010, Pageon 
et al., 2016, Rossy et al., 2013, Scarselli et al., 2012, Williamson et al., 2011). All these 
cluster analyses rely on the local point density and combine individual localisations, with an 
above-threshold density and within a specific search radius, into clusters. However, despite 
being similar in principle, they diverge in many aspects. Ripley’s K-function is a spatial 
statistical algorithm which compares the point pattern distribution of interest with a random 





given distance (Ripley, 1977). DBSCAN and Voronoї tessellation are density-based 
algorithms which differ in some ways. DBSCAN uses a single length scale to estimate the 
local density (Ester et al., 1996) whereas the tessellation relies on the polygonal areas 
(multiple distance scales) of the Voronoї diagram to do so (Andronov et al., 2016, Levet et al., 
2015). In addition, only last year a clustering method based on Voronoї tessellation was 
developed for the analysis of 3D SMLM data (Andronov et al., 2018). Ripley’s K-function, 
like DBSCAN, uses a single length scale when clustering but is limited by the assumption of 
cluster size and shape (circular). Instead, DBSCAN does not suffer from this limitation and 
may be better than Ripley’s K-function at separating close clusters with uniform density and 
low background noise (Deschout et al., 2014a).  
However, all the clustering methods described are limited by user-specified parameters such 
as density threshold and distance, which are difficult to be defined especially when analysing 
heterogeneous samples. A model-based Bayesian method, which takes into account the 
localisation precision, has been validated for the automatic selection of the free parameters 
(Rubin-Delanchy et al., 2015). However, this model is limited by several assumptions which 
are not suitable for many dSTORM datasets. Otherwise, to avoid user bias, automatic 
thresholding can be defined by the average density (Levet et al., 2015) or Monte-Carlo 
simulations (Andronov et al., 2016). In addition, putative multiblinking artifacts represent 
another factor to consider which, if not corrected, can interfere with the reliability of the 
quantitative analysis outcomes (Annibale et al., 2011, van de Linde et al., 2010). Therefore, it 
is clear that, despite being valuable quantitative instruments, cluster analyses are characterised 
by substantial limitations and differences between each other which need to be considered in 





Application of Ripley’s K-function-based cluster analysis in platelets has been demonstrated 
by Pollitt et al. (2014) and Poulter et al. (2017) in the characterisation of CLEC-2 and GPVI 
clusters at the plasma membrane (Pollitt et al., 2014, Poulter et al., 2017). In particular, 
Poulter et al. (2017) proposed the existence of different degrees of GPVI clustering induced 
by different collagenous substrates and fibrinogen, giving rise to the question as to whether 
Ripley’s K-function is the appropriate method to analyse different shapes of clusters (Poulter 
et al., 2017). DBSCAN was implemented in the investigation of the role of GPVI inhibitors 
on receptor clustering induced by platelet adhesion to CRP-XL (Onselaer et al., 2019). 
Furthermore, DBSCAN allowed determination of whether the inhibitory effect of the 
adenosine receptor A2A on collagen-induced platelet activation was dependent on the 
impairment of GPVI clustering in platelets (Clark et al., 2019). To our knowledge, the 
application of Voronoї tessellation has not been reported in platelets. 
In this Chapter, a head-to-head comparison of Ripley’s K-function, DBSCAN and 
tessellation-based cluster analyses has been carried out to explore GPVI cluster formation in 
platelets adhered to fibrous collagen at different time points. In collaboration with the image 
analyst Dr Jeremy Pike (University of Birmingham, UK), we then developed a custom-made 
two-layer DBSCAN-based cluster analysis for the assessment of GPVI nanoclusters only 
along the fibrous structure of collagen. A single-layer DBSCAN was finally employed to 
compare the collagen-induced clustering degree with that elicited by other GPVI ligands such 









3.3.1 dSTORM imaging allows visualisation of GPVI cluster formation in 
platelets interacting with different immobilised substrates 
We have investigated the spatial distribution of GPVI receptors in platelets that have been 
spread on Horm collagen (fibrillar type I collagen), CRP-XL, fibrinogen and fibrin using a 
combination of TIRFM and dSTORM imaging. Washed platelets, labelled for F-actin and 
Pan-GPVI, were allowed to adhere and spread on the immobilised substrates for 1 h and 
platelet spreading and cluster formation were visualised by TIRFM (Fig. 3.1i, ii). All the 
substrates were able to support platelet spreading (Fig. 3.1i). The diffraction-limited imaging 
showed the presence of GPVI clusters on all the substrates investigated, although it is not 
sensitive enough to detect small changes in clustering. Indeed, non-clustered GPVI or small 
clusters appeared to be poorly resolved (Fig. 3.1ii). With a lateral optical resolution of ~20 nm 
(Nicovich et al., 2017), dSTORM enabled mapping the nanoscopic organisation of GPVI in 
platelets adhered to the different substrates. GPVI coalesced to form different types of clusters 
in accordance with the nature of the substrates (Fig. 3.1ii, iii). The TIRFM images show how 
GPVI lined up along Horm collagen fibres (Fig. 3.1Aii) whereas the reconstructed dSTORM 
images allowed us to super-resolve the receptor clustering on fibrous collagen and highlight 
the presence of small clusters in platelet areas where there are no visible collagen fibres (Fig. 
3.1Aiii, iv). Discrete clusters were also detected in platelets spread on CRP-XL, the GPVI-
specific ligand, and appeared to be round oligomers with no specific distribution pattern over 
the platelet surface (Fig. 3.1Bii). dSTORM enabled the visualisation of a mixed population of 
small and big clusters of GPVI receptors bound to CRP-XL (Fig. 3.1Biii, iv). Fibrinogen also 
induced the formation of globular clusters which appear to be similar to those found on CRP-





induced clusters appear to be a mixture of circular and slightly elongated oligomers (Fig. 
3.1Diii, iv). Therefore, it became clear that quantitative methods were needed to extract key 
clustering information from the dSTORM images to describe GPVI organisation at the 












Figure 3.1. TIRFM and dSTORM imaging of GPVI in platelets adhering to immobilised 
Horm collagen, CRP-XL, fibrinogen and fibrin. Human washed platelets, pre-labelled with 
1G5-Fab (2 μg ml
-1
) for Pan-GPVI, were spread on a Horm collagen (A, 10 μg ml
-1
), CRP-XL 
(B, 10 μg ml
-1
), fibrinogen (C, 100 μg ml
-1
) and fibrin (D, generated as described in Materials 
and Methods) monolayers for 1 h at 37 °C and secondary stained with anti-mouse Alexa Fluor 
647 conjugated. F-actin was labelled with Alexa Fluor 488 phalloidin. GPVI distribution was 
assessed by TIRFM and cluster formation was visualised by dSTORM. The whole FOV (i, ii, 
iii) and single platelet (iv) images are representative of three independent experiments. In 







3.3.2 GPVI clustering increases along collagen fibres in spread platelets  
Although dSTORM imaging provided evidence of the ability of GPVI to form oligomers 
specifically along collagen fibres, only quantitative analysis enabled comparison of receptor 
clustering on and off fibrous collagen and investigate whether it is sustained over time. 
TIRFM and dSTORM imaging showed the same organisation of GPVI at the platelet surface 
as that visualised in the previous images after 1 h and 3 h of spreading (Fig. 3.2Ai, ii). Here, 
we adopted a custom-made algorithm based on the Ripley’s K-function run in MATLAB 
(Owen et al., 2010) to quantitatively assess GPVI clustering over time. 2 x 2 µm
2 
non-
overlapping ROIs were placed within the boundary of the platelet either in areas where the 
collagen fibre was visible or regions where there was no observable fibre. For each ROI, 
indicated by the red box area (Fig. 3.2Aii), the cluster analysis was performed and is 
represented by the two-dimensional (2D)-cluster heat map of individual spots (Fig. 3.2Aiii). 
Setting a radius of 50 nm within the MATLAB code, each molecule was given a value based 
on its degree of clustering, calculated by the unitless measure of clustering L(r) where red 
indicates high levels [L(r)>150] of clustering and blue no clustering [L(r)=0] (Fig. 3.2Aiii). 
Clusters are shown in the binary image as defined by the threshold L(r)=100 (Fig. 3.2Aiv). 
Collagen induced a higher degree of GPVI clustering along the fibres than that expected from 
a random distribution. These clusters showed sustained size, number of localisations per 
cluster, number of clusters and density within clusters over time (Fig. 3.2B, C, D, E). Cluster 
formation was also detected in off-collagen areas, although they were 27% smaller and 
contained more than 50% fewer localisations per cluster than those aligned along the fibres 
(Fig. 3.2B, C). The number of clusters out of the collagen-rich areas were 29% higher than on 
collagen after 3h of spreading (Fig. 3.2D), likely due to fibrinogen released from the granules 





In addition, the number of clusters did not change, something which might have been 
predicted as there is a limited number of GPVI binding sites on collagen. However, cluster 
density also increased along fibrillar collagen over time, although this was not statistically 
significant, probably due to the high variability between different donors and the minimum 
number of replicates.  
To confirm the robustness of our data and conclusion, we have run the cluster analysis on a 
small dataset (10 ROIs) changing different parameters such as the cluster size (radius=25 nm 
and 100 nm) and the threshold (50 and 150) within the MATLAB code to verify whether they 
can influence the outcome. The cluster density was used to evaluate the putative change in 
clustering. Setting the radius to 25 nm or 100 nm, GPVI cluster density still increased along 
collagen fibres and over time (Fig. 3.3A, B, C, D). In the same way, maintaining a 50 nm 
radius, but adjusting the threshold value to 50 or 150 did not change the result (Fig. 3.3E, F, 
G, H). Therefore, despite the absolute values being different due to the different settings in the 
MATLAB code, the trend in the GPVI cluster density on and off collagen fibres was 
maintained. Overall, these data suggest that, independently of the clustering scale applied, 
Horm collagen causes specific oligomerisation of GPVI along the fibres characterised by 




















Figure 3.2. Ripley’s K-function-based cluster analysis of GPVI dSTORM imaging in 
platelets spread on Horm collagen for 1 h and 3 h. Human washed platelets spread on a 
Horm collagen (10 µg ml
-1
)-coated surface for 1 h and 3 h were pre-incubated with 1G5-Fab 
(2 µg ml
-1
) for GPVI labelling, secondary stained with anti-mouse Alexa Fluor 647 
conjugated and imaged by TIRFM (Ai). The dSTORM images of the same cells illustrate the 
increased resolution obtained by this cutting-edge technique (Aii). The first panel of images 
refers to the immunolocalisation of GPVI after 1h of spreading whereas the distribution of 
GPVI in platelets spread for 3 h is shown in the second set of images. 2 x 2 µm
2
 square ROIs 
were taken inside platelets and on and off collagen fibres. Heat maps of the clusters (radius= 
50 nm) in the ROI (red box area) are shown in the images Aiii. Binary maps of the clusters 
following thresholding [L(r)=100] of the heat map show clustering of GPVI along the 
collagen fibres (Aiv). Quantification of GPVI clustering on and off collagen fibres is reported 
in the histograms, with each point corresponding to the mean  ± SEM from three independent 
experiments: cluster area (B), number of localisations per cluster (C), number of clusters (D) 
and density within clusters (E). In total, 48 and 43 ROIs were analysed on and off collagen 
fibres after 1 h of spreading (9 FOVs) whereas 61 and 59 ROIs were measured on and off 
collagen fibres after 3 h of spreading (10 FOVs), respectively. Significance was measured 
using one-way ANOVA with Tukey’s multiple comparisons: a significance of P < 0.05 is 























Figure 3.3. Comparison between different radii and thresholds within Ripley’s K-
function-based cluster analysis applied to GPVI dSTORM datasets. A small GPVI 
dSTORM dataset (10 ROIs) was used to test different clustering parameters within the 
Ripley’s K-function algorithm. The cluster heat maps of a representative ROI along collagen 
fibres, with different cluster size (radius= 25 and 100 nm) selected in the MATLAB code, 
show the degree of clustering where red represents the highest value (A, C). Binary images of 
the clusters, obtained applying a threshold of L(r)=100 to the heat maps, illustrate the GPVI 
oligomers along fibrous collagen (A, C). GPVI cluster analysis, with a standard cluster size 
(radius=50 nm) and a lower and higher value of threshold [L(r)=50 and 150] than the standard 
one [L(r)=100] is shown in E, G. The quantitative analysis of GPVI dSTORM images shows 
that the receptor cluster density rises along collagen fibres and over time, independently of the 
clustering parameters selected in the MATLAB code (B, D, F, H). No statistical analysis was 























3.3.3 Comparison between Ripley’s K-function and SR-Tesseler for the 
study of GPVI clustering on fibrous collagen 
Ripley’s K-function-based cluster analysis has been demonstrated to be powerful in 
quantifying cluster parameters in other cell types, particularly T cells (Owen et al., 2010, 
Rossy et al., 2013, Williamson et al., 2011) and above in discriminating GPVI receptor 
organisation on and off collagen fibres. However, quantitation of receptor clustering along the 
fibrous structure of the Horm collagen was limited by the adoption of square ROIs, which 
also included the localisations not in direct contact with visible fibres in the final quantitative 
analysis. To overcome this limitation, we applied a modified approach based on the previous 
Ripley’s K-function cluster analysis to the same dSTORM dataset. GPVI clusters only along 
visible and obvious collagen fibres within each ROI were manually selected in the binary map 
and only those were further analysed in Excel (highlighted in red in Fig. 3.4Aiv). This 
allowed us to assess GPVI oligomerisation specifically localised along collagen fibres and 
verify whether the clustering changed in accordance with the spreading duration. The 
exclusion of localisations off-collagen fibres within each ROI did not affect GPVI cluster area 
and density values (Fig. 3.4B, C) in comparison with the previous result. This approach also 
confirmed the trend followed by GPVI clustering over time: the cluster area and density were 
maintained over the 3 h time frame studied (Fig. 3.4B, C). Notably, the density within clusters 
showed an upward trend over time, but again this result was not statistically significant due to 
the variability between the different replicates. 
A further assessment of GPVI clustering aligned along collagen fibres was obtained 
employing SR-Tesseler (Levet et al., 2015). The Voronoї diagram computed on the dSTORM 
GPVI images shows the segmentation of the data points into separate polygons (Fig. 3.4Di) 





colour-code in the density map (Fig. 3.4Dii). GPVI data points along visible collagen fibres 
were first isolated within the whole FOVs using a density factor δ of 2 and a minimum area of 
1μm x 1μm to generate distinct objects (Fig. 3.4Diii). The detected objects were then 
thresholded by density factor δ of 0.5 and minimum number of points of 10 to group the 
isolated points into individual clusters (Fig. 3.4Div). These parameters were deemed to be the 
most suitable for the segmentation and clustering of GPVI on Horm collagen after running 
different density factors δ on a small dataset (δ = 1, 1.5 and 2 for the I level and δ = 0.125, 
0.25 and 0.5 for the II level). In accordance with the Ripley’s K-function analysis, SR-
Tesseler showed sustained GPVI cluster density along collagen over the 3 h time frame 
investigated (Fig. 3.4E). In contrast to Ripley’s K-function, the cluster area was slightly lower 
at 3 h comparing to 1 h, however, this difference was not statistically significant. Overall, as 
two different cluster algorithms have produced comparable results although being different in 
the absolute values, we can deduce that GPVI clustering on collagen fibres is maintained at a 























Figure 3.4. Cluster analysis of GPVI dSTORM imaging comparing Ripley’s K-function 
and SR-Tesseler. The same dSTORM datasets of previous experiments were analysed using 
the custom-made algorithm based on the Ripley’s K-function. A representative dSTORM 
image of a single platelet is shown in Ai. The cluster heat map of the ROI highlights the high 
degree of clustering along collagen (indicated in red, Aii). In the MATLAB code, the radius 
and threshold were set to 50 nm and 100, respectively. The clusters are shown in the binary 
image (Aiii) after thresholded the cluster heat map. Only clusters distributed along visible 
collagen fibres (highlighted in red, Aiv) were selected and analysed within each ROI. The 
quantitative analysis shows no significant difference in GPVI cluster area and density over 
time (B, C). dSTORM images of GPVI (whole FOVs) were processed using SR-Tesseler 
software. The Voronoї diagram shows the segmentation of the data points into polygonal 
regions (Di) whereas the molecular densities are represented by different colour-coded tiles in 
the density map (Dii). A density factor δ of 2 and minimum area of 1μm x 1μm were used for 
the object isolation (GPVI on collagen fibres, Diii) and density factor δ of 0.5 and minimum 
number of spots of 10 for the cluster segmentation (Div). The cluster area and density 
quantitation are reported in E and F. All the bars in the histograms represent the mean ± SEM 
from three individual experiments. In total, 9 and 10 FOVs for 1 h and 3 h of spreading, 
respectively, were analysed. Significance was measured using unpaired two-tailed t-test (P < 



















3.3.4 DBSCAN confirms sustained collagen-induced GPVI clustering over 
time 
To further validate our data, the DBSCAN algorithm (Ester et al., 1996) was employed to 
investigate GPVI cluster formation in platelets spread on fibrillar collagen for 1 h and 3 h. In 
contrast to SR-Tesseler, DBSCAN only considers a single length scale when grouping 
individual data points into clusters based on the local density. Here, to identify collagen-
induced GPVI clusters, the local density was defined by the search radius of 50 nm and 
minimum number of points of 10. These settings were chosen to sufficiently separate the 
prominent clusters on collagen fibres and limit the background noise. In the DBSCAN map, 
individual clusters are represented by different colours (Fig. 3.5Aii). DBSCAN-based cluster 
analysis demonstrated that GPVI cluster area and density remain constant after 3 h of 
spreading (Fig. 3.5B, C, D), in agreement with Ripley’s K-function and SR-Tesseler analyses. 
The cluster area and number of detections per cluster showed a tendency to rise proportionally 
with the spreading duration, but the variability between different platelet donors did not make 
the result statistically significant. In addition, the absolute values of cluster area and number 
of localisations per cluster appeared to be comparable to those extracted from the Ripley’s K-
function cluster analysis (Fig. 3.2B, C and 3.4B). Therefore, DBSCAN further supports the 










            
Figure 3.5. DBSCAN-based cluster analysis of GPVI dSTORM imaging in platelets 
spread on Horm collagen for 1 h and 3 h. The GPVI dSTORM localised detections within 
whole FOVs (Ai) were grouped into individual clusters (represented by different colours in 
Aii) by applying a single-level DBSCAN clustering method in KNIME setting a search radius 
of 50 nm and a minimum number of points of 10. The background spots are highlighted in 
black and are detected as non-clustered localisations by DBSCAN. The histograms show no 
significant difference in cluster area (B), density within clusters (C) and number of detections 
per cluster (D) over time. Each dot represents the mean ± SEM from three independent 
experiments. In total 10 and 11 FOVs for 1 h and 3 h of spreading, respectively, were 
analysed. Significance was calculated using unpaired two-tailed t-test (P < 0.05) with ns 






3.3.5 Two-layer DBSCAN cluster analysis permits the evaluation of GPVI 
nanoclustering formation on collagen fibres 
The DBSCAN-based cluster analysis employed previously allowed the overall GPVI 
clustering level in platelets adhered to immobilised collagen to be assessed, independently of 
the colocalisation with the fibres. To explore the nanoscale spatial organisation of GPVI 
receptors specifically distributed along visible collagen fibres, a custom-made 2-level cluster 
analysis based on DBSCAN (Ester et al., 1996) was implemented to first identify and isolate 
large clusters of GPVI on collagen (Level I; Fig. 3.6Aii) and then take those clusters and 
subdivide them into nanoclusters (Level II; Fig. 3.6Aiii). This approach allowed us to assess 
only GPVI nanoclusters associated with the visible collagen fibres, to identify any differences 
between the platelets spread for different durations. Before performing the cluster analysis, 
the acquired images were reconstructed in ThunderSTORM plugin for Fiji (Ovesný et al., 
2014) instead of the Nikon STORM analysis software used previously and post-corrected for 
multiblinking artifacts. The algorithm groups the localised data points into individual clusters 
(Level I) and nanoclusters (Level II), based on parameters relating to cluster radius (75 and 30 
nm for Level I and II, respectively) and points number (3 and 10 for Level I and II, 
respectively), with different clusters being represented by different colours (Fig. 3.6Aii, iiii). 
Quantitative analysis of the clusters showed no significant difference in cluster area between 1 
h and 3 h of spreading at either Level I or Level II clustering (Fig. 3.6B, C). Cluster density 
also remained constant over time (Fig. 3.6D, E). Notably, the area of nanoclusters aligned 
along collagen fibres (Level II clustering) appeared to be similar to the one extracted from the 
single-layer DBSCAN (Fig. 3.5B) and Ripley’s K-function analyses (Fig. 3.2B and 3.4B). 
Therefore, this finding further suggests that GPVI receptor-collagen interaction remains 











Figure 3.6. Two-level DBSCAN cluster analysis of GPVI dSTORM imaging in platelets 
spread on collagen for 1 h and 3 h. The acquired GPVI dSTORM images in platelets spread 
on collagen for 1 h and 3 h were reconstructed in ThunderSTORM plugin for Fiji and post-
correction was applied to minimise multiblinking artifacts (Ai). The localised data points were 
grouped into clusters using a 2-level cluster analysis based on DBSCAN (Aii, iii). In the 
Level I clustering, the large clusters corresponding to collagen fibres were segmented using a 
search radius of 75 nm and a minimum number of reachable detections of 3 (Aii). In the Level 
II clustering, these clusters were isolated and divided in nanoclusters using as search radius 
and minimum number of points of 30 and 10, respectively (Aiii). For both scales, quantitative 
analysis of GPVI dSTORM images shows the area and density of individual clusters within 
the whole FOV (B, C). Bars in the histograms represent mean ± SEM from three independent 
experiments. In total, 12 and 13 FOVs for 1 h and 3 h of spreading, respectively, were 
analysed. Significance was measured using unpaired two-tailed t-test P < 0.05: ns indicates 
non-significant difference. Scale bar: 5 μm (dSTORM images) and 1 μm (Level I and II 
cluster plots). The two-level analysis was designed and implemented by Dr Jeremy Pike, 





































3.3.6 GPVI clusters to the same extent on Horm collagen and CRP-XL in 
spread platelets 
To investigate whether the total extent of GPVI cluster formation induced by Horm collagen 
was independent of the other collagen receptor integrin α2β1, GPVI oligomerisation was 
quantitatively compared in platelets adhered to fibrous collagen and non-fibrous CRP-XL. 
The synthetic triple-helical peptide CRP-XL contains multiple and continuous GPO triplets, 
the specific GPVI-binding motif, enabling it to bind different GPVI receptors simultaneously 
and induce receptor clustering (Asselin et al., 1997, Morton et al., 1995). Platelets labelled for 
GPVI were allowed to spread on immobilised Horm collagen and CRP-XL for 1 h and cluster 
formation was monitored by dSTORM. As previously shown in Fig. 3.1, these two ligands 
induced different receptor organisations and clustering patterns, making the choice of the 
cluster analysis to adopt challenging. Since Ripley’s K-function was limited by the use of 
ROIs and objects on CRP-XL were difficult to be defined in SR-Tesseler due to their 
homogeneous distribution, single-layer DBSCAN turned out to be the best method to analyse 
the globular GPVI clusters formed on CRP-XL and compare them with those on Horm 
collagen. The local density, defined by the same search radius and number of points used 
previously (radius = 50 nm and minimum number of points = 10), allowed the segmentation 
of GPVI localisations into clusters marked by different colours (Fig. 3.7Aii). Quantification 
showed that GPVI oligomers induced by CRP-XL have the same properties of those triggered 
by platelet-collagen binding (Fig. 3.7B, C, D). The unchanged cluster area, density and 
number of localisations per clusters suggest that the contribution of integrin α2β1 to GPVI 
cluster formation on fibrous collagen is negligible. 
            





           
Figure 3.7. Single-layer DBSCAN cluster analysis of GPVI dSTORM imaging in 
platelets spread on Horm collagen and CRP-XL. Human washed platelets spread on Horm 
collagen (10 µg ml
-1
) and CRP-XL (10 µg ml
-1
) monolayers for 1 h were labelled for GPVI 
using 1G5-Fab (2 µg ml
-1
) before spreading and secondary stained with anti-mouse Alexa 
Fluor 647 conjugated. GPVI organisation was visualised by dSTORM in TIRF mode (Ai). 
Clustering was assessed by a single-layer DBSCAN cluster analysis where the search radius 
and the minimum number of detections were adjusted to 50 nm and 10, respectively. The 
clusters are highlighted in different colours and the background points in black (Aii). The 
mean ± SEM cluster area, density and number of localisations per clusters are reported in the 
histograms (B, C, D). In total, 12 FOVs for each condition from n=3 individual experiments 
were analysed. Unpaired two-tailed t-test was used to calculate the significance (P < 0.05): ns 






3.3.7 Comparison of GPVI clustering in platelets adhered to immobilised 
collagen, fibrinogen and fibrin 
Fibrinogen and its proteolytic product, fibrin, have recently been discovered to be novel 
ligands for GPVI (Alshehri et al., 2015a, Induruwa et al., 2018, Mammadova-Bach et al., 
2015, Mangin et al., 2018, Onselaer et al., 2017). Since GPVI clusters were also found at the 
platelet surface not in direct contact with visible collagen fibres, we hypothesized that soluble 
granule contents, including fibrinogen, released by adherent platelets may contribute to 
receptor oligomerisation through the ‘outside-in’ signalling. To address the question as to 
whether other GPVI ligands induce the receptor clustering to the same extent as collagen, we 
compared the nanoscopic GPVI organisation in platelets spread on immobilised Horm 
collagen, fibrinogen and fibrin. To verify the successful generation of fibrin (as described in 
Materials and Methods), platelets were allowed to adhere to a fibrinogen and fibrin-Alexa 
488-coated surfaces. The fibrinogen and fibrin monolayers (Fig. 3.8A, E) were then visualised 
by confocal microscopy to compare their localisation with that of adherent platelets (Fig. 
3.8C, G) and GPVI receptors (Fig. 3.8B, F). Fibrinogen inhomogeneously distributed 
throughout the surface due to the presence of aggregates within the fibrinogen preparation 
(Fig. 3.8A) which seem to overlap with the platelet surface and GPVI (Fig. 3.8B, C, D). 
Contrarily, fibrin formed well-defined polymeric structures (Fig. 3.8E) touching the platelet 












Figure 3.8. Confocal imaging of platelets adhered to fibrinogen and fibrin. Human 
washed platelets, pre-labelled with 1G5-Fab (2 μg ml
-1
) for GPVI, were allowed to spread on 
fibrinogen-Alexa 488 (100 μg ml
-1
) and fibrin-Alexa 488 (generated as described in Materials 
and Methods) monolayers for 1 h, secondary stained with anti-mouse Alexa Fluor 647 
conjugated and imaged by confocal microscopy. Fibrinogen and fibrin monolayers are shown 
in A and E whereas GPVI distribution is illustrated in B and F. The Reflection images 
demonstrate the presence of platelets (C, G). The Merge images highlight the localisation of 
platelets and GPVI expressed at the cell surface relative to the fibrinogen/fibrin monolayers 
(D, H). For each condition, 5 random FOVs were acquired using confocal microscopy. The 















dSTORM combined with a single-layer DBSCAN-based clustering method enabled the 
visualisation and quantitation of the different types of clusters (indicated by different colours) 
induced by Horm collagen, fibrinogen and fibrin (Fig. 3.9Ai, ii). The clusters formed on 
fibrinogen were characterised by a circular shape (Fig. 3.9Aii, first panel); on fibrin there was 
a mixture of circular and some slightly elongated clusters (indicated by arrows in Fig. 3.9Aii, 
second panel) whereas on the Horm collagen there were continuous clusters colocalising with 
visible collagen fibres and round clusters outside of the fibres (Fig. 3.9Aii, third panel). In 
addition to the shape, clusters formed on Horm collagen also slightly differed in size from 
those induced by fibrinogen: in platelets adhered to collagen, GPVI clusters (which include 
clusters both on and off visible collagen fibres) were 20% smaller overall than those in 
platelets spread on fibrinogen (Fig. 3.9B). In addition, fibrinogen caused the fusion of larger 
clusters than fibrin (40% increased cluster area, Fig. 3.9B) characterised by ~60% more 
localisations per cluster (Fig. 3.9D). No significant difference between clustering induced by 
Horm collagen and fibrin was found (Fig. 3.9B, C, D). In addition, the density within clusters 
did not change in platelets spread on all the substrates investigated (Fig. 3.9C). Taken 
together these data suggest that, when analysed using DBSCAN at one length scale, 
fibrinogen induces the formation of the largest clusters, however, cluster density remains the 
















Figure 3.9. Single-level DBSCAN cluster analysis of GPVI dSTORM imaging in platelets 
adhered to Horm collagen, fibrinogen and fibrin. Human washed platelets were spread on 
a Horm collagen (10 µg ml
-1
), fibrinogen (100 μg ml
-1
) and fibrin (generated as described in 
Materials and Methods) monolayers for 1 h, labelled for GPVI (using 1G5-Fab, 2 µg ml
-1
) 
and secondary stained with anti-mouse Alexa Fluor 647 conjugated. A single-level DBSCAN 
cluster analysis was applied to the reconstructed dSTORM images (Ai) to evaluate cluster 
formation on different substrates. Representative cluster plots are shown in Aii: individual 
clusters are identified by different colours whereas the background is highlighted in black 
using a search radius of 50 nm and a minimum number of spots of 10 within the analysis. 
Elongated clusters formed on fibrin are indicated by black arrows (Aii, third panel). 
Quantitative cluster analysis of GPVI on Horm collagen, fibrinogen and fibrin is shown in the 
histograms (B, C, D) with each point representing the mean ± SEM from three individual 
experiments. In total, 12 FOVs for each condition were analysed. Statistical analysis was 
performed using one-way ANOVA with Tukey’s multiple comparisons, setting the 
significance to P < 0.05. Non-significant difference is indicated by ns. Scale bar: 5 μm 


























GPVI is the most important signalling collagen receptor expressed at the surface of platelets. 
It has been proposed that clustering of GPVI dimers offers a second level of control for GPVI 
signalling by increasing avidity for collagen and bringing signalling molecules into close 
proximity (Poulter et al., 2017). Furthermore, the recent discovery of additional agonists for 
GPVI such as fibrinogen and fibrin (Alshehri et al., 2015a, Induruwa et al., 2018, 
Mammadova-Bach et al., 2015, Mangin et al., 2018, Onselaer et al., 2017) suggests that 
receptor oligomerisation may be not restricted to the collagen stimulus. Therefore, it appears 
evident that receptor clustering may represent a critical target mechanism to modulate GPVI-
mediated platelet responses and understanding GPVI clustering at the nanoscale will be useful 
in directing the potential mode of action of future therapies. 
In this Chapter, a combination of TIRFM and dSTORM imaging techniques has allowed us to 
explore the nanoscale organisation of GPVI receptors at the platelet surface using 1G5-Fab 
which binds both monomeric and dimeric GPVI (Al-Tamimi et al., 2009). TIRFM highlighted 
the presence of continuous clusters along collagen fibres but failed to resolve small clusters or 
clusters which appeared more randomly distributed such as those formed on non-fibrous 
CRP-XL, fibrinogen and fibrin. With its high spatial resolution (~10-30 nm in xy), dSTORM 
is able to localise single molecules and, in combination with cluster analysis, extract 
quantitative information (e.g. cluster size and molecular density). There has been substantial 
recent work investigating different types of cluster analysis for SMLM (Nicovich et al., 2017) 
and it has become clear that different algorithms may generate different results. Therefore it is 
important to verify the clustering of GPVI using different approaches to determine the 
robustness of our data and conclusions. This has also allowed us to identify the advantages 





employ in accordance with the specific cluster structures in our future work. Ripley’s K-
function-based analysis, firstly described by (Owen et al., 2010), has previously been applied 
to platelet receptors by (Pollitt et al., 2014) and (Poulter et al., 2017). This cluster analysis 
permits the relative quantitative comparison of receptor cluster size, density, number of 
localisations per cluster and number of clusters. However, it is restricted to square ROIs 
placed by the user in platelet areas containing both collagen fibres and random surface regions 
outside the fibres. The use of ROIs introduces the problem of user bias in terms of where the 
ROIs are placed as well as restricts the analysis towards the centre of the cell. ROIs must be 
completely contained within the boundaries of the cell so not to introduce cluster bias and as 
platelets tend to be round when spread, areas towards the periphery of the cell are not able to 
be analysed. Nevertheless, using this method we demonstrated that the receptor cluster area, 
density and number of localisations per cluster all increase along collagen fibres in 
comparison with platelet areas where the collagen is not visibly present. This is in line with 
the ultra-structure of the triple-helical collagen which would potentially induce the binding of 
multiple GPVI receptors to consecutive molecules of tropocollagen and facilitate receptor 
clustering (Herr and Farndale, 2009). Although the cluster density increased along collagen 
fibres, this result was not statistically significant. This may be due to the high variability 
between platelets from the three different donors and suggests that the number of replicates 
may need to be increased to address this. 
All the clustering parameters investigated (size, density, number of clusters and number of 
localisations per cluster) were sustained over time, suggesting that, once GPVI is bound to 
collagen and clustering is induced, no additional receptors are recruited or lost after the initial 
spreading has taken place. Round clusters were also found randomly dispersed throughout the 





localisations per clusters in comparison with the receptor clusters colocalising with the 
collagen fibres. These small clusters may represent GPVI receptors which have bound to very 
small fibrils or non-fibrous collagen not visible by light microscopy as Horm collagen is 
prepared from equine tendons and, although it is predominantly type I fibrils (95%), it may 
contain traces of other collagens e.g. type III collagen (5%) (Favaloro, 2000). They could also 
be GPVI clusters on fibrinogen released from the granules of activated platelets. 
Alternatively, they could represent receptors that are not bound to ligand but may appear as 
small clusters due to the repeated blinking of the fluorescent dye during imaging, a process 
which can be influenced by the buffer used to image the sample (Annibale et al., 2011, van de 
Linde et al., 2010).  
However, the limitation of this analysis method is based on two different aspects: the 
adoption of user-specified parameters such as radius and threshold and user-defined square 
ROIs which do not adapt to the elongated structure of collagen fibrils and would also include 
localisations outside the fibres. Running the cluster analysis on the single-molecule datasets 
using different radii and thresholds confirmed the increase in GPVI clustering induced by 
fibrous collagen. The second point was addressed by selecting and analysing only GPVI 
clusters distributed along collagen fibres and comparing them at different spreading times. 
This allowed us to more accurately investigate whether collagen-induced GPVI clustering is 
sustained over time, based on the hypothesis that it may contribute to the maintenance of 
signalling required for platelet activation (Poulter et al., 2017). This approach confirmed the 
previous finding, demonstrating that GPVI cluster area and density remains steady over the 3 
h time period studied.  
Ripley’s K-function has been shown to be a powerful clustering method in a variety of 





Ripley’s K-function would not be the ideal cluster analysis for the assessment of elongated 
clusters induced by collagen fibres, since it is based on the assumption of cluster size/shape 
(circular clusters) and homogeneous point pattern distribution (Ripley, 1977). Indeed, 
extensions of the function have been developed for the detection of spatial molecular 
complexes in inhomogeneous populations (Baddeley et al., 2000). In light of these 
considerations, alternative algorithms such as Voronoï tessellation (Levet et al., 2015) and 
DBSCAN (Ester et al., 1996), which do not take into account the molecular organisation, 
were explored. Both clustering methods generated comparable results with Ripley’s K-
function. Voronoï tessellation allowed the isolation and quantification of GPVI clusters only 
along collagen fibres. However, the same free parameters successfully selected GPVI clusters 
in some images but failed in others. This may be the reason for the reduced cluster area in 
platelets spread on collagen for 3 h in comparison with the earlier time point investigated, 
although the difference was not statistically significant. Ripley’s K-function and DBSCAN, 
using a single length scale instead of polygonal ‘cells’, were better than Voronoï tessellation 
in separating tight clusters such as those formed on collagen fibres. Indeed, the absolute 
values of cluster size calculated by Ripley’s K-function and DBSCAN were similar but much 
lower than those generated by SR-Tesseler.  
However, when the DBSCAN-based analysis was extended to the whole FOV it was not ideal 
for the quantitation of GPVI clusters only along collagen fibres. To address this, a two-step 
DBSCAN-based cluster analysis was developed and then validated on all the GPVI dSTORM 
datasets. This method successfully marginalised all the large clusters formed on collagen 
fibres and then segmented the selected clusters into nanoclusters, allowing accurate 
quantitative comparisons at the nanoscale level. Multiblinking artifacts can result in the 





in unreliable results (Annibale et al., 2011, van de Linde et al., 2010). To face this drawback, 
the dSTORM images were post-corrected for multiblinking artifacts before performing the 
two-layer analysis. This method demonstrated that the area and density of GPVI nanoclusters 
do not change over time, confirming the outcome of the previous methods investigated. In 




 in size which is comparable to the 
absolute values of cluster area extracted by Ripley’s K-function and one-layer DBSCAN. This 
validated cluster analysis for fibrous structures will be employed to answer a variety of 
biological questions in Chapter 4. 
GPVI formed circular clusters in platelets adhered to CRP-XL, fibrinogen and fibrin. To 
compare these circular clusters with the elongated ones induced by collagen and extract 
clustering information, we used one-step DBSCAN analysis. We found that CRP-XL induces 
the same clustering degree of that triggered by collagen, suggesting that the adhesive receptor 
integrin α2β1, which also binds to collagen in close proximity to GPVI (Herr and Farndale, 
2009), does not significantly contribute to GPVI clustering. This is in accordance with Poulter 
et al. (2017) who demonstrated that the blocking anti-α2β1 antibody Gi9 did not impair 
platelet spreading and dimeric GPVI cluster formation on Horm collagen (Poulter et al., 
2017).  
Immobilised fibrinogen and fibrin were also able to support GPVI clustering in line with 
recent findings showing that both ligands bind to and activate GPVI in human platelets 
(Alshehri et al., 2015a, Induruwa et al., 2018, Mammadova-Bach et al., 2015, Mangin et al., 
2018, Onselaer et al., 2017). This suggests that receptor clustering may be a critical activatory 
mechanism in all the steps of thrombus formation from the initial platelet adhesion to 
thrombus growth and stabilisation. Furthermore, fibrinogen and fibrin may strengthen the 





Horm collagen, fibrinogen and fibrin were similar in density, surprisingly the largest clusters 
with the highest number of localisations per cluster were detected in platelets adhered to 
fibrinogen. The reason may be attributed to the inhomogeneous distribution of fibrinogen 
throughout the glass surface and accumulation in small areas which could also be enhanced 
by soluble fibrinogen released from the α-granules of adherent platelets which has been 
shown to help extend platelet spreading (Sakurai et al., 2015). In addition, the analysis was 
performed on whole FOVs, taking into account the entire set of GPVI localisations, 
independently of their colocalisation with the fibres, leading to the underestimation of the 
collagen-induced clustering. Lastly, how GPVI binds to fibrin(ogen) is still controversial, 
since different groups have reported contrasting results about the exact receptor conformation 
required for ligand binding (Induruwa et al., 2018, Mangin et al., 2018). Poulter et al. (2017) 
showed that fibrinogen induced the formation of smaller but more numerous GPVI clusters 
than Horm collagen (Poulter et al., 2017). The differences in our findings and those reported 
by Poulter et al. (2017) may be due to the different cluster analysis adopted and the use of a 
specific Fab 204-11 which detects only the dimeric conformation of GPVI. Whether GPVI 
clusters are pre-formed and are made up by monomeric and/or dimeric receptors remains to 
be understood. 
Findings from this Chapter highlight the complexity of the clustering field and underline the 
concept that the intrinsic structural properties of the input data drive the selection of the 
appropriate analysis for the quantitative interrogation of proteins in a variety of biological 
systems. We propose a novel two-layer cluster analysis based on DBSCAN for the specific 
assessment of receptor clustering on fibrous structures whereas one-layer DBSCAN has been 





shapes. Future work is needed to integrate these algorithms with simulation methods for the 































Immobilised collagen prevents shedding and induces 

















The first aim of this Chapter was to investigate whether immobilised collagen is able to 
induce the release of GPVI receptors from the platelet surface through the mechanism of 
ectodomain shedding, thereby limiting platelet activation. The underlying hypothesis was that 
receptor clustering may protect from ADAM10-mediated cleavage, allowing the signalling to 
be maintained over time. The second goal was to evaluate the contribution of secondary 
mediators and signalling kinases on GPVI clustering and signalling in platelets interacting 
with collagen. For these purposes, using a combination of biochemical and advanced imaging 
approaches, we have correlated GPVI signalling, clustering and shedding to elucidate the 
events characterising the first step of thrombus formation, namely platelet-collagen 
interaction.  
4.2 Introduction 
Collagen, one of the major components of the ECM, is a potent activator of platelets acting 
through its interaction with the platelet receptor GPVI. The GPVI-FcR-γ complex is a 
signalling rather than an adhesive receptor complex as activation of integrins through inside-
out signalling is required for stable platelet adhesion under flow (Pugh et al., 2017). Collagen 
engagement of GPVI triggers Src family kinase-dependent phosphorylation of the conserved 
tyrosines in the ITAM motif within the associated FcR-γ and binding of the tyrosine kinase 
Syk via its tandem SH2 domains. Activation of Syk, by Src-dependent phosphorylation and 
autophosphorylation, initiates the formation of a LAT-based signalosome that culminates in 
the activation of PLCγ2, intracellular Ca
2+
 increase, integrin activation and full platelet 
activation (Watson et al., 2010). A critical event involved in platelet activation is the secretion 
of secondary mediators, ADP and TxA2, which represents a positive feedback loop to support 





second messenger have been shown to be fundamental for the tyrosine phosphorylation of the 
related hemITAM receptor CLEC-2 as well as platelet aggregation in response to rhodocytin, 
its non-physiological ligand (Pollitt et al., 2010).  
GPVI is found at the platelet surface primarily as a monomer but up to ~29% of the total 
GPVI has been detected in a dimeric state in resting platelets (Jung et al., 2012). Upon platelet 
activation by collagen, the levels of dimeric GPVI receptors increase with the subsequent 
fusion into larger clusters at the platelet surface (Jung et al., 2009, Jung et al., 2012, Loyau et 
al., 2012, Miura et al., 2002, Poulter et al., 2017). Therefore, receptor dimerisation and 
clustering tightly modulate the local density of the GPVI receptor at the platelet surface. It has 
been proposed that GPVI signalling may be influenced by receptor density as decreased GPVI 
levels result in a severe impairment of platelet adhesion to collagen under flow (Sarratt et al., 
2005). In addition, a study conducted in RBL-2H3 cells expressing GPVI at a lower or similar 
density of that found in human platelets has demonstrated that the receptor density modulates 
both platelet adhesion and signalling in response to collagen (Chen et al., 2002). Collagen 
also induces slow but sustained signalling whereas the non-physiological ligand CVX causes 
rapid but transient signalling in platelet suspensions (Tomlinson et al., 2007) and this may be 
due to the difference in spatial distribution of the receptor and its interacting proteins. We 
have shown that GPVI clustering is sustained over time (Chapter 3) and this could represent 
the underlying mechanism involved in maintaining the active signalling required to support 
platelet adhesion to collagen.  
GPVI surface density, and therefore platelet reactivity to collagen, is regulated by ADAM10 
and ADAM17-mediated ectodomain shedding in human and mouse platelets (Bender et al., 
2010, Bergmeier et al., 2004, Facey et al., 2016, Gardiner et al., 2007). In suspension, 





thereby limiting activation (Gardiner et al., 2004). This paradoxically could lead to the 
unwanted embolisation of platelets from an immobilised surface. To date, shedding of GPVI 
in platelets adhered to and spreading on an immobilised collagen substrate, which would 
represent the first step of thrombus formation or adhesion of platelets to the ECM in a blood 
vessel with compromised integrity, has not been investigated. 
In this Chapter, we have used biochemical methods combined with cutting-edge microscopy 
techniques to elucidate the dynamics of GPVI signalling and shedding in platelets spreading 
on fibrillar collagen and compare with those observed in platelets stimulated in suspension. A 
broad investigation of GPVI localisation was then undertaken to understand whether the 
receptor colocalises with downstream signalling mediators and/or the metalloproteinase 
ADAM10. In addition, we have interrogated the putative role of secondary mediators, ADP 
and TXA2, in GPVI cluster forming and whether sustained Src-family and Syk kinases 














4.3.1 GPVI signalling is sustained over time in platelets adhering to  
immobilised collagen 
In vitro studies in platelets and cell lines activated with receptor agonists in suspension have 
demonstrated that fibrillar collagen triggers slow but sustained GPVI signalling (Tomlinson et 
al., 2007) in tandem with shedding of the receptor (Gardiner et al., 2004). This raises the 
question of whether this is also the case on an immobilised surface where shedding might lead 
to loss of adhesion to collagen. In Fig. 4.1A, confocal imaging of F-actin shows that the stress 
fibres are already formed after 15 min of spreading and the fully-spread state is maintained for 
up to 3 h. Reflection images illustrate how spread platelets distribute along the collagen 
fibres. As expected, there was a steady increase in the number of platelets coming into contact 
with the fibres over time, however no change in the platelet surface area was observed (Fig. 
4.1B, C).  
To assess platelet signalling in these cells, whole-cell tyrosine phosphorylation and specific 
phosphorylation sites on two key signalling mediators, Syk and LAT, which are positioned at 
the centre of the GPVI signalling pathway, were measured by Western blot (Fig. 4.2A). Total 
phospho-tyrosine levels, detected by the antibody clone 4G10, increased in adhered platelets 
relative to cells in suspension (non-adhered, NA) and remain sustained over time (Fig. 4.2A). 
Site-specific tyrosine phosphorylation of both Syk (Y525/526) and LAT (Y200), residues 
associated with activation and docking, respectively, was maintained, with no significant 







Figure 4.1. Time course of platelets spreading on a collagen monolayer. Human washed 
platelets were spread on a Horm collagen-coated surface (10 µg ml
-1
) for the indicated times, 
labelled with Alexa Fluor 488 phalloidin (F-actin) and imaged by confocal microscopy. 
Platelet spreading at different time points is illustrated in the confocal images of the actin 
cytoskeleton (A, first panel) whereas the reflection images show how platelets localise along 
the collagen fibres (A, second panel). Mean ± SEM platelet surface area (B) and platelet 
number (C) were measured in KNIME integrated with Ilastik pixel classifier to segment 
individual cells. In total, 15 FOVs for each condition from three representative experiments 
were analysed. Significance (P < 0.05) was measured using one-way ANOVA with Tukey’s 
multiple comparisons. Scale bar: 5 μm. 
                  







Figure 4.2. Whole-cell tyrosine phosphorylation and site-specific phosphorylation of Syk 
and LAT are sustained over time in platelets adhered to collagen. Human washed 
platelets were spread on a collagen (10 µg ml
-1
)-coated surface at 37 °C for the indicated 
times. Spread and non-adherent (NA) platelets were gathered, lysed, separated by SDS-PAGE 
and immunoblotted with the phosphotyrosine antibody (4G10) and antibodies specific for 
phosphorylated Syk (Y525/6) and LAT (Y200) (A). The antibodies against α-tubulin, pan-
Syk and pan-LAT were used as loading controls for total phosphotyrosines, phospho-Syk and 
phospho-LAT, respectively (A). The secondary labelling was carried out using HRP 
conjugated secondary antibody (for 4G10) and IRDye 800CW conjugated secondary 
antibodies (for Syk pY525/6 and LAT pY200). The detection of the bands was performed 
using the Odyssey Fc system (LI-COR) with Syk and LAT appearing at ~72 kDa and ~35 
kDa, respectively (A). Normalized quantification of band intensities against the pan signals is 
shown in B and C as mean ± SEM relative % of protein (the start point was set at 100%) from 





The last step of GPVI signalling transduction is represented by Ca
2+ 
movement from 
intracellular compartments upon activation of PLCγ2 (Nieswandt and Watson, 2003). 
Therefore, we monitored the Ca
2+ 
spiking in platelets labelled with the Ca
2+ 
dye Oregon green 
488 BAPTA-1-AM that had been spread on immobilised collagen for different time periods: 
15 min, 30 min, 1 h and 3 h (Fig. 4.3). From the single-cell analysis, conducted in MATLAB, 
we were able to extract important features such as percentage of spiking platelets, number of 
Ca
2+ 
spikes per platelet, amplitude and the peak duration. The analysis clearly shows that the 
percentage of spiking platelets spread on collagen for 3 h remained constant (Fig. 4.3A) and 
these were still able to spike with the same frequency (Fig. 4.3B), although the amplitude and 
peak duration slightly declined (Fig. 4.3C, D). Overall, immobilised collagen supports platelet 
spreading via GPVI signalling for at least 3 h. 


















Figure 4.3. Collagen-induced Ca
2+ 
mobilisation remains constant in platelets spread for 
3 h. Live-cell imaging of Ca
2+
 mobilisation in platelets labelled with Oregon green-488 
BAPTA-1-AM Ca
2+
 dye and spread on a collagen (10 µg ml
-1
) monolayer at 37 °C for the 
indicated time points. The Ca
2+ 
influx was recorded by epifluorescence microscopy and 
images captured every 1 sec for 2 min (1 or 2 movies for each condition were acquired). 
Using a threshold of 20 fluorescent unit, the percentage of spiking platelets (A), number of 
spikes per platelet (B), amplitude (C) and peak duration (D) were measured in MATLAB on 
three representative FOVs for each time point (~150 platelets in each FOV) from three 
independent experiments. Data are expressed as mean ± SEM. Significance was calculated 
using  one-way ANOVA with Tukey’s multiple comparisons test: a significance of P < 0.05 is 
indicated by *. For each time point, representative Ca
2+ 
traces in a single cell are shown in Ei, 
ii, iii, iv. The MATLAB coding and data analysis were kindly carried out by Christopher 



























4.3.2 GPVI signalling declines over time in platelets stimulated with 
collagen in suspension 
To investigate whether the signalling dynamics underlying GPVI pathway are different in 
non-static conditions, platelets were stimulated with collagen in suspension for 90 sec, 15 
min, 30 min, 1 h and 3 h in the presence of integrilin to prevent integrin αIIbβ3 signalling and 
therefore platelet aggregation. The site-specific phosphorylation of Syk and LAT, central 
mediators of GPVI signalling activation, was followed over time by Western blot. Both Syk 
and LAT were not phosphorylated in unstimulated platelets (Fig. 4.4A). Collagen induced a 
strong and rapid phosphorylation of the signalling proteins after 90 sec of stimulation but the 
signalling activation appeared to decrease over time (Fig. 4.4A, B, C). The drop in tyrosine 
phosphorylation was detected after 15 min of collagen stimulation and the downregulation 
remained steady for up to 3 h (Fig. 4.4A, B, C). From these data we conclude that, unlike 
platelets adhered to a static monolayer, following an initial spike in phosphorylation, collagen 





       
Figure 4.4. Site-specific phosphorylation of Syk and LAT decreases over time in platelets 
stimulated with collagen in suspension. Human washed platelets were stimulated with 
collagen (30 µg ml
-1
) and collagen diluent (unstimulated, UN), in the presence of 9 μM 
integrilin, under stirring conditions at 37 °C for the indicated time course. Stimulated and 
non-stimulated platelets were collected, lysed, separated by SDS-PAGE and Western blotted 
for phospho-Syk (Y525/6) and phospho-LAT (Y200) (A). Pan-Syk and pan-LAT antibodies 
were used to verify the loading. The secondary labelling was carried out using IRDye 800CW 
conjugated secondary antibodies. The fluorescent detection of the phospho-proteins was 
undertaken using the Odyssey Fc system (LI-COR) in the 800 nm channel (A). The signal 
intensities were quantified, normalized against the pan signals and plotted as mean % relative 





4.3.3 Sustained signalling colocalises with GPVI on collagen in spread 
platelets 
Western blot analysis gives an overview of the signalling events taking place in the whole 
platelet but it does not give any spatial information about where these events are taking place. 
To visualise areas where the signalling is occurring, platelets spread on immobilised collagen 
for 1 h were labelled for GPVI using 1G5-Fab and phospho-tyrosines using the antibody 
clone 4G10. High-resolution confocal imaging shows that phosphorylated proteins (magenta) 
are specifically organised along collagen fibres where GPVI (cyan) is abundantly present 
(Fig. 4.5), which is in agreement with similar experiments carried out by (Poulter et al., 
2017). The 4G10 antibody labels all phosphorylated tyrosines, some of which may represent 
negative regulation of the protein. To identify the activated signalling proteins lined up along 
fibrous collagen, spread platelets were labelled for phospho-Syk (Y525/6) and phospho-LAT 
(Y200) and imaged by confocal microscopy. The images in Fig. 4.6A illustrate that, despite 
the different distribution pattern of the two proteins, both pSyk Y525/6 (Fig. 4.6Aii) and 
pLAT Y200 (Fig. 4.6Aiv) are concentrated along collagen (indicated by red arrows) in 
comparison with the lower density of phospho-proteins detected in areas where there are no 
visible collagen fibres. Total (pan) Syk and LAT, used as controls, cover most of the platelet 
surface, resulting in a more homogenous distribution (Fig. 4.6Ai,iii). Dual-colour confocal 
imaging of GPVI and phosphorylated signalling mediators was carried out to assess their 
location in platelets spread on collagen (Fig. 4.6B). A combination of qualitative 
(colocalisation mask, showing pixels which contain both GPVI and phospho-proteins, Fig. 
4.6Biv) and quantitative (Pearson’s correlation coefficient, Fig. 4.6C) analyses demonstrates 
that there is a high degree of colocalisation between the phosphorylated signalling proteins 





up to at least 3 h. Taken together, these data suggest that fibrous collagen represents the site of 
signalling activation where GPVI highly colocalises with phosphorylated signalling mediators 

















                           
Figure 4.5. Phospho-tyrosines are concentrated along collagen fibres in spread platelets. 
Human washed platelets, spread on a collagen (10 µg ml
-1
) monolayer for 1 h, were labelled 
with 1G5-Fab for GPVI (Cyan) and 4G10 Alexa Fluor 647 conjugated for phospho-tyrosines 
(magenta). Samples, secondary stained with anti-mouse Alexa Fluor 488 conjugated for 
GPVI, were imaged via Zeiss LSM 880 with Airyscan Fast. Images are maximum intensity 
projections of confocal z-stacks. The Merge image highlights the colocalisation of GPVI and 
phosphorylated proteins along collagen fibres (indicated by white colour). Visualisation of the 
collagen distribution was carried out using the transmitted light. In total, 12 FOVs from three 
















Figure 4.6. Phosphorylated Syk and LAT colocalise with GPVI along collagen fibres. 
Confocal microscopy imaging of human washed platelets spread on collagen (10 µg ml
-1
) for 
1 h, labelled for (Ai) Pan-Syk, (Aiii) Pan-LAT, LAT pY200 (Aiv) and secondary stained with 
anti-rabbit Alexa Fluor 488 conjugated. Platelets were also labelled for pSyk Y525/6 (Aii) 
using the conjugated antibody Syk pY525/6-Alexa Fluor 647. The enrichment of Syk 
pY525/6 and LAT pY200 along fibrous collagen is indicated by red arrows (Aii, iv). Dual-
colour confocal imaging of platelets, pre-incubated for Pan-GPVI using 1G5-Fab (Bi, first 
panel), spread on collagen for 1 h and 3 h, post-labelled with Syk pY525/6 Alexa Fluor 647 
conjugated and secondary stained with anti-mouse Alexa Fluor 488 conjugated for GPVI 
(Biii, first panel). Platelets, pre-incubated with 1G5-Fab for GPVI (Bi, second panel), were 
also post-labelled for LAT pY200 (Biii, second panel) and secondary stained with anti-mouse 
Alexa Fluor 647 conjugated (for GPVI) and anti-rabbit Alexa Fluor 488 conjugated (for LAT 
pY200). Only the confocal images relative to 1 h of spreading are shown (B). Reflection 
images display the presence of platelets seeded on collagen (Bii). In total, 15 FOVs for each 
condition from three independent experiments were acquired. The qualitative and quantitative 
colocalisation analyses were performed in Fiji. The colocalisation mask shows only the 
colocalising pixels of GPVI and phospho-proteins in the representative FOV (Biv). Scatter 
plot represents mean ± SEM of Pearson’s correlation coefficient measured on n=30 platelets 
from three independent experiments (C). Significance, set to P < 0.05, was measured using 














4.3.4 GPVI shedding is minimal in platelets spreading on collagen 
We hypothesized that GPVI shedding from the platelet surface may regulate the duration of 
the signalling. In human platelets, GPVI is cleaved upon stimulation in suspension with 
different agonists, predominantly through ADAM10 (Gardiner et al., 2004). However, 
whether GPVI is cleaved in platelets that have been spread on an immobile ligand is still 
unknown. Here, we have used an antibody which is specific for the cytosolic tail of GPVI to 
assess the degree of GPVI shedding that is occurring in platelets spread for different time 
periods on collagen. Intact GPVI has a molecular weight of ~65 kDa but, when the 
extracellular domain is shed, the cytosolic tail that remains bound to the platelet is ~10 kDa. 
First, we investigated GPVI shedding in platelets stimulated with collagen in suspension to 
confirm the findings reported in the literature. Platelets, pre-treated with CaCl2 to induce Ca
2+
-
dependent metalloproteinases activation, were stimulated with collagen under stirring 
conditions for different time points and GPVI shedding was assessed over time. Western blot 
showed that, in unstimulated platelets, GPVI remains intact whereas it is cleaved upon 
collagen stimulation, with the decrease in the amount of the receptor full-length and the 
appearance of the membrane-bound tail detected (Fig. 4.7A). The extent of GPVI cleavage 
rose proportionally with the time of stimulation, reaching ~70% of GPVI shed after 3 h of 
stimulation (Fig. 4.7B). As a positive control, platelets were also stimulated with the thiol-
modifying reagent NEM, which triggers activation of human platelet metalloproteinases. 
NEM induced ~100% of GPVI shedding (Fig. 4.7A, B). On the contrary, in platelets adhered 
to a static collagen monolayer, only a minimal amount of GPVI shedding was detected, with 
~15% shed after 3 h of spreading (Fig. 4.7C, D). In platelets that have not come into contact 
with collagen (non-adhered, NA, Fig. 4.7C, D), no GPVI shedding was detected, indicating 





To complement the Western blot data we carried out two-colour immunolocalisation of the 
intracellular tail of GPVI (using the anti-GPVI-tail antibody) and the extracellular domain 
(using 1G5-Fab) to get spatial information on the intact receptor. Epifluorescence imaging 
reveals a strong overlap of the two receptor domains, which was particularly prevalent along 
the collagen fibres, as highlighted in the colocalisation mask (Fig. 4.8A). Dual-colour 
dSTORM imaging confirmed the high degree of colocalisation between the extracellular and 
intracellular domains of GPVI clusters along collagen fibres, indicated in white in the Merge 
image (Fig. 4.8B). This indicates that this pool of GPVI has not been shed from the platelets 
in this 3 h timeframe, in accordance with the biochemical data.  
To further support our hypothesis that GPVI shedding is not occurring in platelets spread on 
collagen we investigated the location of the GPVI sheddase ADAM10 in relation to that of 
GPVI oligomers in spread platelets using two-colour epifluorescence (Fig. 4.8C) and 
dSTORM (Fig. 4.8D) imaging. The images highlight the different distribution of the two 
proteins, with no visible enrichment of ADAM10 at collagen fibres as is seen for GPVI (Fig. 
4.8C). Dual-colour dSTORM imaging enabled us to assess the nanoscale organisation of the 
collagen receptor and the sheddase at the single molecule level (Fig. 4.8D). ADAM10 
appeared to be uniformly distributed at the platelet surface and most of the ADAM10 
localisations do not colocalise with the tightly packed GPVI clusters, suggesting that the 
metalloproteinase may be excluded from the receptor clusters, preventing shedding and 













Figure 4.7. GPVI is shed in platelets stimulated in suspension but not in those spread on 
a monolayer. Human washed platelets, pre-treated with 2 mM CaCl2, were stimulated with 
collagen (30 µg ml
-1
) or collagen diluent (unstimulated, UN) for 15 min, 30 min, 1 h and 3 h 
under stirring conditions. Platelets were also treated with 2 mM NEM for 1 h and used as a 
positive control of shedding (A). For the analysis of GPVI shedding on a monolayer, platelets 
were allowed to spread on a collagen (10 µg ml
-1
)-coated surface for the same time points. 
The supernatant represents the fraction of non-adhered (NA) platelets. The positive control 
NEM (2 mM) was added for 30 min to platelets that have been spread on collagen for 2 and a 
half h (C). Stimulated/adhered and unstimulated/non-adhered platelets were lysed, separated 
by SDS-PAGE and immunoblotted with anti-GPVI-tail antibody. The α-tubulin antibody was 
used as a loading control The secondary labelling was carried out using IRDye 800CW 
conjugated secondary antibodies. Full-length GPVI and GPVI-tail were detected at ~62 kDa 
and ~10 kDa, respectively, using the Odyssey Fc system (LI-COR) (A, C). The band 
intensities were measured using Image Studio: percentage of shedding was calculated as: 
(shed GPVI/full-length GPVI + shed GPVI) *100 (B,D). Bars in the histograms represent the 






















Figure 4.8. GPVI extracellular domain colocalise with the intracellular tail but not 
ADAM10 in platelets spread on collagen. Dual-colour epifluorescence imaging of spread 
platelets labelled for GPVI extracellular domain (pre-incubation with 1G5-Fab, Ai) and 
intracellular tail (post-incubation with anti-GPVI-tail, Aiii) and secondary labelled with anti-
mouse Alexa Fluor 647 and anti-rabbit Alexa Fluor 488 conjugated, respectively. The 
distribution of fibrous collagen is shown in the DIC image (Aii). The high level of 
colocalisation between the two GPVI domains along collagen fibres is highlighted in the 
colocalization mask (Aiv). In total, 15 FOVs from three independent experiments were 
acquired. Two-colour dSTORM imaging illustrates the colocalising clusters of extracellular 
(Bi) and intracellular (Bii) GPVI on collagen, highlighted in white in the Merge image and 
magnification of the boxed area (Biii, iv). In total, 7 FOVs from two separate experiments 
were acquired. Dual-colour epifluorescence imaging of spread platelets pre-labelled with 
1G5-Fab for Pan-GPVI (Ci) and post-stained with Alexa Fluor 647 conjugated ADAM10 
[11G2] antibody (Ciii). Secondary labelling of GPVI was carried out using anti-mouse Alexa 
Fluor 488 conjugated. Platelet adhesion to collagen is shown in the DIC image (Cii) whereas 
the overlapping pixels are selected in the colocalization mask (Civ). In total, 15 FOVs from 
three independent experiments were acquired. Two-colour dSTORM imaging of the same 
platelets allows to visualise the distribution of ADAM10 (Dii) relative to that of GPVI (Di) at 
the single-molecule level (as shown in the Merge image, Diii, iv). In total, 13 FOVs from 
three independent experiments were acquired. Scale bar: 5 µm (whole FOVs and single 


















4.3.5 Effect of metalloproteinases inhibition and activation on GPVI cluster 
formation  
To further investigate whether GPVI remains intact and clustered at the cell surface, 
dSTORM imaging and two-level DBSCAN cluster analysis was carried out in the presence of 
the broad-spectrum metalloproteinase inhibitor GM6001, the ADAM10-specific inhibitor 
GI254023 (pre-spreading) or the generic activator of metalloproteinases NEM (post-
spreading) to block or induce receptor shedding, respectively. The concentrations used have 
previously been shown to block/activate GPVI shedding in platelets (Facey et al., 2016, 
Gardiner et al., 2004, Gardiner et al., 2007). If GPVI shedding is occurring in spread platelets 
then we would expect to see an increase in the cluster parameters we are measuring when the 
metalloproteinase inhibitors are present. NEM is a positive control to show that shedding can 
occur in spread platelets if stimulated to do so. Both metalloproteinase inhibitors have no 
effect on platelet spreading (Fig. 4.9A, B). Notably, unlike GM6001, the ADAM10-specific 
inhibitor GI254023 induced a change in the actin cytoskeleton as shown by the stretching of 
stress fibres along collagen, likely due to the generation of actin-defined confinement regions 
for the accumulation of GPVI (Fig. 4.9A). NEM significantly impaired the ability of platelets 
to bind to collagen showing a significant reduction in the surface area in comparison to the 
control (Fig. 4.9A, B). No effect on cell count was found in platelets treated with all the 









    
Figure 4.9. Effect of metalloproteinase inhibitors and NEM on platelet spreading. 
Human washed platelets were treated with GM6001(100 µM) or GI254023 (2 µM) before 
spreading on a collagen (10 µg ml
-1
) monolayer for 1 h. NEM (2 mM) was added after 
spreading and left at 37 °C for 30 min. Control platelets were pre-treated with DMSO (vehicle 
for metalloproteinases inhibitors), spread on collagen and post-incubated with ethanol 
(vehicle for NEM) for 30 min. F-actin was labelled with Alexa Fluor 488 phalloidin and 
imaged by epifluorescence microscopy (A, first panel). The DIC images (A, second panel) 
illustrate the distribution of platelets on collagen fibres. Quantification of platelet surface area 
(B) and platelet number (C) in control and treated platelets was performed in KNIME on 15 
FOVs for each condition from three independent experiments. Each dot represents the mean 
of each of the replicates with the overall mean ± SEM shown in the histograms. The 
significance (P < 0.05) was calculated using one-way ANOVA with Tukey’s multiple 







In accordance with this finding, TIRFM and dSTORM imaging allowed the visualisation of 
discrete GPVI clusters along collagen in platelets treated with each of the metalloproteinase 
inhibitors (Fig. 4.10Ai, ii). The DBSCAN-based two-layer cluster analysis enabled the 
isolation of these large and continuous oligomers colocalising with collagen fibres (Level I 
clustering, Fig. 4.10Aiii) and further segmentation into nanoclusters (Level II clustering, Fig. 
4.10Aiv) in both control and treated platelets. The detected GPVI clusters and nanoclusters 
along collagen fibres in GM6001 and GI254023-treated platelets were not significantly 
different from those formed in control platelets in terms of area and density at both clustering 
levels (Fig. 4.10B, C, D, E). Contrarily, NEM-activating ADAM10 triggered the release of 
~90% of GPVI localisations from the human plasma membrane with very few clusters 
detected (Fig. 4.10F) making the two-level cluster analysis impossible to perform. This again 






















Figure 4.10. Effect of metalloproteinase inhibitors and NEM on GPVI clustering. Human 
washed platelets, treated with GM6001, GI254023 and NEM as described before, were pre-
incubated with 1G5-Fab (2 μg ml
-1
) for Pan-GPVI, spread on a collagen (10 μg ml
-1
) 
monolayer and secondary labelled with anti-mouse Alexa Fluor 647 conjugated to allow 
GPVI visualisation. Receptor distribution was assessed using dSTORM imaging in TIRF 
mode in both control and treated platelets (Ai, ii). GPVI clustering (Level I clustering) and 
nanoclustering (Level II clustering) along collagen fibres were quantified using two-level 
DBSCAN-based cluster analysis (Aiii, iv) as described in Chapter 3 with the same parameters 
and threshold values. In total, 14 or 15 FOVs were analysed for the control, GM6001and 
GI254023-treated platelets whereas only 8 FOVs for the NEM-treated platelets. Quantitative 
analysis relative to GPVI cluster area and density at both clustering levels is reported in B, C, 
D, E as mean ± SEM from three independent experiments. One-way ANOVA with Tukey’s 
multiple comparisons (P < 0.05) shows non-significant (ns) difference in the cluster and 
nanocluster area and density between the control and platelets treated with metalloproteinase 
inhibitors. Only a few clusters were detected in platelets incubated with NEM: the histogram 
in F shows a significantly lower number of localisations in comparison with the control (P < 
0.05 using unpaired two-tailed t-test). Scale bar: 5 μm (dSTORM images) and 1 μm (Level I 
and II cluster plots). The two-level DBSCAN was designed and implemented by Dr Jeremy 






4.3.6 Effect of secondary mediators inhibition on platelet spreading, GPVI 
signalling and clustering on collagen 
The secondary mediators, TxA2 and ADP, enhance the integrin activation on adherent 
platelets and induce the thrombus development through the recruitment and activation of 
additional platelets. We, therefore, wanted to test whether secondary mediators have any 
effect on platelet spreading on collagen as well as collagen-mediated GPVI signalling and 
oligomerisation. Platelets were pre-incubated with the ADP scavenger apyrase and the 
cyclooxygenase inhibitor indomethacin at concentrations able to block collagen-induced 
platelet aggregation (Atkinson et al., 2001), prior to spreading on collagen. Inhibition of 
secondary mediators did not prevent platelet spreading on collagen as the surface area and 
count were not affected (Fig. 4.11A, B, C).  
The effect of ablation of the secondary mediators pathway on downstream GPVI signalling 
was then investigated by measuring the total level of tyrosine phosphorylation and the site-
specific phosphorylation of Syk and LAT using Western blot. The combined treatment of 
platelets with indomethacin and apyrase did not have a major effect on whole-cell 
phosphotyrosines and tyrosine phosphorylation of Syk (Y525/6) and LAT (Y200) in platelets 
spread on collagen (Fig. 4.12A, B, C), suggesting that secondary mediators are not critical for 








                
Figure 4.11. Platelet spreading on immobilised collagen occurs independently of 
secondary mediators signalling. Human washed platelets, pre-incubated with indomethacin 
(10 µM) and apyrase (2 U/ml) or DMSO (vehicle control) for 10 min, were allowed to spread 
on a collagen (10 μg ml
-1
)-coated surface for 1 h, stained with Alexa Fluor 488 phalloidin for 
actin and imaged by confocal microscopy. The effect of secondary mediators inhibitors on 
platelet actin cytoskeleton (F-actin images, first panel) and platelet adhesion to collagen 
(Reflection images, second panel) is shown in A. Measurement of platelet surface area and 
count, conducted in KNIME on 15 FOVs for each condition from three independent 
experiments, shows non-significant difference between control and treated platelets (B, C). 





                  
Figure 4.12. Total phosphotyrosines and site-specific phospho-Syk and phospho-LAT 
levels in platelets spread on collagen in the presence of secondary mediators inhibitors. 
Human washed platelets, in the presence of indomethacin and apyrase or DMSO (vehicle 
control), were spread on a collagen (10 μg ml
-1
) monolayer for 1 h before being lysed. Lysates 
from non-adhered (NA) and spread platelets were separated by SDS-PAGE and Western 
blotted using the phosphotyrosine antibody 4G10 and the phospho-specific antibodies against 
pSyk Y525/6 and pLAT Y200 (A). Antibodies detecting tubulin, pan-Syk and pan-LAT were 
used as loading controls. The secondary labelling was carried out using HRP conjugated 
secondary antibody (for 4G10) and IRDye 800CW conjugated secondary antibodies (for Syk 
pY525/6 and LAT pY200). The detection of the bands was performed using the Odyssey Fc 
system (LI-COR) (A). The normalized quantification against the pan signals is represented as 
mean ± SEM relative % of protein (the control was set at 100%) from three independent 





As we hypothesized that GPVI clustering on collagen is a mechanism to sustain and 
potentiate the signalling transduction, we expected no effect of ADP and TxA2 blockers on the 
ability of GPVI to coalesce in clusters at the cell surface. Indeed, GPVI spatial organisation 
and oligomerisation in platelets adhered to collagen was not perturbed by the abolishment of 
secondary mediators activity as shown in the TIRFM and dSTORM images (Fig. 4.13Ai, ii). 
The two-layer DBSCAN clustering method was still able to isolate large and dense clusters 
along collagen in treated platelets (Level I clustering, Fig. 4.13Aiii, B, D). The quantitative 
analysis also shows that secondary mediators inhibitors did not alter GPVI nanoclusters with 
unchanged cluster area and density in comparison with the control (Level II clustering, Fig. 

























Figure 4.13. Inhibition of secondary mediators does not perturb GPVI cluster formation 
in platelets spread on collagen. Human washed platelets, pre-treated with secondary 
mediators inhibitors or DMSO (vehicle control) and pre-labelled with 1G5-Fab (2 μg ml
-1
) for 
GPVI, were spread on a collagen (10 μg ml
-1
)-coated surface for 1 h. Secondary labelling of 
spread platelets was carried out using anti-mouse Alexa Fluor 647 conjugated before being 
imaged by dSTORM in TIRF mode. The diffraction-limited images show the effect of 
indomethacin and apyrase on GPVI organisation (Ai) whereas dSTORM allows visualisation 
of their contribution to GPVI cluster formation on collagen (Aii). GPVI clustering and 
nanoclustering were assessed using the two-level clustering tool based on DBSCAN (Aiii, iv) 
with the same parameters and filtering setting applied in the previously described experiment 
(A). A total of at least 13 FOVs for each condition from three independent experiments were 
analysed. The histograms show non-significant (ns) difference in the area and density of 
clusters (B, D) and nanoclusters (C, E) between the control and treatment, calculated using 
one-way ANOVA with Tukey’s multiple comparisons (P < 0.05). Data are presented as mean 
± SEM from three independent experiments. Scale bar: 5 μm (dSTORM images) and 1 μm 
(Level I and II cluster plots). Raw dSTORM image data was collected by Mark Probert, 
















4.3.7 Effect of inhibiting Src-family and Syk kinases on platelet spreading 
on collagen  
Our results show that immobilised collagen supports platelet spreading for at least 3 h. To 
investigate whether Src-family and Syk kinases, fundamental for the initiation of GPVI 
signalling cascade, are required to maintain platelet spreading downstream of the platelet-
collagen interaction, we interrupted the signalling using either the Src-family kinase inhibitor 
PP2 or the Syk kinase inhibitor PRT-060318 (PRT). To test the efficacy of both compounds, 
collagen-induced platelet aggregation was carried out in the presence of increasing 
concentrations of PP2 (10, 20 and 50 μM) and PRT (5, 10 and 20 μM) or DMSO (vehicle). 
Fig. 4.14 shows that collagen at 10 μg ml
-1 
stimulated ~70% of the maximal aggregation in a 5 
min time frame. PP2 and PRT completely blocked platelet aggregation in response to collagen 
at all the concentrations tested (Fig. 4.14A, B). Therefore, we decided to use concentrations 
already reported in the literature for further experiments: 20 μM PP2 (Mangin et al., 2018, 






Figure 4.14. Test of increasing concentrations of PP2 and PRT on collagen-induced 
platelet aggregation. The effect of different concentrations of (A) PP2 (10, 20, 50 μM) or (B) 
PRT (5, 10, 20 μM) or DMSO (vehicle control) on collagen (10 μg ml
-1
)-induced platelet 
aggregation was recorded by light transmission aggregometry at 37 °C under constant stirring 
conditions (1200 rpm) for 5 min. The aggregation traces (representative of n=1 experiment) 
show that PP2 and PRT at all the concentrations tested block platelet aggregation in response 







In accordance with previous results (Poulter et al., 2017), pre-incubation of platelets with 
either PP2 or PRT significantly reduced the extent of platelet spreading on collagen (Fig. 
4.15A). The platelet surface area was diminished by ~40% in the presence of PP2 whereas 
PRT had a more marked effect (~78% reduction) with a complete abolishment of platelet 
lamellipodia, filopodia and stress fibres formation (Fig. 4.15A, B, D). The number of platelets 
coming into contact with collagen did not change in the presence of PP2 and PRT (Fig. 
4.15A, C, E). 
To investigate whether both kinases are necessary to maintain platelet adhesion to collagen 
once the spreading has already occurred, we post-treated fully spread platelets for 15 min with 
each of the inhibitors or the vehicle control. We found that sustained spreading did not require 
Src-family kinase signalling as demonstrated by the lack of an effect of PP2 on platelet 
surface area and count (Fig. 4.16A, B, C). On the contrary, PRT-treatment slightly reduced 
platelet surface area but not platelet number (Fig. 4.16D, E). PRT also had a dramatic effect 
on the cortical actin cytoskeleton with depolymerisation of stress fibres and the appearance of 
actin nodule-like structures (white arrows in Fig. 4.16A), suggesting that Syk kinase activity 
may play a role in the maintenance of platelet morphology. Despite PRT slightly decreasing 
the platelet surface area in all the three experiments performed on different donors, this result 
was not significantly different from the control, indicating that a higher number of replicates 
may be needed to reduce the inter-experimental variability caused by different donors. 
Overall, these results show that Src-family and Syk kinases are fundamental for the initial 
interaction of platelet with collagen and propose that Syk, but not Src, may play an important 






             
Figure 4.15. Pre-incubation of platelets with PP2 and PRT decreases platelet spreading 
on collagen. Human washed platelets were pre-incubated with PP2 (20 μM) or PRT (10 μM) 
or DMSO (vehicle control) for 10 min prior to spreading on a collagen (10 μg ml
-1
)-coated 
surface for 1 h. The effect of PP2 and PRT on F-actin cytoskeleton (labelled with Alexa Fluor 
488 phalloidin) and platelet distribution on collagen (Reflection) is illustrated in the confocal 
images (A). Quantitative analysis of platelet spreading conducted in KNIME shows a 
significant reduction in the surface area, but not adhesion, of platelets treated with PP2 or 
PRT in comparison with DMSO (B, C, D, E). The analysis, performed on 15 FOVs for each 
condition from three independent experiments, is reported as mean ± SEM. The significance 





             
Figure 4.16. Effect of PP2 and PRT post-treatment on platelet spreading on collagen. 
Human washed platelets spread on collagen (10 μg ml
-1
) for 45 min were post-incubated with 
PP2 (20 μM) or PRT (10 μM) or DMSO (vehicle control) for 15 min, labelled with Alexa 
Fluor 488 phalloidin for actin and imaged by confocal microscopy (A). The effect of PRT on 
the actin cytoskeleton is indicated by white arrows. The collagen distribution on the surface is 
illustrated in the Reflection images (A). The quantification of platelet surface area and 
number of platelets per FOV was performed in KNIME (B, C, D, E) on 15 separate confocal 
images for each condition from three independent experiments. The significance was 
measured using unpaired two-tailed t-test where P < 0.05. The data are reported as mean ± 





4.3.8 Effect of Src-family and Syk kinases inhibition on collagen-induced 
GPVI signalling in spread platelets 
As GPVI signalling is sustained in spread platelets, with Syk and LAT maintaining tyrosine 




active after 3 h of 
spreading, we sort to investigate whether Src-family and Syk kinases are required to maintain 
collagen-induced GPVI activation. Spread platelets were post-treated with PP2 and PRT as 
described above and the signalling events were analysed by Western blot using phospho-
specific antibodies against members of early (Syk), intermediate (LAT) and late (PLCγ2) 
signalling nodes to evaluate the entire GPVI cascade. Both inhibitors impaired GPVI 
downstream signalling as shown by the decrease in pSyk Y525/6 and pPLCγ2 Y1217 levels 
(Fig. 4.17A, B, D). Inhibition of Src kinases reduced the phosphorylation of LAT Y200 
whereas the Syk inhibitor did not have a major effect (Fig. 4.17A, C). Notably, PP2 or PRT 
treatment post-spreading impaired full GPVI activation but did not completely abolish the 
signalling since tyrosine phosphorylation was still detected, suggesting that, once platelets are 
adhered and spread on collagen, some signalling activation can be maintained even when one 









                
Figure 4.17. Effect of PP2 and PRT post-treatment on tyrosine phosphorylation of Syk, 
LAT and PLCγ2 in platelets spread on collagen. The effect of PP2 (20 μM) or PRT (10 
μM) or DMSO (vehicle control) post-treatment on signalling was evaluated by Western blot 
analysis. Treated and untreated spread platelet lysates on collagen (10 μg ml
-1
) were 
immunoblotted for pSyk (Y525/6) and pLAT (Y200), secondary labelled using anti-rabbit 
IRDye 800CW conjugated secondary antibodies and fluorescently revealed using the Odyssey 
Fc system (LI-COR) in the 800 nm channel (A). Lysates, immunoblotted for pPLCγ2 
(Y1217) and secondary labelled using anti-rabbit HRP conjugated secondary antibody, were 
detected using the autoradiographic film (A). Anti-Pan Syk and PLCγ2 antibodies were used 
as loading controls. The quantitative analysis of the band intensities normalized against the 
pan signals is shown as mean ± SEM % relative of protein (the control was set at 100%) from 





GPVI-mediated platelet activation culminates with the Ca
2+ 
movement from intracellular 
compartments. Therefore, we examined the effect of Src and Syk inhibition on Ca
2+ 
spikes 
within a 2 min time period in platelets already spread on collagen. Post-treatment with PP2 
and PRT reduced the percentage of platelets experiencing the collagen-induced Ca
2+
 elevation 
with a dramatic drop in the frequency of spikes detected in these cells (Fig. 4.18A, B). The 
Ca
2+ 
spikes in treated platelets were also characterised by a significant decrease in the 
amplitude and duration in comparison with the control (Fig. 4.18C, D). Together, these data 
suggest that sustained activation of Src-family and Syk kinases plays a major role in 











Figure 4.18. PP2 and PRT post-treatment impairs collagen-induced Ca
2+ 
mobilisation in 
spread platelets. Real-time platelet imaging of Ca
2+
 mobilisation in platelets labelled with 
Oregon green-488 BAPTA-1-AM Ca
2+
 dye, spread on collagen (10  µg ml
-1
) for 45 min and 
post-treated with PP2 (20 μM) or PRT (10 μM) or DMSO (vehicle control). Images were 
acquired every 1 sec for a 2 min time frame using epifluorescence microscopy (1 or 2 movies 
for each condition were acquired). The quantitative analysis of Ca
2+ 
spiking was performed in 
MATLAB applying a threshold of 20 fluorescent unit. The histograms show a decrease in the 
mean ± SEM percentage of spiking platelets (A), number of spikes per platelet (B), amplitude 
(C) and peak duration (D) induced by PP2 or PRT treatment. In total, ~150 platelets within a 
whole FOV were analysed for each individual experiment (n=3). The significance was 
measured using one-way ANOVA with Tukey’s multiple comparisons test where P < 0.05. 
Representative single-cell Ca
2+ 
traces in control and PP2 or PRT-treated platelets are shown in 



















4.3.9 Src-family and Syk kinases are not required to maintain GPVI 
clusters on collagen 
We next evaluated the potential feedback exerted by Src-family and Syk kinases on the 
receptor spatial nanoscale patterning at the platelet plasma membrane. Platelets labelled for 
GPVI were treated with PP2 and PRT post-spreading and receptor cluster formation was 
visualised by dSTORM in TIRF mode. Super-resolution imaging demonstrates that GPVI was 
still clustered along collagen fibres upon Src-family and Syk kinases inhibition (Fig. 4.19Aii) 
with neither inhibitor affecting the cluster parameters being measured as confirmed by the 
Level I clustering analysis (Fig. 4.19Aiii, B, D). Interestingly, Syk, but not Src, inhibition 
resulted in the appearance of slightly larger individual nanoclusters in comparison with the 
control as shown in the Level II clustering analysis (Fig. 4.19C). However, despite the size, 
these nanoclusters were characterised by unchanged density (Fig. 4.19E). Overall, these data 
suggest that there is no positive feedback exerted by Src-family and Syk kinases on GPVI 

















Figure 4.19. Effect of PP2 and PRT post-treatment on GPVI clustering in spread 
platelets. Human washed platelets, stained for GPVI using 1G5-Fab (2 μg ml
-1
), were spread 
on collagen (10 μg ml
-1
) for 45 min and post-incubated with PP2 (20 μM) or PRT (10 μM) or 
DMSO (vehicle control) for 15 min. dSTORM imaging of platelets, labelled with anti-mouse 
Alexa Fluor 647 conjugated, was carried out in TIRF to allow visualisation of GPVI 
distribution at the cell surface in the presence of PP2 or PRT (Ai, ii). GPVI clusters were 
quantitatively compared in control and treated platelets using DBSCAN-based two-step 
cluster analysis (Aiii, iv) with the application of the same settings used in the previous 
experiments. Mean ± SEM cluster area and density of clusters and nanoclusters are shown in 
B, C, D, E (n=3). In total, 14, 12 and 13 FOVs were analysed for the control, PP2 and PRT-
treated platelets, respectively. Significance was measured using one-way ANOVA with 
Tukey’s multiple comparisons (P < 0.05). Scale bar: 5 μm (dSTORM images) and 1 μm 





















4.3.10 Inhibition of Syk but not Src-family kinases impairs clustering of 
integrin α2β1 along collagen fibres 
To further address the long-term effect of Src-family and Syk inhibition on collagen-induced 
platelet spreading and signalling, we investigated the distribution of the other collagen 
receptor, integrin α2β1, which has been shown to mediate the outside-in regulation of platelet 
spreading through Src and Syk activation (Inoue et al., 2003). Platelets, completely spread on 
a collagen surface, were treated with PP2 and PRT for 15 min and the localisation of integrin 
α2β1 was super-resolved and quantitatively assessed using the two-level cluster analysis. In 
accordance with previous findings (Poulter et al., 2017), integrin α2β1 aggregated specifically 
at the collagen fibres in control platelets (Fig. 4.20Ai, ii, iii, iv, first panel). Inhibition of Src 
kinases had no effect on the integrin location and agglomeration on collagen (Fig. 4.20Ai, ii, 
iii, iv, second panel). However, in contrast to what was observed for GPVI, Syk inactivation 
induced the disruption of the long integrin clusters aligned along collagen (Fig. 4.20Ai, ii, 
third panel). Large and dense clusters were still detected by the Level I cluster analysis (Fig. 
4.20B, D) but these were not lined up along collagen fibres (Fig. 4.20Aiii, third panel), 
probably due to the impairment of the cortical actin cytoskeleton shown above. Once 
segmented in the Level II clustering analysis (Fig. 4.20Aiv, third panel), these oligomers were 
made up by slightly smaller nanoclusters in comparison with the control (Fig. 4.20C), 
suggesting a compromised interaction of the integrin with its ligand which may affect the size 
of resulting nanoclusters. However, the cluster density was not affected by PRT-treatment 
(Fig. 4.20E). Therefore these results suggest that, contrarily to GPVI receptors, Syk kinase 
appears to be fundamental for the maintenance of integrin α2β1 clustering along collagen 











Figure 4.20. PRT but not PP2 impairs integrin α2β1 clustering on collagen in spread 
platelets. Human washed platelets spread on collagen (10 μg ml
-1
) and post-treated with PP2 
(20 μM) or PRT (10 μM) or DMSO (vehicle control) as previously described, were labelled 
for integrin α2β1 and secondary stained with anti-mouse Alexa Fluor 647 conjugated. TIRFM 
highlights the lack of enrichment of integrin α2β1 on collagen upon PRT treatment (Ai). The 
dSTORM image of the same cells confirms the absence of receptor clustering along collagen 
fibres (Aii). Receptor clustering was quantitatively determined by the application of two-level 
cluster analysis based on DBSCAN. Both clustering levels show the absence of continuous 
clusters along fibrous collagen in comparison with control and PP2-treated platelets (Aiii, iv). 
The quantification of integrin α2β1 cluster and nanocluster area and density is reported in B, 
C, D, E as mean ± SEM from three independent experiments (a total of at least 12 FOVs for 
each condition were analysed). One-way ANOVA with Tukey’s multiple comparisons was 
used to evaluate the statistical significance (P < 0.05). Scale bar: 5 μm (dSTORM images) and 




















In this Chapter, we have used a variety of advanced microscopy, image analysis and 
biochemical techniques to demonstrate that GPVI-mediated signalling is sustained in platelets 
adhering to and spreading on an immobilised collagen surface. Our data show that GPVI 
clustering along collagen fibrils leads to a concentration of the receptor and activated 
downstream signalling molecules such as pSyk and pLAT. Downstream signalling events, 
such as Ca
2+
 spiking is also maintained over the 3 h time period. Our epifluorescence and 
single molecule imaging data show a little overlap of GPVI with its sheddase ADAM10. This 
is consistent with no significant shedding of GPVI taking place in collagen-adhered platelets 
over a 3 h time frame. Furthermore, once bound to collagen, GPVI does not require positive 
feedback from secondary mediators or Src-family and Syk kinases to maintain the clusters. 
This is in contrast to integrin α2β1 which necessitates continued Syk, but not Src, activity to 
remain bound to collagen fibrils. 
In Chapter 3, we have shown that GPVI is enriched along collagen fibres and remains 
clustered over a 3 h time frame. We hypothesized that clustering of GPVI may support and 
potentiate signalling at the platelet surface through the recruitment and activation of signalling 
proteins. Our data support this hypothesis with sustained tyrosine phosphorylation of Syk and 
LAT and Ca
2+ 
mobilisation which maintain platelet spreading on collagen for at least 3 h. This 
is in line with studies under flow conditions which demonstrated that GPVI activation results 




under flow which is sufficient to mediate the 
integrin-dependent firm adhesion of platelets to collagen (Mazzucato et al., 2009, Pugh et al., 
2017). However, the signalling dynamics observed in platelets stimulated in suspension were 
different with downregulation in Syk and LAT phosphorylations over time. This is in contrast 





signal transduction in platelets and GPVI-expressing cell lines (Tomlinson et al., 2007). This 
discrepancy is likely due to the different antibodies used to measure the levels of tyrosine 
phosphorylations; the 4G10 antibody used by Tomlinson et al. (2007) detects whole-cell 
tyrosine phosphorylations, which also include negative regulations. Syk downregulation 
within the GPVI signalling pathway has previously been attributed to the phosphatase T-cell 
ubiquitin ligand-2 (TULA-2) in human platelets stimulated with CVX (Thomas et al., 2010). 
Furthermore, this regulatory mechanism has recently been mathematically modelled (Dunster 
et al., 2015); however, the model did not take into account spatial information relating to 
GPVI within the platelet PM which will undoubtedly affect the signalling transduction.  
A major difference between the two stimulations is that, in the spreading experiment, the 
GPVI ligand (collagen) is immobilised on a surface whereas, in solution, the collagen and the 
platelets are continuously moving so contact between the two might be more transient and 
less stable. Signals emanating from smaller, more mobile clusters would be more prone to 
downregulation from negative regulators such as phosphatases or sheddases as these would 
have easier access to the receptor and downstream signalling proteins. However, once bound 
to an immobilised ligand, GPVI would not be able to move within the plane of the platelet 
PM and as the platelet spread more receptors bind to the collagen increasing the cluster size 
and facilitating the formation of signalling complexes that may help to exclude negative 
regulators. These functional advantages of receptor clustering has also been studied in other 
cell types (Cebecauer et al., 2010). T cells are a good example as an immunological synapse 
can be experimentally induced by immobilising activating antibodies on a glass slide and 
allowing T cells (e.g. Jurkat T cells) to interact with them. Studies on this model system have 
demonstrated the formation of TCR clusters and large signalosomes within the T cell PM 





signalling transduction (Douglass and Vale, 2005, Furlan et al., 2014, Lin and Weiss, 2003). 
In spreading platelets we have shown that total phosphotyrosines and particularly 
phosphorylated LAT and Syk were specifically enriched at the large collagen-bound clusters 
even after 3 h of spreading, supporting the hypothesis that clustering facilitates sustained 
signalling. It would be interesting to investigate whether phosphatases known to be involved 
in downregulation of GPVI signalling such as TULA-2 (Dunster et al., 2015, Thomas et al., 
2010) are excluded from these clusters as seen for CD45 (Furlan et al., 2014) and CD148 (Lin 
and Weiss, 2003) in T cells.  
GPVI density at the platelet surface is also modulated by cleavage of the extracellular region 
by members of the ADAM family of sheddases. It is known that shedding of GPVI can be 
induced by a number of physiological and non-physiological stimuli (Montague et al., 2018a). 
Here, we have shown that GPVI is only shed at very low levels in spread platelets but can be 
cleaved in platelets stimulated in suspension. A recent work by Facey et al. (2016) has shown 
that ADAM10 activity is not affected by collagen engagement but GPVI shedding occurs 
(Facey et al., 2016), suggesting the existence of another level of control which could include 
altered ADAM10 or GPVI localisation within the PM. Our findings have shown that there is 
no clear colocalisation of GPVI and ADAM10 at collagen fibres and, as the cluster size and 
density do not decrease over time, little shedding is occurring in these regions, likely due to 
the exclusion of the sheddase. Other possible components involved in the protection from 
shedding are tetraspanins, a superfamily of 33 four-transmembrane proteins, which can 
interact with both ADAM10 and GPVI. Indeed, recent findings from Noy et al. (2016) have 
demonstrated that Tspan14, which belongs to TspanC8 subgroup and regulates ADAM10 
maturation and trafficking, was the only tetraspanin able to inhibit GPVI cleavage by 





interaction of GPVI and ADAM10 with different tetraspanin partners may drive the 
activation/blocking of receptor shedding (Noy et al., 2016). 
In addition to ADAM10, platelets express and release several metalloproteinases [matrix 
metalloproteinases (MMPs) and ADAMs] which regulate platelet functions (Montague et al., 
2018a), raising also the question whether ADAM10-independent shedding takes place at the 
platelet surface. Using the broad-spectrum metalloproteinase inhibitor, GM6001 and the 
ADAM10-specific inhibitor, GI254023, we correlated GPVI clustering pattern and size with 
the block of shedding. GPVI oligomerisation was not affected when the sheddases, including 
ADAM10, were blocked further reinforcing our proposed model. Contrarily, NEM, which 
enhances ADAM10 activity (Facey et al., 2016) and induces ~100% shedding as shown by 
Western blot, triggered the release of the majority of GPVI receptors from the platelet surface. 
Only a few localisations were detected by dSTORM indicating that some receptors may be 
trapped between platelets and collagen and therefore they are not accessible for release. The 
thiol-modifying reagent NEM may represent a stronger and/or faster stimulus than the GPVI 
physiological ligand, collagen, or they may induce shedding through a different mechanism. 
Indeed, GPVI shedding induced by ligand engagement is thought to require receptor 
clustering, dissociation of CaM from the intracellular tail and activation of the signalling 
cascade (Gardiner et al., 2004). Platelet spreading on collagen was impaired upon NEM-
induced shedding, suggesting that intact GPVI receptors are fundamental for the initial steps 
of platelet activation and spreading on a collagen surface. This is in accordance with previous 
studies conducted in GPVI-deficient patients (Arai et al., 1995, Boylan et al., 2004, Dumont 
et al., 2009, Matus et al., 2013, Sugiyama et al., 1987, Takahashi and Moroi, 2001) and mouse 





2001a, Nieswandt et al., 2001b) which all exhibited impaired platelet adhesion and 
aggregation in response to collagen. 
Upon collagen-adhesion, activated platelets release soluble agonists from the storage 
organelles such as ADP and TxA2 which act as pro-thrombotic triggers through the 
amplification of the signalling cascades, ultimately leading to enhanced integrin activation 
and platelet aggregation (Bye et al., 2016). Despite all these roles in platelet responses, the 
discharge of secondary mediators is not needed to potentiate platelet spreading on collagen 
and GPVI signalling or cluster formation, as these events were not altered in the presence of 
indomethacin and apyrase. This is in contrast to CLEC-2 signalling which requires second 
messenger as platelets treated with indomethacin and apyrase showed a dramatic impairment 
of CLEC-2 phosphorylation, whole-cell tyrosine phosphorylation and rhodocytin-induced 
platelet aggregation (Pollitt et al., 2010). Therefore, these results suggest that soluble agonists 
do not function as a positive feedback loop of the initial stimulus on collagen in contrast to 
their fundamental role in supporting collagen-induced platelet aggregation during thrombus 
growth (Atkinson et al., 2001). 
GPVI activation by collagen results in a potent cascade of protein tyrosine phosphorylation 
initiated by Src-family and Syk kinases and culminating in Ca
2+
 elevation (Watson et al., 
2010). The Src-family kinase inhibitor PP2 (Ezumi et al., 1998, Li et al., 2010, Spalton et al., 
2009) and Syk inhibitor PRT (Badolia et al., 2017, Jooss et al., 2019, Reilly et al., 2011) have 
been widely used to investigate the Src and Syk-dependent platelet activation processes 
mediated by GPVI. At concentrations able to block collagen-induced platelet aggregation, 
inhibition of either kinases interfered with platelet spreading. The effect was more marked 
with the Syk inhibitor in accordance with previous findings (Poulter et al., 2017), indicating 





by collagen. On the other hand, when platelets were already spread, Src kinases activity was 
not needed to support platelet spreading along collagen fibres. Notably, Syk kinase appeared 
to be important for the maintenance of platelet morphology during spreading with the 
detection of foci of actin depolymerisation, likely due to the inhibition of downstream targets 
implicated in the cytoskeletal regulation such as Vav1 and SLP-76 (Judd et al., 2000, 
Obergfell et al., 2002, Obergfell et al., 2001).  
Since receptor cluster formation seems to play a role in sustaining the signalling over time, 
the signalling itself, once activated, may contribute to the ability of GPVI to coalesce in large 
clusters in a double-positive loop manner. Our results have demonstrated that Src-family and 
Syk kinases signalling are fundamental for sustaining full GPVI activation as tyrosine 
phosphorylation of Syk and PLCγ2 were decreased and Ca
2+ 
spiking was severely impaired 
by PP2 and PRT treatment post-spreading. Notably, phosphorylation of LAT in its Tyr 200 
was reduced by Src but not Syk inhibition. This could be related to the specific tyrosine 
residue investigated which is a docking and not an activation site (Balagopalan et al., 2010) 
and may be not affected by Syk inhibition. Therefore, other tyrosine residues should be 
explored to evaluate the effect of Syk inhibition on the adapter LAT.  
Despite the effect on GPVI-mediated signalling, inhibition of Src or Syk in spread platelets 
did not impair receptor cluster formation along collagen fibres, with only a slight increase in 
GPVI nanocluster area seen upon Syk inhibition. It has previously been shown that disruption 
of the actin cytoskeleton reduces the formation of GPVI dimers (Poulter et al., 2017). Here, 
we have found that Syk inhibition triggers the actin depolymerisation which may disrupt 
GPVI dimers and result in the deposition of slightly larger nanoclusters at the platelet surface. 
However, this finding is in contrast to work on the FcγR in macrophages where Syk inhibition 





et al., 2014). Together, these results suggest that, whereas sustained collagen-induced platelet 
activation requires intact Src and Syk activity, prolonged GPVI cluster formation does not. 
This is in line with findings from Poulter et al. (2017) who showed that pre-treatment of 
platelets with Src and Syk inhibitors does not preclude the formation of GPVI oligomers on 
collagen (Poulter et al., 2017). On the contrary, only Syk kinase activity was required for 
maintaining integrin α2β1 clustering along collagen since its inhibition induced the disruption 
of the long and continuous clusters aligned on collagen fibres. Unlike GPVI whose affinity 
for collagen is regulated via dimerisation, integrins fluctuate between an ‘on’ and ‘off’ state 
and only the conversion into the active conformation allows the high-affinity ligand binding 
(Hynes, 2002, Spiess et al., 2018). The F-actin cytoskeleton plays an important role in the up-
regulation of integrin activity (Zhu et al., 2008) through the engagement of different adaptor 
proteins such as kindlin, vinculin and talin which couple integrins to the F-actin (Horton et al., 
2015). Syk inhibition using piceatannol has previously been shown to cause a redistribution of 
the actin cytoskeleton in macrophages (Jaumouillé et al., 2014). Here, we have shown that 
Syk inhibition via PRT treatment also results in the disruption of the cortical actin 
cytoskeleton in spread platelets. Integrin α2β1 is linked to the actin cytoskeleton via talin 
(Beckerle et al., 1989) and we propose that actin disruption causes the inactivation of the 
integrin and its subsequent dissociation from collagen. Indeed, loss of talin from platelets 
causes a massive reduction in β1 integrin-mediated platelet adhesion under flow conditions, 
with no stable adhesion or microthrombi formed (Petrich et al., 2007), demonstrating the 
importance of this interaction. As GPVI clusters are largely unaffected by the PRT treatment 
it implies that, once bound to collagen, GPVI remains bound and does not have such a 
dependence on the actin cytoskeleton, although there is some evidence that actin is involved 





Overall, the findings in this Chapter propose that clustering of GPVI on immobilised collagen 
protects GPVI from shedding, possibly through the marginalisation of ADAM10, to maintain 
sustained Src and Syk kinases-dependent signalling, integrin activation and continued 
adhesion to collagen. The sustained adhesion and signalling is likely to be important for 
thrombus stability and the prevention of bleeding associated with disrupted vascular integrity 






















Purification and characterisation of different 

















The company VIB Nanobody Core (Brussel, Belgium) was contracted to raise nanobodies 
against a recombinant form of dimeric GPVI (hGPVI-Fcα-His6). In total, 54 different 
nanobody sequences, from 33 different families (based on CD3 sequences), were obtained 
from the immunization of two llamas. VIB provided us with vials of E. coli TG1 harbouring 
recombinant phagemid pMECS containing the nanobody genes. The pMECS vector enabled 
the addition of an HA tag and a His6 tag to the nanobodies to allow their purification and 
further detection. The main aim of this Chapter was to find a nanobody that was suitable for 
super-resolution imaging of GPVI in platelets. Initially, all 54 nanobodies were produced and 
screened for reactivity to native GPVI and then 3 of the candidate nanobodies were taken 
forward to fully characterise for imaging purposes. 
5.2 Introduction 
Antibodies are fundamental tools in biomedical research and typically share a common 
structure consisting of a combination of heavy and light chains which are required for the 
recognition of the target antigen. Simpler antibodies lacking the light chains are naturally 
found in sera of camelids and sharks. These ‘heavy-chain only’ antibodies have been widely 
used for the engineering of nanobodies which are composed of only a single antigen-binding 
domain, namely the variable region of the heavy chain (camelid VHHs or shark VNARs, Fig. 
5.1). They only measure ~4 nm in length (MW: ~15 kDa) and therefore are much smaller than  
than full-length antibodies (length: ~15 nm and MW: 150 kDa) and Fab fragments (length: ~9 






Figure 5.1. Structural properties of canonical antibodies, Fab fragments and camelid 
‘heavy-chain only’ antibodies. The canonical antibody structure (150 kDa, 15 nm) contains 
two heavy (H) and two light (L) chains, each with variable (V) and constant (C) regions. The 
Fab fragment (50 kDa, 9 nm) represents the antigen-binding domain of a standard antibody 
which can be chemically separated from the Fc portion, resulting in a monomeric antibody. 
Nanobodies (15 kDa, 4 nm) are single antigen-binding domain antibodies corresponding to 
the variable region of the heavy chain of camelid and shark ‘heavy chain only’ antibodies 
(VHHs in camelids and VNARs in sharks). VH: variable domain of the heavy chain; VL: 
variable domain of the light chain; CH: constant domain of the heavy chain; CL: constant 
domain of the light chain; VHH: variable domain of the heavy chain of ‘heavy-chain only 












Despite the small dimensions, nanobodies exhibit the same specificity as standard antibodies 
and provide numerous advantages in biological, diagnostic and therapeutic approaches 
(Beghein and Gettemans, 2017, Siontorou, 2013). Their small size, in combination with an 
extended CDR3 loop, allows them to bind hidden or difficult-to-access antigens such as 
enzyme active sites (De Genst et al., 2006), infectious agents (Stijlemans et al., 2004) and 
conformational epitopes (Manglik et al., 2017). In vivo, this unique property can be exploited 
for diagnostic and therapeutic applications, due to their efficient tissue penetration, rapid 
blood clearance, high stability and low immunogenicity (Hu et al., 2017, Siontorou, 2013). In 
particular, nanobodies targeting tumour markers have been successfully adopted in cancer 
biology for non-invasive in vivo tumour imaging in xenograft cancer models (Kijanka et al., 
2013, Oliveira et al., 2012) and for the development of drug delivery strategies, for example 
using nanobody-coupled liposomes and micelles delivery systems (Talelli et al., 2013, Talelli 
et al., 2011, Van Der Meel et al., 2012, van der Meel et al., 2013). This is also achieved 
because they can be easily genetically engineered, allowing the generation of customized 
constructs, such as bivalent and bispecific nanobodies (Els Conrath et al., 2001, Ulrichts et al., 
2011). An interesting example in the platelet biology is represented by the antithrombotic 
agent ALX-0081, a bivalent anti-vWF nanobody which is currently under clinical trials 
(Ulrichts et al., 2011). In cellular biology, nanobodies have been successfully used in the 
purification of native protein complexes by affinity chromatography (Fridy et al., 2015, 
Pleiner et al., 2015) and in the investigation of protein localisation by super-resolution 
microscopy (Platonova et al., 2015, Pleiner et al., 2015, Ries et al., 2012, Virant et al., 2018). 
In addition, nanobodies have been used as crystallization chaperones in structural biology 






Despite numerous advantages, nanobodies do have several limitations. They are usually well-
expressed in E. coli strains and purified from their periplasmic space where they are secreted. 
However, purification of proteins from the periplasm is much more difficult than from the 
cytoplasm and can compromise the final yield, due to the limited secretion capacity and the 
elevated number of proteases which can catalyze the proteolysis of the final recombinant 
proteins (Rosano and Ceccarelli, 2014). Nanobodies are characterised by a convex shape in 
comparison with the flat or concave conformation of conventional antibodies. While this 
feature represents an advantage for the binding to concave-shaped enzyme active sites (De 
Genst et al., 2006), it also limits the use of nanobodies for the detection of small molecules, 
since their topology would not be suitable for the binding of targets with limited size 
(Muyldermans, 2013). 
Despite these limitations, there is a growing interest in using nanobodies as alternatives to 
full-length antibodies and Fab fragments in super-resolution microscopy to exploit the full 
potential of this cutting-edge technique in localising target proteins to the highest precision 
(Traenkle and Rothbauer, 2017). In immunofluorescence microscopy, the use of a primary 
and a fluorescently-conjugated secondary antibody to detect the epitope of interest would 
displace the fluorophore from the epitope by ~30 nm (Deschout et al., 2014b). Nanobodies 
have turned out to be the ideal substitute for conventional antibodies since they significantly 
decrease the label-epitope distance and enhance the achievable spatial resolution of protein 
localisation by super-resolution microscopy (Platonova et al., 2015, Pleiner et al., 2015, Ries 
et al., 2012, Virant et al., 2018). However, the direct conjugation of nanobodies with 
fluorescent dyes represents a critical point which may result in poor labelling, low signal-to-
noise ratio or even loss of functionality. Traditional labelling strategies include the 





Alexa Fluor dyes at lysine residues (Platonova et al., 2015, Ries et al., 2012). However, this 
labelling method is not site-specific and often results in a high background staining (Pleiner et 
al., 2015, Virant et al., 2018). Alternative site-specific labelling approaches have been 
proposed and involve the enzymatic coupling of fluorophores to protein tags (Virant et al., 
2018) or via cysteines engineering with maleimide fluorophores (Pleiner et al., 2015), 
resulting in a high-quality super-resolution performance. 
In this Chapter, we have produced and initially characterised the first 20 nanobodies against 
human GPVI expressed in TG1 E. coli strain. The remaining 34 nanobodies of the full set 
were purified, characterised and screened by the research technician Ying Di to select three 
candidates (two for imaging purposes and one as inhibitory reagent) to express in the WK6 E. 
coli strain to generate pure nanobodies. A full investigation of these three nanobodies, 
belonging to different CDR3 groups, has been carried out in human platelets with one 
nanobody being selected as a promising tool for dSTORM imaging and fluorescently labelled 












5.3.1 Expression, purification and initial characterisation of 20 nanobodies 
targeting human GPVI cloned in pMECS vector by TG1 E. coli strain 
We have expressed and purified the first subset of 20 nanobodies against human GPVI from 
the TG1 E.coli strain in two consecutive rounds (I and II batches of 10 nanobodies each, as 
described in Materials and Methods). These 20 nanobodies are taken from a number of 
different CDR3 families, with some families having more than one nanobody associated with 
it. Those classified in the same CDR3 family recognize the same epitope on GPVI; however, 
due to small sequence differences, other characteristics such as affinity, potency, stability and 
expression yield of individual nanobodies may be different. The successful generation of 
nanobodies is shown in Fig. 5.2 where 1 μg of each nanobody was loaded into a 
polyacrylamide gel and the purity of the nanobodies was inspected by Coomassie staining 
under reducing conditions. The bands relating to the pure nanobodies appeared at ~17 kDa 
whereas the top bands at ~58 kDa correspond to the nanobodies fused with the protein III of 
the phage (Fig. 5.2A, C). The fused proteins were detected in some clones but not in others, 
likely due to the different percentage of suppression of the amber stop codon following the 
His6 tag in TG1 strains. Western blot confirmed the presence of nanobodies using anti-His6 
tag for the detection (Fig. 5.2B, D). The nanobodies were detected at ~17 kDa as shown 
previously whereas the fused proteins were undetectable, indicating that the His6 tag may be 
covered by the protein III of the phage. 
To investigate whether the nanobodies were able to efficiently bind GPVI in human platelets, 
we performed flow cytometry analysis in resting platelets and platelets activated by CRP-XL, 





antibody were used as negative controls (Fig. 5.3Ai, B). All the nanobodies were able to bind 
human GPVI as shown by the increase in the mean fluorescence intensity (MFI) in resting 
and activated platelets in comparison with the negative control (Fig. 5.3Aii, iii, C). However, 
for all the nanobodies (except nanobody #15), the extent of binding appeared to increase in 
CRP-stimulated platelets, likely due to the recognition of the dimeric conformation of GPVI 























   
Figure 5.2. Purification of 20 nanobodies against human GPVI cloned in pMECS vector 
by TG1 E.coli strain. Coomassie staining of SDS-PAGE gels under reducing conditions 
loaded with 1 μg of 20 different nanobodies (Nbs) purified in two consecutive rounds (A, C). 
The pure Nbs appear at ~17 kDa whereas the Nbs fused with the protein III of the phage 
become visible at ~58 kDa (indicated by black arrows). Western blot confirms the presence of 
Nbs detected by anti-His6 tag HRP conjugated secondary antibody (1/1000) at ~17 kD. The 
chemiluminescent detection of the Nbs was undertaken using the Odyssey Fc system (LI-
COR) (B, D). Technical assistance in expressing and purifying the nanobodies was kindly 





     
Figure 5.3. Flow cytometry analysis of nanobodies binding in resting and CRP-activated 
platelets. Human washed platelets, unstimulated (PBS) or stimulated with 10 μg ml
-1
 CRP-




secondary stained with anti-His6 HRP 
conjugated (1/500) + anti-Mouse IgG Alexa Fluor 647 conjugated (1/500) and GPVI-binding 
was assessed by flow cytometry. The fluorescence signal on gated platelets was detected in 
the FL4 channel and is expressed as MFI (n=1). The flow cytometry traces in Ai and the 
histogram in B show a representative example (Nb #1) of the increased signal in platelets 
stained with the Nb in comparison with unstained platelets and platelets labelled only with the 
secondary antibody (2 Ab only). For all the purified Nbs, the extent of binding in resting and 





5.3.2 Expression and purification of three nanobodies targeting human 
GPVI cloned in pMECS vector by WK6 E. coli strain 
Once the full set of 54 nanobodies had been expressed and purified in TG1 E. coli strain, they 
were further characterised by the research technician Ying Di to select good candidates to 
express and produce in WK6 E. coli strain. The nanobodies extracted from WK6 E. coli are 
pure since the amber stop codon, which follows the His6 tag in the pMECS vector, is read as a 
stop codon and therefore the production of the nanobody fused with the protein III of the 
phage is suppressed. Nanobodies #14 and #27 were chosen as potential good candidates for 
imaging applications whereas nanobody #21 was selected as a putative blocking reagent. 
These three nanobodies are classified in different CDR3 families suggesting their epitopes are 
slightly different.  
All the three nanobodies were successfully expressed and purified in WK6 E. coli strain as 
shown by the bands appearing at ~17 kDa in the Coomassie staining of SDS-PAGE gel 
loaded with 100 μg ml
-1 
nanobodies (Fig. 5.4A). Higher MW bands corresponding to fused 
proteins did not appear, confirming the nanobody purity. Western blot confirmed that the 
eluted proteins correspond to the nanobodies since they were detected by antibodies against 











                       
Figure 5.4. Purification of nanobodies #14, #21 and #27 against human GPVI cloned in 
pMECS vector by WK6 E.coli strain. The purity of nanobodies (Nbs) #14, #21 and #27 
(100 μg ml
-1
) extracted from WK6 E.coli strain was checked by Coomassie staining of SDS-
PAGE gel under reducing conditions. Bands corresponding to the Nbs appear at ~17 kDa (A). 
Western blot and anti-His6 tag and HA tag HRP conjugated secondary antibodies (1/1000) 
were used to confirm the presence of Nbs. The chemiluminescent detection of the Nbs was 





5.3.3 Binding of nanobodies #14, #21 and #27 to recombinant GPVI  
To investigate whether nanobodies #14, #21 and #27 were functional and able to bind GPVI 
in a monomeric and/or dimeric conformation, an ELISA binding assay was carried out using 
recombinant monomeric (mGPVI) and dimeric GPVI (GPVI-Fc/dGPVI) proteins (as 
described in Materials and Methods). The Fc domain and BSA were used as negative 
controls. Fig. 5.5A, B, C shows that all the nanobodies, at a concentration of 1 μM, bound 
both monomeric and dimeric GPVI with no selectivity for one of the two receptor 
conformations. 
To further explore the position of the nanobody-binding sites on GPVI, ELISA-based assay 
using different recombinant proteins corresponding to the monomeric full-length GPVI 
(GPVI FL) and the D1 and D2 domains of the receptor extracellular region was performed. 
The protein named CD200 represents the negative control. The linear dose-response plot 
shows that nanobody #14 bound only GPVI FL with the maximal response obtained at 100 
nM (Fig. 5.5D), indicating that it likely binds GPVI at the interface between D1 and D2 
domains. Contrarily, nanobodies #21 and #27 were able to bind both GPVI FL and D1 (Fig. 
5.5E, F), suggesting that they may interact with the same binding domain as collagen. Like 
nanobody #14, the highest binding of nanobody #27 to GPVI FL was detected at 100 nM 
(Fig. 5.5F). Contrarily, nanobody #21 required lower concentration (1.23 nM) to induce the 
maximal response (Fig. 5.5E). However, this result is representative of only one experiment 
and further research needs to be done to determine the binding affinity of each nanobody by 














Figure 5.5. ELISA assay of nanobodies #14, #21 and #27 binding to recombinant GPVI 
constructs. The ELISA-based assay was performed in Nunc MaxiSorp® micro-titer 96 well 
plates coated with 0.1 μM recombinant mGPVI, dGPVI (GPVI-Fc) and Fc domain (negative 
control) at 4 °C overnight. A 3% BSA-coated well was used as an extra negative control. 
Nanobodies (Nbs) #14, #21 and #27 (1 μM) were allowed to bind to the recombinant proteins. 
Bound Nbs were detected using anti-His6 tag HRP conjugated secondary antibody (1/10,000). 
The histograms show the mean ± SEM absorbance (OD = 405 nm) for each Nb compared 
with the controls from three replicates (A, B, C). The significant difference was evaluated 
using one-way ANOVA with Tukey’s multiple comparisons (P < 0.05). The ELISA binding 
assay was also performed on additional recombinant proteins: monomeric GPVI FL, GPVI 
D1 and D2 domains and CD200 (negative control). The Nbs were used at the initial 
concentration of 300 nM and then diluted 1:3. Bound Nbs were detected using anti-HA HRP 
conjugated secondary antibody (1/10,000). The linear dose-response plots (D, E, F) show the 
specific binding of Nb #14 to GPVI FL and Nbs #21 and #27 to GPVI D1 domain (n=1). The 
data in parts D-F was kindly provided by Dr Ruben Barroso and Dr Yi Sun, University of 






















5.3.4 Nanobody #14 but not #21 and #27 binds GPVI in human platelets 
To confirm the binding of nanobodies #14, #21 and #27 to endogenous GPVI in human 
platelets, flow cytometry analysis was carried out in resting platelets and platelets stimulated 
with different agonists, namely PAR1 peptide and CRP-XL which induce platelet activation 
in a GPCR and ITAM-dependent manner, respectively. P-selectin exposure was used as a 
marker of platelet activation (Fig. 5.6Ai, ii). In addition, unspecific binding was monitored by 
labelling platelets with only the secondary antibody (anti-His6 Alexa Fluor 647 conjugated, 
Fig. 5.6B, C, D). At the final concentration of 8 μg ml
-1
, nanobody #14 was able to bind 
endogenous GPVI. This is shown by the significant increase in the MFI value induced by 
nanobody #14 in both resting and activated platelets in comparison with platelets stained only 
with the secondary antibody (5 different donors, Fig. 5.6Bi, ii). Contrarily, at the same final 
concentration used for nanobody #14, no binding of nanobodies #21 and #27 was detected (2 
of the 5 donors used to test nanobody #14, Fig. 5.6C, D, E, F). Hypothesizing that the 
concentration of nanobodies #21 and #27 was not sufficient to bind GPVI in human platelets, 
we have repeated the experiments on other 3 different donors (the same donors used to test 
nanobody #14) using higher concentrations of both nanobodies (38 and 63 μg ml
-1
 for #21 and 
#27, respectively). Nanobodies #21 and #27 did not induce a significant increase in the MFI 
value relative to the negative control even at higher concentrations (Fig. 5.6 G, H), suggesting 
that they may induce a change in GPVI conformation or localisation, thereby making it 











Figure 5.6. Flow cytometry analysis of nanobodies #14, #21 and #27 binding to GPVI in 
resting and PAR1 and CRP-activated platelets. Unstimulated human platelets (PBS) or 
platelets stimulated with 200 μM PAR1 peptide or 10 μg ml
-1
 CRP-XL, were labelled with PE 
anti-human CD62-P to monitor P-selectin exposure as a marker of platelet activation (Ai, ii). 
Resting and activated platelets were also incubated with 8 μg ml
-1 
nanobody (Nb) #14 and 
secondary labelled with anti-His6 Alexa Fluor 647 conjugated (1/80) (Bi, ii, n=5). In the first 2 
experiments, Nbs #21 and #27 were used at the same concentration of Nb #14 (8 μg ml
-1
, C, 
D, E, F) whereas higher concentrations (38 and 63 μg ml
-1 
for #21 and #27, respectively) were 
tested on the last 3 donors (G, H). Platelets stained only with the secondary antibody were 
used as a negative control. On gated samples, positive signals for P-selectin and Nbs were 
detected in the FL2 and FL4 channels, respectively. The flow cytometry analysis 
demonstrates that only Nb #14 can bind GPVI in human platelets (Bi, ii). One-way ANOVA 
with Tukey’s multiple comparisons shows a significant increase (P < 0.05) in the MFI value 
induced by Nb #14 in resting and activated platelets compared with platelets labelled only 







5.3.5 Nanobodies #21 and #27 but not #14 induce GPVI shedding in human 
platelets 
In addition to the other mechanisms, the antibody-induced shedding has been described as a 
potent trigger of GPVI shedding in patients and mouse models (Boylan et al., 2006, Boylan et 
al., 2004, Nieswandt et al., 2001b, Schulte et al., 2003). In light of the lack of binding of 
nanobodies #21 and #27 in human platelets, we postulated that they may induce the release of 
GPVI from the platelet surface, thereby preventing the binding. For this purpose, platelets 
were stimulated with each of the three nanobodies under stirring conditions for 1 h and GPVI 
cleavage was explored by Western blot using the anti-GPVI-tail antibody. In control platelets 
(stimulated with PBS) and platelets incubated with nanobody #14, GPVI shedding was not 
triggered as the band relating to the intracellular tail at ~10 kDa did not appear (Fig. 5.7A). 
However, nanobodies #21 and #27 caused receptor cleavage from the cell surface with 
detection of the band relative to the 10 kDa membrane-bound tail (Fig. 5.7A). ~25% of total 
GPVI receptor underwent proteolytic cleavage after 1 h of stimulation with nanobodies #21 
and #27 (Fig. 5.7B). Therefore, this finding could, at least partially, explain the loss of GPVI 
signal in flow cytometry and proposes a novel, unexplored mode of action of anti-GPVI 










      
Figure 5.7. GPVI shedding in platelets stimulated with nanobodies #14, #21 and #27. 
Human washed platelets, pre-incubated with 2 mM CaCl2, were stimulated with 8 μg ml
-1 
nanobodies (Nbs) #14, #21 and #27 or PBS (control) for 1 h under stirring conditions. SDS-
PAGE analysis and western blot were carried out on lysates from both control and stimulated 
platelets. GPVI shedding was evaluated by immunoblotting with the anti-GPVI-tail antibody, 
secondary labelled with anti-rabbit IRDye 800CW conjugated secondary antibody and 
fluorescently revealed by Odyssey Fc system (LI-COR). The loading was monitored using the 
α-tubulin antibody (A). The percentage of shed GPVI was calculated on the fluorescent signal 








5.3.6 Nanobodies #21 and #27 but not #14 inhibit platelet aggregation in 
response to collagen 
Previous work performed on recombinant GPVI proteins has demonstrated that nanobody #14 
binds full-length GPVI whereas nanobodies #21 and #27 interact specifically with the GPVI 
D1 domain, the major collagen-binding site. Thus, we hypothesized that nanobodies #21 and 
#27 could potentially compete with collagen for binding to GPVI and interfere with collagen-
induced platelet aggregation. Fig. 5.8A, B shows that collagen at 3 μg ml
-1 
triggered ~70% of 
the maximal aggregation within a 5 min time in control samples. At 10 μg ml
-1 
nanobody #14 
did not significantly affect platelet aggregation in response to collagen (Fig. 5.8A, B). 
However, there was significant inter-donor variability, with the platelets from some donors 
aggregating normally to collagen stimulation whilst the platelets from other donors did not 
aggregate at all. On the contrary, nanobodies #21 and #27 at the same concentration used for 
nanobody #14, completely blocked platelet aggregation induced by collagen compared with 
control platelets (Fig. 5.8A, B). Therefore, this result demonstrates that nanobodies #21 and 
#27 interfere with platelet function in response to collagen and supports previous findings 
proposing that they may occupy the collagen-binding site of GPVI and induce the proteolytic 





    
 
Figure 5.8. Effect of nanobodies #14, #21 and #27 on collagen-induced platelet 
aggregation. The effect of nanobodies (Nbs) #14, #21 and #27 (10 μg ml
-1
) or PBS (control 
vehicle) on platelet aggregation in response to collagen (3 μg ml
-1
) was monitored by light 
transmission aggregometry at 37 °C under steady stirring conditions (1200 rpm) within a 5 
min time frame. The aggregation traces shown in A are representative of n=4 separate 
experiments. The histogram reports the mean ± SEM % of aggregation in control platelets and 
platelets incubated with Nbs (B). One-way ANOVA with Tukey’s multiple comparisons 








5.3.7 Effect of nanobodies #14, #21 and #27 on platelet spreading on 
collagen 
To further investigate whether the nanobodies compete with collagen for binding to GPVI, we 
evaluated their effect on platelet adhesion and spreading on immobilised collagen in static 
conditions. Based on the ELISA and aggregation data, we expect that pre-incubation of 
platelets with nanobodies #21 and #27 would prevent GPVI-collagen interaction with the 
subsequent impairment of platelet adhesion and spreading. The platelet count, used as a 
quantitative parameter of platelet adhesion, was not hampered by nanobodies #14, #21 and 
#27 (Fig. 5.9B). The spreading of platelets in the presence of the different nanobodies was 
also not significantly affected in comparison with the control platelets (Fig. 5.9C). However, 
we again found a high inter-experimental variability with the platelets from some donors 
showing a normal spreading whilst the platelets from other donors exhibiting a partial 
reduction in spreading. Therefore, it would be good to test the effect of the nanobodies on 
collagen-induced platelet aggregation and spreading using the same platelet donor to 
understand whether the outcomes correlate to each other. In summary, whilst nanobodies #21 
and #27 block platelet aggregation in response to collagen, they do not profoundly impair 
collagen-induced platelet spreading, likely due to the ability of integrin α2β1 to support 
platelet adhesion and spreading on collagen.  








Figure 5.9. Effect of nanobodies #14, #21 and #27 on collagen-induced platelet adhesion 
and spreading. Human washed platelets, pre-incubated with nanobodies (Nbs) #14, #21 and 
#27 (5 μg ml
-1
) or PBS (control vehicle) for 10 min, were spread on an immobilised collagen 
(10 μg ml
-1
) surface for 1 h. F-actin was stained with Alexa Fluor phalloidin 488 and imaged 
by epifluorescence microscopy (A, first column). The DIC images (A, second column) 
illustrate the adhesion and spreading of platelets on the collagen monolayer. The quantitative 
analysis of platelets count (B) and surface area (C) was performed in KNIME and is reported 
as mean ± SEM from 5 independent experiments (in total, 25 FOVs for each condition were 
analysed). One-way ANOVA with Tukey’s multiple comparisons shows non-significant 
difference (P < 0.05) between the control platelets and platelets incubated with the Nbs. Scale 






5.3.8 Generation and fluorescent labelling of SNAP-tagged nanobody #14 
The full characterisation of nanobodies #14, #21 and #27 enabled the selection of nanobody 
#14 as the best candidate for imaging applications. For SMLM the ideal protein label would 
have a single fluorescent tag to enable accurate quantification. For this purpose, we 
genetically fused the SNAP-tag protein to the N-terminus of the nanobody gene (as described 
in Materials and Methods, Fig. 5.10A) and further purified by FPLC. The FPLC profile 
illustrates that the eluted protein was collected in the fractions 4-8 (Fig. 5.10B) of which 7 and 
8 contained the nanobody with the highest purity, as shown by Coomassie staining of SDS-
PAGE gel (Fig. 5.10C). Western blot confirmed that the bands between 46 and 32 kDa 



















               
Figure 5.10. Production of SNAP-tagged nanobody #14. Nanobody (Nb) #14 was cloned 
into the BamHI and Xhol sites of the SNAP-tag vector as described in Materials and 
Methods. The SNAP-tag lies at the N-terminus of the Nb sequence, the PelB signal sequence 
is lost whereas the HA and His6 tags are still located at the C-terminus of the Nb gene (A). 
FPLC elution profile of SNAP-tagged nanobody #14 (SNAP-Nb #14) where absorbance at 
280 nM is plotted against the elution volume. The protein was eluted by applying a pump B 
gradient which was equilibrated in 500 mM imidazole. The eluent was collected in the 
fractions 4-8 and is represented by a peak (red) in the graph (B). Coomassie staining of SDS-
PAGE gel loaded with the whole-cell lysates (WCL) I and II (from the two bacteria colonies 
harbouring the right insertion of the Nb #14 into the SNAP-tag vector), the flow-through (FT) 
liquid and the fractions 4-8 correspondent to the eluted Nb. The SNAP-Nb #14 was detected 
between 46 and 32 kDa (C, circled in red) as confirmed by Western blot using anti-His6 tag 
HRP conjugated secondary antibody (D). Dr Alex Slater (University of Birmingham, UK) 





The advantage of the SNAP-tag protein is its irreversible, site-specific and quantitative self-
labelling using commercial in vitro kits which covalently attach the fluorophore to the active 
site cysteine (Cole, 2013). We, therefore, exploited the full potential of the SNAP-tag by 
directly conjugating the protein with Alexa Fluor 647, resulting in the generation of SNAP-
nanobody #14-Alexa Fluor 647. The covalent bond between the fluorescent probe and the 
SNAP-nanobody #14 allowed its detection by SDS-PAGE and exposure on the Odyssey 
fluorescence detection system. Fig. 5.11A shows the successful conjugation of the SNAP-
tagged nanobody #14 with the Alexa Fluor 647 dye. We then tested the ability of the 
fluorescently conjugated SNAP-nanobody #14 to efficiently immunolocalise GPVI in 
platelets spread on immobilised collagen compared with 1G5-Fab which has been shown to 
successfully label GPVI in all our previous experiments. Fig. 5.11B shows that whereas 
SNAP-nanobody #14-Alexa Fluor 647 was able to target GPVI as shown by the classical 
enrichment along collagen fibres, it is characterised by a lower signal-to-noise ratio compared 
to 1G5-Fab. Furthermore, we detected non-specific binding to the collagen fibres even outside 
the platelet surface, probably due to the unreacted substrate still present in solution or the 
SNAP-tag itself may non-specifically interact with the collagen substrate. Therefore, this 
finding suggests that further optimisation is required to evaluate the fluorescent SNAP-









          
 
Figure 5.11. Confocal imaging of GPVI labelled with SNAP-nanobody #14-Alexa Fluor 
647 or 1G5-Fab in platelets spread on collagen. The SNAP-tagged nanobody #14 
conjugated with Alexa Fluor 647 (SNAP-Nb #14-Alexa 647) was run on an SDS-PAGE gel 
and detected using Odyssey Fc-system in the 700 nm channel (A). Human washed platelets 
were spread on an immobilised collagen (10 μg ml
-1
) monolayer for 1 h and GPVI was 
labelled with SNAP-Nb #14-Alexa 647 (5 μg ml
-1
, post-spreading) or 1G5-Fab (2 μg ml
-1
, 
pre-spreading) and secondary stained with anti-mouse Alexa Fluor 647 conjugated. Confocal 
imaging shows the comparison between the labelling efficiency of SNAP-Nb #14 and 1G5-
Fab (B, left-hand side). The presence of platelets was confirmed by Alexa Fluor phalloidin 
488 staining of F-actin (B, right-hand side) whereas the collagen distribution was visualised 






Nanobodies are promising experimental tools in a variety of biological applications, including 
super-resolution microscopy for the interrogation of surface receptors localisation (Manglik et 
al., 2017, Traenkle and Rothbauer, 2017). In this Chapter we present the first toolset of 54 
nanobodies generated against the human platelet GPVI receptor. The initial characterisation 
of a subset of 20 impure nanobodies shows high specificity of binding to GPVI in human 
platelets. Ultimately, the full validation of three selected nanobodies, which recognise 
different epitopes of GPVI, highlights their diversity in a variety of biological assays. 
Our ELISA binding assay shows that they were able to specifically bind both recombinant 
monomeric and dimeric GPVI which may represent an advantage for the accurate detection of 
GPVI in activated platelets which is predominantly found in a dimeric conformation (Jung et 
al., 2012, Loyau et al., 2012). The identification of the specific binding site of nanobodies #21 
and #27 in the D1 domain, which represents the major collagen-binding loop (Smethurst et 
al., 2004), gave rise to the hypothesis that they may interfere with GPVI-collagen interaction. 
On the contrary, nanobody #14 only bound the full-length GPVI protein, suggesting that it 
interacts with a different site compared to #21 and #27, probably located at the interface 
between the D1 and D2 loops and therefore not competing with collagen. Surprisingly, flow 
cytometry of GPVI failed to detect binding of nanobodies #21 and #27 to human GPVI 
whereas nanobody #14 successfully labelled GPVI with a large shift in fluorescence detected, 
proposing a compromised presence of GPVI at the platelet surface upon stimulation with the 
first two nanobodies. GPVI surface expression within the PM can be controlled by different 
regulatory mechanisms, most importantly receptor endocytosis and receptor shedding. 
Shedding of GPVI can be induced by a number of physiological/non-physiological stimuli in 





2004), synthetic compounds (Bergmeier et al., 2004, Facey et al., 2016, Gardiner et al., 2004, 
Gardiner et al., 2007), coagulation factors (Al-Tamimi et al., 2011b), shear stress (Al-Tamimi 
et al., 2012, Facey et al., 2016), activation of (hem)ITAM receptors (Gardiner et al., 2008, 
Gitz et al., 2014) and anti-GPVI antibodies (Nieswandt et al., 2001b, Schulte et al., 2003). 
Here, we found that nanobodies #21 and #27 induced ~25% shedding of GPVI, a 
phenomenon that has previously been proposed for conventional antibodies in 
immunodepletion strategies in mouse models (Nieswandt et al., 2001b, Schulte et al., 2003) or 
in patients affected by immune thrombocytopenia as a result of autoimmune processes 
(Boylan et al., 2004, Sugiyama et al., 1987, Takahashi and Moroi, 2001). However, this does 
not explain the total lack of GPVI signal detected by flow cytometry, suggesting that 
additional mechanisms may be involved in affecting the GPVI expression levels at the platelet 
surface. One possibility is that the nanobodies also induce internalisation of GPVI, rendering 
it unavailable to be bound by the fluorescently tagged secondary antibody. It is known that 
CLEC-2 can be internalised following antibody-binding (Lorenz et al., 2015, May et al., 
2009) whereas there is a rudimentary knowledge of whether GPVI can be endocytosed. One 
study has demonstrated the efficacy of an engineered anti-hGPVI antibody, labelled with a 
fluorescent endocytosis probe, to induce a cAMP-dependent GPVI internalisation in both in 
vitro and in vivo systems using cynomolgus monkeys as a model (Takayama et al., 2008). 
Therefore, it would be interesting to investigate whether the anti-GPVI nanobodies can also 
deplete GPVI through endocytosis as described by Takayama et al. (2008). The block of 
platelet aggregation in response to collagen induced by nanobodies #21 and #27 is also in line 
with their putative interaction with the collagen-binding site and the loss/reduction of GPVI 
receptors available to bind collagen and induce aggregation. However, the mechanisms 





conformational change and interfere with receptor dimerisation and clustering, allowing the 
exposure of the cleavage site for metalloproteinases. Alternatively, they may prevent binding 
of a protective protein, for example, a member of the tetraspanin superfamily as proposed by 
the model from (Noy et al., 2016). In addition, whether they induce shedding through 
ADAM10 remains to be verified. The hypothetical change in GPVI distribution relative to 
e.g. ADAM10 and tetraspanins would be revealed by super-resolution microscopy. Taken 
together, these findings propose nanobodies #21 and #27 as potential inhibitory reagents to 
limit platelet activation.  
Nanobody #14 did not induce GPVI shedding or block platelet aggregation. However, the 
aggregation data in the presence of nanobody #14 were characterised by high inter-
experimental variability using platelets from different donors (different gender, age and 
nationality). The same issue was detected in the platelet spreading assay, making the result 
inconclusive. This inter-donor variability may be associated with the expression of a different 
GPVI haplotype (GP6a or GP6b) as platelets homozygous for GP6b express GPVI at a lower 
level and are less able to aggregate compared to homozygous for GP6a (Joutsi-Korhonen et 
al., 2003). One approach to address this issue would be to use the same donor for all the 
assays to verify if the results correlate.  
Taken together, the experimental observations propose nanobody #14 as a non-blocking 
nanobody making it the most promising candidate for SMLM imaging. In our standard 
staining procedure for SMLM imaging of GPVI (Chapter 3 and 4), the epitope is displaced 
from the fluorophore by ~24 nm, interfering with the effective spatial resolution of the 
receptor achieved during imaging. In a previous attempt, the labelling of a nanobody with 
standard NHS ester fluorophores (data not shown) resulted in a poor staining and low signal-





Virant et al., 2018). This labelling procedure is also not site-specific and may compromise the 
epitope-binding. Here, we genetically fused nanobody #14 with the SNAP-tag to obtain an 
irreversible, site-specific and quantitative labelling of the nanobody using a commercial in 
vitro kit (Cole, 2013). This way, we successfully immunolocalised GPVI by epifluorescence 
microscopy. Unfortunately, the fluorescent SNAP-nanobody #14 performed worse than the 
anti-GPVI Fab detected by a fluorescently-conjugated secondary antibody as shown by the 
lower signal-to-background ratio and some unspecific binding to the collagen fibres outside 
the platelet surface. This may be caused by the inefficacy of the dialysis in removing the 
unreacted substrate or the high reactivity of the SNAP-tag. Furthermore, the SNAP-tag is a 
quite large molecule (~20 kDa) and therefore, despite the advantages in specific tagging with 
fluorophores, it is not the ideal solution for SMLM applications.  
Overall, findings from this Chapter represent the first generation and characterisation of 
nanobodies targeting human platelet GPVI and highlight their heterogeneity and suitability 
for many different applications, from anti-platelet approaches to super-resolution imaging. 
Future work is needed to confirm the inhibitory effect of nanobodies #21 and #27 in flow 
assays and in in vivo and ex vivo studies. Moreover, other labelling strategies need to be 
contemplated to adopt and optimise nanobody #14 as a tool for the spatial investigation of 
GPVI receptor by super-resolution imaging. The array of assays reported in this Chapter 
should be taken as an example for the future characterisation of the other unexplored anti-





























6.1 Summary of results 
The platelet collagen receptor GPVI is a current antithrombotic drug target due to its platelet 
(and MK)-specific expression profile and its minimal role in haemostasis. Despite there being 
extensive data on the components of the GPVI signalling cascade, there is negligible 
understanding of how the spatial organisation of GPVI at the platelet PM regulates the 
intracellular signalling. Recent advances in super-resolution microscopy and accompanying 
analysis methods have the potential to address this lack of understanding and it is this which 
has driven the work of this PhD project. The 3 main points addressed in this research are: 1) 
identifying the clustering approach suitable for the analysis of different cluster shapes; 2) 
elucidating the mechanisms of clustering, signalling and shedding in human platelets adhered 
to collagen; 3) employing the nanobody technology to construct a more accurate map of 
GPVI nanoscale organisation via single molecule super-resolution microscopy. 
6.2 Challenges in quantitative analysis of GPVI clustering in platelets 
The work in this thesis presents the application of the most widely used clustering methods, 
namely Ripley’s K-function, DBSCAN and Voronoï tessellation, for the quantitative study of 
GPVI nanoscopic distribution in the form of dSTORM pointillistic dataset. The main aim was 
to identify the most appropriate approach for quantitative interrogation of elongated clusters 
such as those formed by GPVI when bound to fibrous collagen. All the cluster analyses 
investigated show that the higher-order clustering of GPVI on collagen is maintained for up to 
3 h of spreading. The first characterisation of GPVI clustering on fibrillar collagen was 
carried out by Poulter et al. (2017) employing Ripley’s K-function-based cluster analysis 
(Poulter et al., 2017). In our study, the same clustering method adopted by Poulter et al. 
(2017) allowed us to discriminate between GPVI clusters formed on collagen-rich and -poor 





most appropriate analysis method for these elongated clusters due to its dependence on square 
ROIs. Based on its statistical nature, this method is more often used for global distribution 
analyses to identify the presence of clusters within the localisation dataset. For example, it 
allowed mapping the localisation of phosphoproteins and integrin clusters at the platelet actin 
nodules (Poulter et al., 2015b). Ripley’s K-function also enabled the identification of the 
presence of receptor clusters in different types of cells as has been described for CLEC-2 in 
platelets (Pollitt et al., 2014), TCR-CD3 in T cells (Pageon et al., 2016) and the GPCR β2-
adrenergic receptor in cardiomyocytes (Scarselli et al., 2012). Additionally, Ripley’s K-
function has been applied as a quantitative method for the analysis of circular clusters such as 
those formed by the adapter LAT and the kinase Lck in T cells (Owen et al., 2010, Rossy et 
al., 2013, Williamson et al., 2011). User bias can be introduced by the selection of a limited 
number of representative areas. This drawback is bypassed by DBSCAN which takes into 
account the entire density map of spatial localisations within the super-resolved image. The 
benefits of DBSCAN as a clustering approach have been highlighted in a variety of biological 
systems (Endesfelder et al., 2013, Nan et al., 2013, Pageon et al., 2016), including platelets 
(Clark et al., 2019, Onselaer et al., 2019), since it is not sensitive to cluster size and 
morphology like Ripley’s K-function. In our study, DBSCAN also proved to be powerful in 
separating different types of cluster shapes such as those induced by collagen and the other 
substrates investigated, providing important quantitative information on individual clusters 
and allowing further relative comparisons. In Chapter 3, the finding that fibrinogen induced 
larger GPVI clusters than Horm collagen was surprising. However, this may be attributed to a 
variety of factors associated with the experimental and analysis procedures such as: 1) 
activation-induced deposition of fibrinogen on the glass surface which may induce the 





due to the inclusion of small clusters outside the visible collagen fibres; 3) lack of correction 
for multiblinking artifacts; 4) cluster detection hampered by varying local density. The latter 
point could be addressed by the application of novel clustering methods based on topological 
data analysis (TDA) such as persistence based clustering and persistence homology (Pike et 
al., 2019). These analysis tools have been proposed to be superior over the conventional 
cluster algorithms since they also take into account topological information relative to 
nanostructures and nanoclusters unknown a priori. The Topological Mode Analysis Tool 
(ToMATo) has already been used to analyse the integrin α2β1 clustering on collagen (Pike et 
al., 2019), providing the same result as the two-layer DBSCAN method presented in this 
thesis. Therefore, it would be interesting to employ these new cluster analyses for the study of 
GPVI clustering induced by the heterogeneous repertoire of ligands to allow us to confirm our 
results and conclusions. 
SR-Tessler, based on Voronoï tessellation, has been demonstrated to perform robustly in a 
number of biological samples and is able to overcome the drawbacks introduced by Ripley’s 
K-function (sensitivity to cellular morphology) and DBSCAN (sensitivity to background and 
noise) (Levet et al., 2015). It has been applied to both dSTORM and PALM biological 
datasets and allowed segmentation of cell bodies such as in neurons and fibroblasts as well as 
provided quantitative insights into the nanoscopic organisation of receptors (e.g. neuronal 
glutamate receptor) and structures (e.g. microtubules) (Andronov et al., 2016, Levet et al., 
2015). In our study, SR-Tesseler allowed the successful segmentation of GPVI clusters along 
collagen fibres in some dSTORM datasets but it failed in others. Where SR-Tesseler fails, the 
extended two-layer cluster analysis based on DBSCAN demonstrates its robustness and 
consistency in isolating the large and continuous GPVI clusters along visible collagen fibres 





aim of the study. This method, which also accounts for multiblinking artifacts, enables a more 
accurate quantification of GPVI nanocomplexes lined up along the fibrous structure of Horm 
collagen over the other clustering approaches investigated. The two-step DBSCAN-based 
cluster analysis, detailed for the first time in this thesis, can be applied to a variety of 
biological models where the investigation of cellular components or signalling 
receptors/mediators that coalesce in elongated macromolecular complexes is required. Future 
work is needed to integrate this novel clustering tool with an automatic thresholding function 
such as that implemented in SR-Tesseler (Monte-Carlo simulations) (Andronov et al., 2016), 
to allow an unbiased segmentation of the SMLM dataset of interest. Additionally, since DIC 
imaging only detects the big collagen fibrils, an important extension of this work would be the 
fluorescently labelling of Horm collagen to allow the segmentation of platelet areas 
corresponding to the collagen fibres and the further analysis of bound GPVI clusters. 
Ultimately, a significant step forward would be the development of in vivo models and iPSC 
to generate platelets (Thon et al., 2017) which express CRISPR-Cas9-tagged PALM 
fluorophores (Khan et al., 2017) to enable the real-time visualisation of endogenous GPVI 
cluster formation and extend the relative comparisons to absolute quantitative analyses. The 
CRISPR-Cas9 genome editing methodology would allow genetically expressing PALM 
fluorescent tags under the control of endogenous promoters without encountering the issues 
relative to plasmid transfection such as the experimental variation and the over-expression of 
fusion proteins. This way a direct correlation between the cellular expression of tagged GPVI 
and its fluorescent detection can be achieved, allowing to fully exploit the quantitative nature 
of SMLM (Khan et al., 2017). Dynamic analysis of GPVI clustering in platelets spread on 
collagen could be performed by PALM imaging and single-particle tracking using a 





depolymerizing drugs, would also provide further insights into the involvement of the actin 
cytoskeleton in the diffusion of GPVI clusters at the platelet surface. 
6.3  GPVI clustering as a mechanism to enhance the signalling transduction 
Receptor clustering has been proposed as a key mechanism to potentiate the quantitative and 
qualitative features of the signalling transduction and limit the signal downregulation 
emanated by negative regulators (Cebecauer et al., 2010). Experimental evidence has 
suggested that GPVI cluster formation at the plasma membrane plays a central role in 
regulating the signalling intensity in platelets and cell lines (Berlanga et al., 2007, Horii et al., 
2009, Poulter et al., 2017). However, studies performed in human platelets activated in 
suspension have shown that GPVI surface expression is negatively regulated by ectodomain 
shedding mediated predominantly by ADAM10 (Facey et al., 2016, Gardiner et al., 2004). 
This gives rise to the question of whether a platelet suspension is the appropriate experimental 
model to mimic the signalling dynamics underlying GPVI-collagen interaction within the 
vasculature. Findings from this thesis demonstrate that the dynamics of GPVI signalling 
remarkably differ between platelets adhered to an immobile collagen substrate and those 
stimulated with the agonist in suspension. In the first experimental condition, GPVI signalling 
machinery remains active for up to 3 h of spreading in tandem with minimal shedding 
occurring in these platelets. On the contrary, the signalling is markedly downregulated along 
with up to ~70% of GPVI receptors being cleaved from the cell surface when platelets are 
stimulated in suspension. The results support a model (Fig. 6.1) in which GPVI clustering 
induced by immobilised collagen triggers the assembly of signalling complexes at the platelet 
surface via the engagement of downstream signalling proteins, increasing the avidity for 
ligand-binding and strengthening the signal. This way the sheddase ADAM10 would be 





on individual GPVI molecules and enhancing the duration of signalling (Fig. 6.1 A). 
Contrarily, in platelets stimulated with collagen in suspension, the stirring forces would lead 
to the formation of smaller clusters and more volatile signalling complexes which are more 






                          
Figure 6.1. Model of GPVI signalling in platelets adhered to an immobilised collagen 
monolayer and stimulated with collagen in suspension. We propose that immobilised 
collagen initiates the signalling cascade via GPVI clustering and organisation of signalling 
complexes which hinder the GPVI cleavage-site for ADAM10, allowing sustained signalling 
(A). Contrarily, stimulation of platelets with collagen in suspension triggers GPVI 
downregulation through the formation of unstable clusters and signalling systems and 





In addition to protection from ADAM10 activity, stable signalling complexes may also be 
insensitive to phosphatase-mediated downregulation such as that exerted by TULA-2, which 
has been shown to target Syk in platelet suspensions stimulated with CVX (Thomas et al., 
2010). Therefore, an interesting topic for future investigation would be mapping the location 
of TULA-2 relative to GPVI at the platelet surface. A similar signalling mode has already 
been described in T cells where the TCR coalesces in large clusters at the cell surface which 
traps signalling proteins such as LAT and Lck (Douglass and Vale, 2005) and marginalises 
phosphatases such as CD45 (Furlan et al., 2014) and CD148 (Lin and Weiss, 2003). The 
employment of super-resolution microscopy in combination with newly-discovered DNA-
based approaches such as DNA-PAINT for the simultaneous labelling of multiple targets and 
qPAINT to extract numerical information (Jungmann et al., 2016, Jungmann et al., 2014), will 
enable the construction of a qualitative and quantitative map of GPVI receptor, signalling 
mediators and negative regulators at the platelet PM. However, these techniques require a 
long and laborious optimisation process which did not fit with the duration of my PhD. 
The sustained GPVI signalling observed in platelets adhered to a static collagen monolayer is 
corroborated by studies performed under flow conditions (Mazzucato et al., 2009, Pugh et al., 
2017), which would be the ideal experimental model to mimic the vasculature system in vivo. 
Notably, a significant difference between platelets stimulated in suspension and spread on a 
monolayer is the shear stress. The shear forces present in platelet suspensions may prevent the 
formation of robust and longer-lasting clusters and induce shedding. Indeed, a compelling 
study using an ADAM10-specific substrate, which becomes fluorescent when cleaved, has 
shown that shear stress and NEM are the only stimuli able to induce shedding increasing 





Therefore, extending our study to a flow model of haemostasis will be fundamental to verify 
the advanced hypotheses and confirm our conclusions. 
The importance of GPVI-collagen interaction in spreading and aggregation has been reported 
in a variety of studies performed in GPVI-deficient patients (Arai et al., 1995, Boylan et al., 
2004, Dumont et al., 2009, Matus et al., 2013, Sugiyama et al., 1987, Takahashi and Moroi, 
2001) and mouse models (Kato et al., 2003, Lockyer et al., 2006, Nieswandt et al., 2000, 
Nieswandt et al., 2001a, Nieswandt et al., 2001b). In our study, the relevance of GPVI 
shedding in limiting platelet activation in response to collagen is highlighted by the effect of 
NEM. NEM triggers ~100% of GPVI shedding from the platelet surface which remarkably 
impaired platelet spreading on collagen. Therefore, the main conclusion of this work is that 
the negligible level of GPVI shedding and the sustained clustering and signalling induced by 
immobilised collagen function to maintain integrin-dependent platelet adhesion and spreading 
on collagen. Current anti-thrombotic strategies targeting GPVI aim to interfere with the 
receptor-collagen interaction via fusion proteins or anti-GPVI monoclonal antibodies and 
these have had positive functional outcomes in clinical trials and animal models (Goebel et 
al., 2013, Lebozec et al., 2017, Li et al., 2007, Massberg et al., 2004, Ohlmann et al., 2008). 
The development of novel agents targeting collagen-induced GPVI clustering combined with 
in vivo and ex vivo studies will be pivotal in determining whether this mechanism has 
(patho)physiological relevance to prevent bleeding and maintain vascular integrity during 
inflammation (Boulaftali et al., 2018). This would also be of pharmacological interest in the 
treatment of atherosclerotic plaque rupture-driven thrombus formation where GPVI-collagen 
interaction plays a key role (Kuijpers et al., 2009, Penz et al., 2005). Losartan, an angiotensin 
II receptor antagonist, has been proposed to inhibit platelet responses to collagen via the 





did not inhibit platelet activation ex vivo, ruling out its potential as an antiplatelet agent (Jiang 
et al., 2015). Indeed, whilst Onselaer et al. (2019) confirmed the inhibitory effect of Losartan 
and that of another compound, Honokiol, on collagen-induced platelet aggregation, they did 
not find any impairment of GPVI clustering by super-resolution microscopy, which is 
undoubtedly more reliable than the Duolink methodology (Onselaer et al., 2019). To our 
knowledge, chemical agents able to block collagen-induced GPVI clustering have not been 
developed yet, due to the lack of crystallography and cryo-electron microscopy studies of 
GPVI in combination with the agonist. 
The finding that fibrinogen and fibrin are also able to cluster GPVI highlights the importance 
of receptor oligomerisation in the later stages of platelet aggregation and thrombus growth 
and stabilisation, where these ligands have been shown to play a critical role (Alshehri et al., 
2015a, Induruwa et al., 2018, Mammadova-Bach et al., 2015, Mangin et al., 2018, Onselaer et 
al., 2017). Fibrin, but not fibrinogen, also induces GPVI shedding in platelet suspensions 
(Montague et al., 2018b); whether these two ligands can trigger the receptor cleavage under 
static conditions remains to be investigated. The fibrin-induced GPVI shedding has been used 
as a marker of platelet activation in inflammatory settings characterised by unregulated fibrin 
formation such as thermal injury, sepsis and inflammatory bowel disease (IBD) (Montague et 
al., 2018b). Furthermore, the binding sites between GPVI and fibrin(ogen) have been mapped 
to a different location to that for collagen (Induruwa et al., 2018, Onselaer et al., 2017). 
Therefore, specifically targeting GPVI clustering triggered by fibrinogen and fibrin could 
have therapeutical applications in inflammatory conditions characterised by minimal 
activation by collagen.   





6.4 How does GPVI cluster at the platelet surface? 
Whether GPVI is pre-clustered in resting platelets remains to be established. Previous 
attempts from members of the Watson laboratory (University of Birmingham, UK) using 
polylysine-coated coverslips and fixed platelets in solution have been made to answer this 
question. However, the comparison between resting platelets characterised by a 3D geometry 
and spread platelets with a 2D conformation resulted to be technically difficult and therefore 
the project was not pursued further. As discussed by Jung et al. (2012), the early formation of 
GPVI dimers in resting platelets may serve to prime GPVI for activation when the 
subendothelial collagens, which are located in the interstitial layers of the vessel wall, will be 
exposed upon vascular injury. Platelet activation will then increase the dimer formation as it 
has been shown in thrombin and CRP-XL-stimulated platelets (Jung et al., 2012) and induce 
further clustering to ensure sustained signalling and stable adhesion of platelets to collagen. In 
this context, integrin α2β1 synergizes with GPVI in supporting firm adhesion to collagen 
(Auger et al., 2005, Lecut et al., 2004, Mazzucato et al., 2009, Pugh et al., 2017) but it does 
not contribute to GPVI cluster formation as our findings and those reported by (Poulter et al., 
2017) show that GPVI clusters on collagen and CRP-XL to the same extent. However, as 
dSTORM uses fixed material it does not give any information on the dynamics of the 
clustering. Therefore, we can not rule out the possibility that the integrin may aid faster 
formation of the clusters and this is something that could be verified in future experiments 
using single-particle tracking. 
The work from this thesis also establishes a negligible role of second messengers, signalling 
kinases and actin cytoskeletal dynamics in maintaining GPVI clustering on collagen. 
However, the cytoskeleton may play a crucial role in facilitating GPVI dimer formation and 





appears clear that further research is required to investigate the driving forces behind this 
process. GPVI has been localised in membrane lipid rafts at the platelet surface, although it is 
not clear whether it is constitutively associated with these microdomains or if it translocates 
upon activation (Ezumi et al., 2002, Locke et al., 2002, Wonerow et al., 2002). A recent 
proteomic study proposed that platelet activation through GPVI or CLEC-2 induces a change 
in the lipid rafts as well as cytoskeleton proteins composition, suggesting a cooperative role 
(Izquierdo et al., 2019). Such concerted regulation may drive GPVI clustering at the platelet 
surface. Super-resolution microscopy and the design of specific probes to directly image lipid 
rafts components will be vital to establish their role in GPVI clustering and signalling in 
platelets.  
GPVI is also organised into tetraspanins microdomains within the platelet PM which may 
represent key players in modulating its lateral mobility and oligomerisation, as has been 
reported for Tspan9 whose deficiency in a mouse model impaired GPVI lateral diffusion 
within the membrane (Haining et al., 2017b). This study proposed a role for Tspan9 in the 
‘fine-tuning’ of GPVI signalling. The development of further Tspan knockout mice will be 
pivotal in identifying additional tetraspanins involved in the regulation of GPVI clustering 
and signalling at the platelet surface. 
Of considerable interest in this thesis is the finding that, contrarily to GPVI, integrin α2β1 
clustering is found to be dependent on Syk kinase activity. This has been attributed to the 
effect of the kinase inhibitor on the actin cytoskeleton disruption which would block the 
integrin in the inactive state (Zhu et al., 2008). Integrin α2β1 is linked to F-actin through the 
adapter protein talin (Horton et al., 2015) which is fundamental in mediating platelet adhesion 





the binding of α2β1 to talin or other cytoskeletal adaptors such as kindlin and vinculin will be 
crucial to verify our hypothesis. 
6.5 Anti-GPVI nanobodies as promising tools for the study of platelet 
biology 
The work discussed at the end of this thesis presents the first generation and validation of 
nanobodies targeting human platelet GPVI. The project revealed to be challenging due to the 
large repertoire of nanobody genes provided by the VIB Nanobody Core (Brussel, Belgium) 
and the wide range of paratopes generated, resulting in different final yields and modes of 
action in in vitro assays. However, the characterisation of the three candidate nanobodies for 
imaging applications generated fascinating and unexpected data. Two of them (#21 and #27) 
appears to be anti-GPVI blocking nanobodies since they interact with the same binding 
domain of collagen and induce the proteolytic cleavage of GPVI from the platelet surface. 
These findings correlate with the block of collagen-induced platelet aggregation detected 
upon nanobody stimulation. Such mechanisms are not novel and have already been proposed 
for canonical antibodies. For example, the monoclonal antibody JAQ1 targeting the major 
collagen-binding site of mouse GPVI has been shown to immunodeplete GPVI from 
circulating platelets in vivo and completely block platelet responses to collagen and CRP-XL 
ex vivo, generating a long-term antithrombotic effect (Nieswandt et al., 2001b). Further 
antibodies against different epitopes of mouse GPVI (JAQ2 and JAQ3) were then developed 
and showed the same properties of JAQ1 (Schulte et al., 2003). However, the inhibitory 
effects were negligible in in vitro systems, suggesting the presence of additional stimuli in 
vivo (Nieswandt et al., 2001b, Schulte et al., 2003, Schulte et al., 2001). A similar 
phenomenon has been found in patients affected by immune thrombocytopenia who develop 





Moroi, 2001). In all these studies, the mechanisms underlying GPVI clearing from the platelet 
surface have not been investigated. As suggested by our findings, it can be a combination of 
receptor shedding and receptor endocytosis. Although the data from this thesis represent only 
the starting point of a long-term project, they propose these two nanobodies as potential 
candidates in anti-thrombotic approaches whose inhibitory effect would need to be confirmed 
in flow assays, in vivo and ex vivo studies and in experimental thrombosis models before 
potentially introducing them into clinical trials.  
Due to the different performance in the in vitro assays, the last nanobody (#14) was exploited 
as an imaging tool and therefore genetically fused with the SNAP-tag to allow a site-specific 
and quantitative nanobody labelling (Cole, 2013). The SNAP-tag was chosen for its easy self-
labelling by commercial in vitro kits but, on the other hand, its large size and high reactivity 
represent a disadvantage for super-resolution imaging. Indeed, the labelling procedure appears 
to be unsuccessful due to the lower signal-to-background ratio compared with the 1G5-Fab 
and the unspecific binding to the collagen outside the boundary of the platelets. Alternative 
small peptide-tags genetically fused to nanobodies have shown to allow the quantitative and 
site-specific labelling via a Sortase A system, resulting in high-quality dSTORM imaging 
(Virant et al., 2018). Another successful method, involving the labelling of nanobodies with 
maleimides at engineered cysteines, has been demonstrated to be site-specific, does not 
perturb the epitope recognition and displaces the label from the target by only ~1-2 nm 
(Pleiner et al., 2015). These are just a few solutions that could be considered to render the 
nanobody into a powerful tool for the qualitative and quantitative investigation of platelet 






6.6 Concluding remarks 
Findings from this thesis provide novel insights into the signalling mechanisms initiate by the 
GPVI-collagen interaction in human platelets. GPVI clustering helps to potentiate the 
signalling and prevent negative regulation mediated by the sheddase ADAM10 to maintain 
platelet activation and adhesion to collagen. Due to the restricted role of GPVI in haemostasis, 
the selective inhibition of the receptor clustering induced by collagen, fibrinogen and fibrin 
provides an interesting target for the development of novel therapeutic approaches to improve 
the functional outcomes of a variety of thrombotic and inflammatory conditions and reduce 
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Appendix I - Matlab code for the single-cell Ca
2+ 
mobilisation analysis  
(Christopher O’Shea, University of Birmingham, UK) 
function [amp,dur,no_of_peaks,alll] = plat_analysis(x); 
  





    y=x(:,j); 
    if strcmp(class(y(Rayes et al.)),'double') == 1 
        if y ~= 0 
            rcount=rcount+1; 
            for t=1:tlen 
                vals(t,rcount)=y(Abbe); 
            end 
        end 






se = strel('line', 30, 90); %Baseline correction settings 
Threshold=20; %Amplitude of Peak thresholds 




for i = 1:size(vals,2) %Loop through all ROIs in the image 
    sig=squeeze(vals(:,i)) 
     
%% Baseline Correction 
    BL = imopen(sig, se); 
    sig=sig-BL; 
    sig=smooth(sig); 
    ssig=zeros(numel(sig),1); 
     
%% Find areas of amplitude greater than threshold 
    for n=1:numel(sig) 
        if sig(n) > Threshold 
            ssig(n)=sig(n); 





    end 
     
%% Find maximum fluorescent value of ROI  
    amp(i,tp)=max(ssig); 
     
%% Find other peaks in the signal 
    [pks1 
locs1]=findpeaks(ssig,'MinPeakHeight',Threshold,'MinPeakPr
ominence',Prominence); 
    pks(1:numel(pks1),i,tp)=pks1; %Peak amplitudes 
    locs(1:numel(locs1),i,tp)=locs1; %Peak times 
    no_of_peaks(i,tp)=numel(pks1); %Total number of peaks 
     
     
%% Count number of peaks where amplitude drops below 
threshold 
    gaps=find(ssig==0); 
    gcount1=0; 
     
    for c=2:numel(gaps); 
        if gaps(c)-gaps(c-1)>1 
            gcount1=gcount1+1; % if non consecutive 
integers, there is a peak between the two timepoints 
        end 
    end 
     
%% Check to account for peaks that happen at the start or 
end of the recording 
    if isempty(gaps) == 0 
        check1=gaps(1)==1 
        check2=gaps(end)==numel(ssig); 
        if check1 == 1 && check2 == 1 
            check=0; 
        else 
            check=1; 
        end 
    end 
     
%% Save number of peaks, amplitude and duration 
    gcount(i,tp)=gcount1+check; 
    dur(i,tp)=[121-numel(gaps)]*(tim(4)-     
tim(3))*(1/gcount(i,tp)); 
    if numel(gaps) > 120 
        gcount(i,tp)=NaN; 
        dur(i,tp)=NaN; 





    end 








Appendix II - Workflows of DBSCAN-based cluster analyses in KNIME 
(Dr Jeremy Pike, University of Birmingham, UK) 
Single-layer analysis 
 
 
Two-layer analysis 
 
